DPP4 in MERS-CoV Transmission and Pathogenesis by Widagdo, W. (Widagdo)

The research described in this thesis was mainly conducted at the Department of Viroscience, Erasmus MC, Rotterdam, The 
Netherlands within the framework of the Erasmus Post Graduate School of Molecular Medicine. The research presented in this 
thesis was financially supported by Nederlandse Organisatie voor Wetenschappelijk Onderzoek (TOP project Grant 91213066) 
and Zoonotic Anticipation and Preparedness Initiative (Innovative Medicines Initiative grant 115760), with assistance and financial 
support from Innovative Medicines Initiative and the European Commission and contributions from European Federation of 
Pharmaceutical Industries and Associations partners. The financial support for printing of this thesis by Viroclinics Biosciences 
B.V. and Cirion Foundation is gratefully acknowledged.
Cover and lay-out design : Nadia Ayu Lestari
Curriculum Vitae Photograph  : Aditya Perkasa
Print : ProefschriftMaken (www.proefschriftmaken.nl)
ISBN : 978-94-6380-349-6
© Widagdo, 2019. All rights reserved. No part of this thesis may be reproduced or transmitted, in any form or by any means, 
without the permission of the author. 
DPP4 in MERS-CoV Transmission
and Pathogenesis
DPP4 in MERS-CoV transmissie en pathogenese
Thesis
to obtain the degree of Doctor from the
Erasmus University Rotterdam
by command of the
rector magnificus
Prof.dr. R.C.M.E. Engels 
and in accordance with the decision of the Doctorate Board.
The public defence shall be held on
Tuesday 18 June 2019 at 9.30 hours
by
Widagdo
born in Cirebon, Indonesia
Doctoral Committee
Promotor : Prof. dr. M.P.G. Koopmans
Other members : Prof. dr. T. Kuiken
Prof. dr. M. de Jong
Dr. B.J. Bosch
Copromotor : Dr. B.L. Haagmans
This thesis is dedicated to my grandmothers that
taught me hope, sacrifice, and faith – and to




Chapter 1 General Introduction
Partly based on One Health. 2016 Dec 23;3:11-16 9
Part 1 | MERS-CoV Transmission
Chapter 2 Differential Expression of the Middle East 
Respiratory Syndrome Coronavirus Receptor 
in the Upper Respiratory Tracts of Humans and 
Dromedary Camels 
J Virol. 2016 Apr 14;90(9):4838-42 19
Chapter 3 Tissue Distribution of the MERS-Coronavirus 
Receptor in Bats 
Sci Rep. 2017 Apr 26;7(1):1193 27
Chapter 4 Livestock Susceptibility to Infection with Middle 
East Respiratory Syndrome Coronavirus. 
Emerg Infect Dis. 2017 Feb;23(2):232-240 39
Chapter 5 Middle East Respiratory Syndrome Coronavirus 
Transmission in Rabbits 
Viruses 2019, 11(4), 381 53
Chapter 6 Species-specific Co-localization of MERS-CoV 
Entry and Attachment Receptors
Submitted manuscript 67
Part 2 | MERS-CoV pathogenesis
Chapter 7 DPP4, the Middle East Respiratory Syndrome 
Coronavirus Receptor, is Upregulated in Lungs 
of Smokers and Chronic Obstructive Pulmonary 
Disease Patients
Clin Infect Dis. 2018 Jan 6;66(1):45-53 81
Chapter 8 DPP4-expressing type I pneumocytes in a fatal 
human MERS-coronavirus case 
(Manuscript in preparation) 99
Chapter 9 Summarizing discussion 
Based on Viruses 2019, 11(3), 280 119
Chapter 10 English Summary / Nederlandse Sammenvatting 
/ Ringkasan 133


















Coronaviruses  (CoVs) are known to cause mild upper respiratory tract infections 
in humans, as exemplified by OC43, NL63, 229E, and HKU1-CoV1. This paradigm 
was challenged when severe acute respiratory syndrome (SARS)-CoV emerged in 
20022. This virus mainly causes lower respiratory tract infections, such as bronchitis 
and pneumonia. Approximately 10% of SARS-CoV patients developed severe com-
plications and succumbed to a fatal outcome. Further studies showed that this virus 
originated from bats and was transmitted to humans through civet cats, highlighting 
its zoonotic capacity. This virus managed to spread worldwide and infected ~8000 
individuals within a year but was fortunately contained in 20033. There is currently no 
evidence of SARS-CoV circulating in the human population, however, SARS-CoV-
like-viruses that are able to directly infect human cells have been recently identified in 
horseshoe bats in China4, hence continuous surveillance remains necessary.
At mid 2012s, a 60-year-old Saudi Arabian was admitted to a private hospital in Jeddah, 
Saudi Arabia with a 7-day history of fever, cough, expectoration, and shortness of 
breath. His chest radiography showed opacities in the middle and lower lung fields. 
His condition was quickly deteriorating thus he was transferred to an intensive care 
unit at day 2 post admission to receive mechanical ventilation. He developed acute 
renal failure at day 3 post admission. He died at day 11 due to progressive respiratory 
and renal failure5. Upon cell culture, PCR, and sequencing analysis on the sputum 
sample from this patient, a novel CoV belonged to genus betacoronavirus lineage C, 
later named Middle East respiratory syndrome (MERS)-CoV, was identified5. 
Since then MERS-CoV has been causing multiple outbreaks in the Arabian Peninsula, 
mainly in Saudi Arabia6. These outbreaks mostly occur in health-care settings6,7, 
although have also been described to take place in dromedary camel farms and 
household settings8,9. Human MERS-CoV cases have also been reported in other 
countries, however they are associated with recent travel history to countries in the 
Arabian Peninsula6,10,11, and mostly does not lead to an outbreak, except in South 
Korea12. Further studies suggest overcrowding of emergency room and lack of 
infection control measures in the health-care facilities in South Korea as the essential 
factors instigating this outbreak12,13. So far over 2000 individuals worldwide had been 
infected with MERS-CoV and ~35% of them succumbed to fatal outcome. New cases 
are still being reported6, thus highlight the necessity to study this virus, especially its 
transmission and pathogenesis, as well as develop intervention measures.  
Through molecular characterization, it has been shown that MERS-CoV is an 







to other CoVs5,14. Its genome consists of two large replicase open reading frames, 
ORF1a and ORF1b, that occupies three-fourth of the 5′-proximal part, and other genes 
that encode several nonstructural and structural proteins, i.e. spike (S), envelope (E), 
membrane (M), and nucleocapsid (N)14. The protruding trimeric S proteins of CoVs 
form the crown-like appearance and can further be divided into S1 and S2 protein 
(Figure 1A). S1 protein is known to initiate infection by attaching to host receptor at the 
surface of target cell15,16. Thus, S1 proteins can be used as a tool to assess specific 
immune response, develop vaccine candidate, as well as identify host receptor. 
Figure 1. Schematic figure depicting four structural proteins of MERS-CoV, i.e. S, E, M, and N proteins (A); and a cartoon 
representation of MERS-CoV S1 protein binding to DPP4 (PDB code 4L72) (B). S protein can further be divided into S1 and S2 
protein. α/β hydrolase domain of DPP4 is indicated in red, β-propeller domain in green, while part of MERS-CoV S1 protein in 
blue.
MERS-CoV Receptor, Dipeptidyl Peptidase-4
Our studies showed that MERS-CoV S1 protein recognizes two different host 
structures, a host exopeptidase called dipeptidyl peptidase-4 (DPP4) and several 
glycotopes of α2,3-sialic acids17,18. In vitro, polyclonal antibodies against DPP4 protect 
against MERS-CoV infection in susceptible cells, while transient expression of DPP4 
in the non-susceptible Cos-7 cells renders these cells susceptible to MERS-CoV18. 
Meanwhile, elimination of α2,3-sialic acids in a susceptible cell line does not fully 
protect these cells against MERS-CoV, but still significantly reduce the number of 
infected cells17. Thus, we concluded that DPP4 is the functional receptor for MERS-
CoV, while α2,3-sialic acids function as an attachment factor17,18. 
DPP4 is a serine exopeptidase known to cleave-off dipeptides out of polypeptides 
with either L-proline or L-alanine at the penultimate position. Accordingly, DPP4 is 
capable of cutting various substrates, such as hormones, cytokines, chemokines, 
neuropeptides, digestive enzymes, and etc. therefore involved in multiple physiological 
functions as well as pathophysiological conditions19. However, this enzymatic activity 
is not related to DPP4 function as MERS-CoV receptor, since DPP4 inhibitors are not 









MERS-CoV S1 protein binds to the β-propeller domain of DPP4 instead of the α/β 
hydrolase domain where its enzymatic reaction is taking place (Figure 1B). Besides 
that, these studies also reported eleven critical residues in DPP4 that binds to S1 
protein20-22. Ferret and mice that merely have ~50% similarities in these residues to 
that of humans are not susceptible to MERS-CoV22-24. Meanwhile, DPP4 of camels, 
horses, llamas, pigs, sheep, rabbits, and bats, that have >80% similarities in these 
residues to that of humans, are able to recognize MERS-CoV S1 protein22,23,25,26. It is 
then important to investigate these animals’ susceptibility to MERS-CoV, and more 
importantly their capability to transmit this virus.
MERS-CoV Transmission
The zoonotic capacity of MERS-CoV was already suspected at the beginning of its 
emergence since this virus is closely related to bat CoVs, i.e. HKU4 and HKU5, but 
not to the other human CoVs5. Subsequently, other MERS-like-CoVs have been 
sequenced from either fecal samples or rectal swabs of insectivorous bats27-32. This 
indicates insectivorous bats as the natural hosts for MERS-like-CoVs and further 
supports the animal origin of MERS-CoV. Regardless, there is currently limited 
evidence indicating transmission of these viruses from insectivorous bats to humans 
or other animal species (Figure 2). 
Meanwhile, epidemiological studies reported that MERS-CoV seropositive dromedary 
camels are highly prevalent in the Arabian Peninsula and Africa33-37. These seropositive 
camels could even be detected as early as the 1980s33,35,36, indicating that MERS-CoV 
did circulate in this animal long before being introduced to the human population. 
Upon experimental inoculation, dromedary camels developed mild upper respiratory 
infection38,39. Screening of nasal swabs obtained from dromedary camels subsequently 
led to identification and isolation of MERS-CoV from these animals, confirming its 
circulation in this animal species9,40-42. Two studies of human MERS cases post-
contact with infected camels reported high similarity in virus sequences obtained 
from both the camels and humans9,43. These studies along with a case control study 
identifying direct exposure to camels as a risk factor for MERS-CoV infection44,45, and 
serology studies showing higher seropositivity among camel contacts compared to 
non-camel contacts46, support camel-to-human transmission of MERS-CoV (Figure 
2). Wide geographical distribution of MERS-CoV seropositive dromedary camels, thus 
poses a risk of multiple zoonotic introductions to human population37. It remains to be 
determined whether there are other animals besides dromedary camels that could 
efficiently transmit MERS-CoV. Alpacas and llamas have been reported to be naturally 
seropositive and developing neutralizing antibodies against MERS-CoV47,48. However, 







they are capable of independently maintaining this virus in their population, as well as 
transmitting this virus to humans or other species. Meanwhile, sheep, horses, goats, 
and bovines have not been described to be naturally seropositive, but their DPP4 
have been shown to facilitate MERS-CoV infection in vitro25,49-52. Experimental MERS-
CoV infection and transmission experiment in these animals would then be necessary 
not only to confirm their susceptibility to MERS-CoV but also to assess their capacity 
to spread the virus.
Besides transmitted between camels and from camel to human, MERS-CoV has 
also been reported to be transmitted between humans8. This is in line with the fact 
that most of the outbreaks occur in healthcare settings6,7. However, unlike in camels, 
MERS-CoV mainly causes lower respiratory tract infection in humans10,11,53. Viral RNA 
levels in MERS-CoV patients are generally much higher in the lower respiratory tract 
compared to that in the upper respiratory tract10,11,54. MERS-CoV isolation from human 
samples was only successful when lower respiratory tract samples were used5,10,55. 
Autopsy result from fatal human MERS-CoV cases and ex vivo infection experiments 
using human lung explants showed that this virus does infect human lower respiratory 
tract epithelium53,56,57. This lower respiratory tract tropism might partly explain why 
contact tracing of symptomatic MERS-CoV patients showed that human-to-human 
transmission is rather limited, thus requires close contact and relatively high amount 
of virus being shed7,8,13,58.
Figure 2. Schematic representation of MERS-CoV transmission. MERS-CoV has been circulating in dromedary camels for 
decades and could transmit to humans. Human-to-human transmission, besides camel-to-human transmission, has also been 
shown to occur. In humans, this virus causes respiratory infection ranging from asymptomatic to severe. Asymptomatic and mild 
cases consist of healthcare workers, family members, slaughterhouse workers, and camel shepherds. Severe MERS patients 
mainly consist of individuals with advance age and underlying comorbidities. Bats, on the other hand, have been suggested to 
be the natural hosts of MERS-CoV-like-viruses, however, the evidence supporting the transmission of these voruses from bats 










Besides offering insight in MERS-CoV transmission, contact tracing studies on MERS-
CoV patients also reveal that MERS-CoV does not always cause severe pneumonia, 
acute respiratory distress syndrome, and fatal outcome. It can also cause mild and 
even subclinical manifestations8,13,58,59. These subclinical cases are easily missed 
and unrecorded in the field hence might lead to underestimation on the prevalence 
and overestimation on the fatality rate of MERS-CoV. These asymptomatic and 
mild cases mostly consist of slaughterhouse workers, camel shepherds, as well as 
health-care workers and family members having close contact with severe MERS-
CoV patients7,8,46,58. While these individuals are mostly young-age and generally 
healthy, severe to fatal MERS-CoV cases are characterized by advance age and 
having multiple underlying chronic comorbidities, such as diabetes mellitus, chronic 
kidney diseases, heart diseases, chronic lung diseases, and etc.6,60 (Figure 2). These 
differences between individuals having mild and severe MERS-CoV infection highlight 
the role of host factors in determining the outcome of MERS-CoV infection. It is currently 
unclear what these host factors are and how they influence MERS-CoV pathogenesis. 
DPP4, the MERS-CoV receptor, is one of the host factors that worth to look into. Since 
DPP4 is mainly studied in immunology and cancer field, there is not much known 
regarding the localization and function of DPP4 in the respiratory tract. Besides DPP4, 
MERS-CoV attachment factors, such as α2,3-sialic acids, carcinoembryonic antigen 
related cell adhesion molecule 5, and membrane-associated 78 kilodalton glucose-
related protein17,61,62; as well as host innate and adaptive immune response might also 
influence MERS-CoV pathogenesis. 
Outline of This Thesis
MERS-CoV is a novel zoonotic pathogen that uses DPP4 as its host receptor. The 
studies presented in this thesis aimed to gain insight into the role of DPP4 in MERS-
CoV transmission and pathogenesis. The studies aimed to investigate the role of 
DPP4 in MERS-CoV transmission, i.e. chapter 2-6, are compiled in part 1 of this 
thesis. Meanwhile, chapter 7 and 8 in part 2 of this thesis focused more on the role 
of DPP4 in MERS-CoV pathogenesis.
MERS-CoV is known to mainly causes lower respiratory tract infection in humans, 
while in dromedary camels, it merely causes upper respiratory tract infection. In 
chapter 2, we investigated whether such difference could be associated with DPP4 
localization in the respiratory tract tissues of both species. We then extended our study 
by mapping DPP4 localization in various tissues of different bat species in chapter 







and subsequently studied the association between DPP4 localization and MERS-
CoV tropism in the different livestock animals. In chapter 5, we described our virus 
transmission experiment in rabbits, a susceptible small animal species, to gain insight 
on the host factors affecting MERS-CoV transmission. In chapter 6, we described 
α2,3-sialic acids glycotopes as an additional factor besides DPP4 that could influence 
MERS-CoV transmission and pathogenesis. To further study MERS-CoV pathogenesis 
in human, in chapter 7 we reported our investigations on whether DPP4 expression in 
the lungs could be upregulated under certain chronic comorbidities. Later in chapter 8 
we investigated MERS-CoV tropism, DPP4 expression, and histopathological lesions 
in the lungs of a fatal MERS-CoV infection case; and also performed experimental 
MERS-CoV infection in cynomolgus macaques. Key findings of this thesis are then 
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CHAPTER 2
Differential Expression of the Middle East 
Respiratory Syndrome Coronavirus Receptor 
in the Upper Respiratory Tracts of Humans and 
Dromedary Camels
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Middle East respiratory syndrome coronavirus (MERS-CoV) is not efficiently 
transmitted between humans, but it is highly prevalent in dromedary camels. Here we 
report that the MERS-CoV receptor – dipeptidyl peptidase 4 (DPP4) – is expressed 
in the upper respiratory tract epithelium of camels but not in that of humans. Lack of 
DPP4 expression may be the primary cause of limited MERS-CoV replication in the 
human upper respiratory tract and hence restrict transmission.
Brief Communication
Middle East respiratory syndrome coronavirus (MERS-CoV) is a novel coronavirus 
that causes pneumonia in humans, which may lead to acute respiratory distress 
syndrome1. Currently, more than 1,500 confirmed cases have been reported, with 
a relatively high case fatality rate. Although most MERS outbreaks have been 
reported in the Middle Eastern countries, travel-related cases may seed outbreaks in 
other regions, such as in South Korea2. In principle, they can be controlled through 
implementation of early viral diagnostics, strict hygiene measures, and isolation of 
patients. However, there is still a lack of understanding of how this virus is transmitted, 
both between humans and from camels to humans.
Dromedary camels are currently considered the only zoonotic source of MERS-
CoV. This is largely based on the fact that closely related viruses have been isolated 
only from this species thus far3,4. Although studies in the Middle East and several 
northeastern African countries revealed a high percentage of serological positivity 
among dromedary camels4-8, there seems to be limited MERS-CoV transmission from 
camels to humans. Recent studies have shown that only 2 to 3% of persons in Saudi 
Arabia and Qatar that come into close contact with dromedary camels have neutralizing 
antibodies to MERS-CoV8,9. Additionally, most of the notified MERS patients to date 
did not report any contact with camels or other livestock animals, consistent with the 
fact that most outbreaks took place in hospitals10,11. On the other hand, studies in 
hospital and household settings also reported a low percentage of confirmed MERS 
cases among patient contacts10,11. As a result, over a 3-year period, the number of 
MERS cases is relatively low, providing evidence that MERS-CoV transmission to 
humans and between humans is relatively inefficient.
One factor considered to be critical for the transmission of MERS-CoV is the ability 
of the virus to replicate in the upper respiratory tract. Differences in viral shedding in 
dromedary camels and humans have been observed. Relatively high levels of infectious 
virus can be detected in nasal swabs of dromedaries infected with MERS-CoV but 
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not in MERS patients12,13. We hypothesized that a critical determinant of MERS-CoV 
replication in the respiratory tracts of different hosts is the differential expression of 
the viral receptor. Dipeptidyl peptidase 4 (DPP4), a serine exopeptidase involved in 
various biological functions14, has been shown to act as the functional MERS-CoV 
receptor15. Although there is ample evidence that it is expressed in different tissues 
and cell types, including kidney cells, small intestine cells, and T lymphocytes14,16, its 
expression in the upper respiratory tract has not been investigated thus far. Here we 
addressed this knowledge gap by analyzing the tissue localization of DPP4 along the 
human and dromedary camel respiratory tracts.
We obtained 14 human respiratory tract and 3 human kidney formalin-fixed, paraffin-
embedded (FFPE) tissue samples from the Erasmus MC Tissue Bank. These 
respiratory tract tissue samples were six nasal tissue samples (three superior and 
three inferior concha tissue samples) and two tracheal, three bronchial, and three 
lung tissue samples. These tissue samples were taken either from healthy donors or 
from patients with nonmalignant tumors. Kidney tissue was used as a positive control 
because of its abundant expression of DPP414. These tissue samples were residual 
human biomaterials that were collected, stored, and issued by the Erasmus MC Tissue 
Bank under ISO 15189:2007 standard operating procedures. Use of these materials 
for research purposes is regulated according to reference17. Dromedary camel tissue 
samples were obtained from animals used in an experimental MERS-CoV infection18. 
DPP4 immunohistochemistry staining of these 3-μm-thick FFPE tissue sections was 
then performed. Antigen was retrieved by boiling these sections in 10.0 mM citric acid 
buffer, pH 6, for 15 min in a 600-W microwave. Endogenous peroxidase was blocked 
by incubating the slides with 3% hydrogen peroxidase for 10 min. DPP4 was detected 
with 5 μg/ml polyclonal goat IgG anti-human DPP4 antibody (R&D Systems, Abingdon, 
United Kingdom), while negative controls were stained with normal goat serum (MP 
Biomedicals, Santa Ana, CA, USA) in equal concentrations. This primary antibody 
staining was done overnight at 4°C. Secondary antibody staining was performed 
with peroxidase-labeled rabbit anti-goat IgG (Dako, Glostrup, Denmark) at a 1:200 
dilution for 1 h at room temperature. The sections were then treated with 3-amino-9-
ethylcarbazole (Sigma-Aldrich), counterstained with hematoxylin, and embedded in 
glycerol-gelatin (Merck, Darmstadt, Germany).
In the human respiratory tract tissue samples, DPP4 was detected in the lower part, 
i.e., alveolar epithelial cells and macrophages but mostly type II alveolar epithelial 
cells (Fig. 1). In addition, DPP4 expression was also detected to a limited extent on 
the apical surface of the terminal bronchioles and bronchial epithelium of two lung 
samples and one bronchus sample. In sharp contrast, DPP4 was not detected in 
any of our nasal respiratory and olfactory epithelium or trachea samples (Fig. 1). 
In the submucosal layer of these tissue samples, DPP4 was detected in the serous 
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glandular epithelium, inflammatory cells, and vascular endothelium. In contrast to 
humans, DPP4 was detected in the ciliated epithelial cells of the upper respiratory tract 
epithelium of dromedary camels (Fig. 1). Additionally, it was also present in the ciliated 
epithelial cells of the tracheal and bronchial epithelium of these animals. However, in 
the alveoli, it was detected mostly in the endothelial cells and barely in the alveolar 
epithelial cells. Therefore, we conclude that there is differential expression of DPP4 in 
the respiratory tracts of humans and dromedary camels. The absence of DPP4 in the 
upper respiratory tract epithelium of humans may keep MERS-CoV from replicating 
efficiently here. To confirm the localization of DPP4 expression, we performed 
in situ hybridization to detect mRNA transcripts. On the RNAscope platform19 with 
commercially available probes for DPP4, mRNA was detected in human submucosal 
glands but not in the nasal epithelium (Fig. 2A and  and B). Probes for ubiquitin C and 
DapB (Advanced Cell Diagnostics, Hayward, CA, USA) were used as positive and 
negative controls, respectively. Ubiquitin C is encoded by a housekeeping gene and 
is abundantly present in human tissue, while DapB is encoded by a bacterial gene and 
should not be present in healthy human tissue.
Figure 1. DPP4 expression in the upper respiratory tracts of 
camels and humans. DPP4 immunohistochemistry staining 
of human and dromedary camel respiratory tissue samples 
was performed; kidney tissue was used as the positive 
control. Nose, trachea, bronchus, and kidney samples, ×200 
magnification; bronchiole, terminal bronchiole, and alveolar 
samples, ×400 magnification. Positive staining is red. 
Alternatively, other as-yet-unidentified 
MERS-CoV receptors may localize in the 
upper respiratory tract. To investigate the 
presence of such receptors, we performed 
immunohistochemistry staining of frozen 
human tissue material with the spike S1 
protein of MERS-CoV. The spike protein is 
one of the structural proteins that form the 
outer layer of the MERS-CoV particle and 
bind to DPP415. By fusion of the MERS-
CoV S1 protein to the mouse IgG2a Fc 
fragment (mFc-S1 MERS), binding of the 
S1 protein to cells or proteins in human 
tissue sections could be investigated. 
The S1 protein of coronavirus OC43 
was used as a positive control, since this 
virus is commonly known to cause upper 
respiratory tract infection in human20. 
Meanwhile, as a negative control, we 
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used the S1 protein of porcine epidemic diarrhea virus (mFc-S1 PEDV) and mouse 
isotype antibodies (Dako, Glostrup, Denmark). Additionally, immunohistochemistry 
with mouse monoclonal antibody (MAb) against human DPP4 (anti-DPP4 MAb; Santa 
Cruz Biotechnology, Dallas, TX, USA) was performed to further confirm the absence 
of the MERS-CoV receptor in the same nasal epithelium. Frozen human nose and 
kidney tissue samples for this experiment were also obtained from the Erasmus MC 
Tissue Bank, and sections of 6 μm were cut. Kidney tissue was again used as a 
DPP4 positive control. These sections were fixed in acetone and incubated in room 
temperature for 1 h with mFc-S1 MERS-CoV, mFc-S1 OC43, mFc-S1 PEDV, anti-
DPP4 MAb, or isotype mouse antibody at 1 μg/ml. They were subsequently incubated 
with peroxidase-labeled goat anti-mouse IgG (Dako, Glostrup, Denmark) at a 1:100 
dilution for 1 h at room temperature and processed as described above. mFc-S1 
OC43 bound to the nasal epithelium surface, while mFc-S1 MERS and anti-DPP4 
MAb did not. Similar to our results depicted in Fig. 1 and  2, mFc-S1 MERS-CoV and 
anti-DPP4 MAb bound to the nasal submucosal glands and kidney proximal tubuli. 
Meanwhile, our negative control, mFc-S1 PEDV and mouse isotype antibodies, did 
not bind to either nasal or kidney tissue samples (Fig. 3). This result suggests that 
neither DPP4 nor any other alternative receptor is capable of binding spike protein of 
MERS-CoV in the upper respiratory tract epithelium of humans.
Here we report that the MERS-CoV receptor is expressed in the human lower 
respiratory tract but not in the upper respiratory tract epithelium. Similar results were 
recently reported by Meyerholz et al., who used a different MAb21. Our results with 
respect to the localization of DPP4 in the human lower respiratory tract are consistent 
with earlier studies showing MERS-CoV tropism in the alveolar and bronchial epithelial 
cells of ex vivo infected human lung tissue samples22. The presence of the receptor at 
this location is also in line with clinical observations showing that MERS is considered 
in essence a lower respiratory tract infection and the fact that MERS-CoV RNA is 
detected in larger amounts in the tracheal aspirate and sputum samples of MERS 
patients than in nasal or throat swabs13,23. The lack of DPP4 in the human upper 
respiratory tract epithelium may limit MERS-CoV infection and replication at this site and 
hence impede viral transmission. Expression of viral receptors in the upper respiratory 
tract epithelium has been shown to be critical in the transmission of viral infections, 
as exemplified by respiratory infections caused by influenza viruses. Efficient airborne 
transmission of influenza viruses between humans and ferrets requires binding to 
α2,6-sialic acid, which is strongly expressed in the upper respiratory tract. In contrast, 
influenza viruses that bind exclusively to α2,3-sialic acid, which is expressed mostly 
in the lower respiratory tract, are less likely to be transmitted24.
Although there is limited DPP4 expression in the human upper respiratory tract 
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epithelium, we observed expression of the MERS-CoV receptor in glands located 
in the submucosa of the upper respiratory tract. These glands have been shown to 
be targeted by other coronaviruses, such as SARS-CoV and rat sialodacryoadenitis 
virus25,26. We therefore cannot exclude the possibility that MERS-CoV can replicate in 
submucosal glands that are connected to the respiratory epithelium by their secretory 
ducts. It remains to be investigated whether viral replication in patients who have been 
shown to shed MERS-CoV for a long time could be linked to the presence of virus at 
these locations. The susceptibility of these cells and their capacity to support MERS-
CoV replication need to be investigated in future studies.
Figure 2. Presence of DPP4 mRNA and protein in the human nasal epithelium and submucosal glandular epithelial cells. (A) 
DPP4 mRNA was detected in the kidney but not in the nasal epithelium (×200 magnification). (B) DPP4 mRNA (arrows) and 
protein were detected in the submucosal gland cells by in situ hybridization and immunohistochemistry, respectively (×400 
magnification). A positive in situ hybridization signal is marked by red dots. Kidney tissue was used as a positive control for both 
in situ hybridization and immunohistochemistry. For in situ hybridization, ubiquitin C and DapB mRNAs were used as positive 
and negative controls, respectively.
Figure 3. mFc-S1 MERS binds to human kidney proximal tubuli and nasal submucosal glands but not nasal epithelium. Mouse 
MAb against human DPP4 (MAb anti-DPP4) showed binding similar to that of mFc-S1 MERS-CoV. mFc-S1 OC43 binds to the 
nasal epithelium (indicated by arrows) and was used as a positive control. As a negative control, mFc-S1 PEDV and mouse 
IgG2a and IgG2b isotype antibodies were used. The panels showing the mouse isotype control antibody are representative of the 
two isotype control antibodies used in this  experiment. Positive staining is red. All panels were made at magnification of ×200. 
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Although DPP4 is not expressed in the human upper respiratory tract epithelium tissue 
samples analyzed in this study, it remains possible that the expression pattern could 
depend on several factors. DPP4 expression in the lower respiratory tract seemed to 
vary between individuals and as shown by previous studies with T lymphocytes, DPP4 
is not stably expressed on the cell surface but can be upregulated upon activation16. 
Interestingly, one study demonstrated that cultured primary human nasal epithelial 
cells expressed DPP427, which likely reflects upregulated expression as a result of 
cell division, as also observed in different cell lines28. Whether DPP4 expression in 
respiratory tract tissues is regulated by certain host or environmental factors remains 
to be studied. In general, our study highlights a critical difference between humans 
and camels in the distribution of DPP4 expression. Future studies should investigate 
this DPP4 distribution in other species, which would be relevant to further understand 
the transmission of MERS-CoV. 
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Middle East respiratory syndrome coronavirus (MERS-CoV) has been shown to 
infect both humans and dromedary camels using dipeptidyl peptidase-4 (DPP4) as 
its receptor. The distribution of DPP4 in the respiratory tract tissues of humans and 
camels reflects MERS-CoV tropism. Apart from dromedary camels, insectivorous 
bats are suggested as another natural reservoir for MERS-like-CoVs. In order to 
gain insight on the tropism of these viruses in bats, we studied the DPP4 distribution 
in the respiratory and extra-respiratory tissues of two frugivorous bat species 
(Epomophorus gambianus and Rousettus aegyptiacus) and two insectivorous bat 
species (Pipistrellus pipistrellus and Eptesicus serotinus). In the frugivorous bats, 
DPP4 was present in epithelial cells of both the respiratory and the intestinal tract, 
similar to what has been reported for camels and humans. In the insectivorous bats, 
however, DPP4 expression in epithelial cells of the respiratory tract was almost 
absent. The preferential expression of DPP4 in the intestinal tract of insectivorous 
bats, suggests that transmission of MERS-like-CoVs mainly occurs via the fecal-oral 
route. Our results highlight differences in the distribution of DPP4 expression among 
MERS-CoV susceptible species, which might influence variability in virus tropism, 
pathogenesis and transmission route.
Introduction
Middle East respiratory syndrome coronavirus (MERS-CoV) emerged in the human 
population in 2012 and has been causing multiple outbreaks of human disease, 
mainly in the Arabian Peninsula1. The dromedary camel (Camelus dromedarius) has 
been shown to be the reservoir host for primary human infections2-8, although other 
susceptible animals9-11, including bats12,13, are suspected also to be hosts for this virus. 
MERS-like-CoVs have been sequenced from bat samples, mainly from insectivorous 
bats, but they have not yet been successfully isolated14-21. Screening of over 5000 
insectivorous bats from Ghana, Ukraine, Romania, Germany, and the Netherlands 
showed that MERS-CoV-like viruses were detected in 24.9% of Nycteris bats and 
14.7% of Pipistrelle bats14.
MERS-CoV uses dipeptidyl peptidase-4 (DPP4) as its receptor to infect its target 
cells, including bat cells22. Analysis of DPP4 sequences from different bat species 
and in vitro infection studies with various bat cell lines suggested that multiple bat 
species are susceptible to MERS-CoV12,22,23. MERS-like-CoVs probably also use 
DPP4 as indicated by studies on the Tylonycteris bat CoV HKU4, one of the MERS-
like-CoVs21. HKU4 uses DPP4 to infect both bat and human cells in vitro24,25. It is 
known that DPP4 is differently distributed in the respiratory tract of humans and other 
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susceptible livestock animals, including dromedary camels4,11. DPP4 expression in the 
nasal epithelium of the camel, llama, and pig allows them to develop upper respiratory 
tract infection upon intranasal inoculation with MERS-CoV4,11,26, while in humans, 
DPP4 is exclusively expressed in the lower respiratory tract epithelium, which is in 
line with acute pneumonia being the main clinical outcome of MERS-CoV infection4,27. 
Additionally, the absence of DPP4 expression in the upper respiratory tract epithelium 
of sheep renders this tissue to be non-susceptible in vivo11. These data indicate that 
the localization of DPP4 expression in tissues reflects MERS-CoV susceptibility and 
tropism in vivo. The localization of DPP4 expression in bat tissues, however, has not 
been studied, unlike that in other MERS-CoV susceptible species4,11.
Our study aimed to understand the tropism of MERS-like-CoVs in bats by mapping 
the distribution of DPP4 expression in tissues from four bat species. DPP4 
immunohistochemistry staining was performed on tissues collected from two 
widespread insectivorous bat species in Europe and Asia, the common pipistrelle 
bat (Pipistrellus pipistrellus) and the serotine bat (Eptesicus serotinus)28,29; and two 
common frugivorous bat species in Africa, i.e. the Gambian epauletted fruit bat 
(Epomophorus gambianus) and the Egyptian fruit bat (Rousettus aegyptiacus)30,31. 
These four bat species were chosen based on their interactions with humans as they 
roost and forage in the human habitat or serve as a human food source28-31. We show 
that DPP4 localization varies not only among MERS-CoV susceptible species4,11, but 
also between bat species, which may imply variability in MERS-like-CoVs tropism, 
pathogenesis, and transmission route.
Results
Immunohistochemistry to detect DPP4 was performed on nose, lung, intestine, kidney, 
salivary gland, and liver tissues of different bat species: common pipistrelle bat, 
serotine bat, Gambian epauletted fruit bat (further referred as Gambian fruit bat), and 
Egyptian fruit bat. The assay was replicated two-three times for each tissue. We have 
used the same technique to map DPP4 localization in the respiratory tract tissues of 
human, dromedary camel, sheep, horse, pig, and llama4,11. The antibody used in this 
study recognizes bat DPP4 as was demonstrated in transfection experiments using 
cloned Pipistrelle bat DPP422. Hematoxylin and eosin staining on subsequent slides of 
the same tissues from the bats did not show significant histological changes.
DPP4 was not found in the nasal olfactory epithelial cells of common pipistrelle bat, 
serotine bat, Gambian fruit bat, or Egyptian fruit bat (Fig. 1). In the nasal tissues 
of common pipistrelle bat, DPP4 was not detected in the respiratory epithelial cells 
lining the nasal cavity, but was detected in the epithelial cells lining the ducts of the 
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Figure 2. DPP4 expression in the intestine, kidney, salivary 
gland, and liver tissues of the common pipistrelle bat, serotine 
bat, Gambian epauletted fruit bat, and Egyptian fruit bat. In 
all four bat species, DPP4 (indicated in red) is detected on 
the apical surface of the intestinal epithelium, proximal tubular 
epithelium of the kidney, and in the salivary glands. Normal 
goat serum is used as isotype control for each tissue and 
showed no background signal. Only isotype control staining 
of the small intestines is shown. Original magnification x400 
for all images. 
In the intestinal tissues of all four bat spe-
cies, DPP4 was prominently expressed 
on the apical surface of both small and 
large intestinal epithelial cells (Fig. 2). In 
the kidney of all four bat species, DPP4 
was found in glomerular cells, parietal 
squamous epithelial cells of the Bow-
man’s capsule, and in the proximal tubu-
lar epithelial cells. In the salivary gland of 
common pipistrelle bat, DPP4 was only 
detected in the ductular epithelial cells, 
while in the serotine bat, it was detected 
in a limited number of glandular epithelial 
submucosal glands in this species. 
In the serotine bat and Gambian fruit 
bat, multifocal DPP4 expression was 
detected in a limited number of nasal 
respiratory epithelial cells. In contrast, in 
the nasal tissues of the Egyptian fruit bat, 
DPP4 was prominently detected at the 
apical surface of the respiratory epithelial 
cells lining the nasal cavity as well as in 
glandular and ductular epithelial cells of 
the submucosal glands. In the lungs of 
the common pipistrelle and serotine bat, 
DPP4 was found in the endothelial cells 
of the capillaries but not in the bronchial, 
bronchiolar or alveolar epithelial cells. 
In the Gambian and Egyptian fruit bat, 
DPP4 was detected in the bronchial, 
bronchiolar and alveolar epithelial cells 
as well as in endothelial cells of small 
blood vessels (Fig. 1).
Figure 1. DPP4 expression in the respiratory tract tissues 
of common pipistrelle bat, serotine bat, Gambian epauletted 
fruit bat, and Egyptian fruit bat. DPP4 (indicated in red) is 
expressed in the nasal, bronchiolar and alveolar epithelium 
of the fruit bats, with limited expression in the epithelium 
lining the nasal cavity of serotine bats, and not detected in the 
epithelium lining the respiratory tract of the common pipistrelle 
bats. Original magnification x400 for all images. 
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cells. In the Gambian and Egyptian fruit bat, it was detected in both the glandular and 
ductular epithelial cells of the salivary gland. In the liver of the common pipistrelle bat 
and serotine bat, DPP4 was present in a limited number of endothelial cells lining the 
sinusoids. In contrast, in the liver of the Gambian and Egyptian fruit bat, DPP4 was 
detected in the bile duct epithelial cells, in the endothelial cells of the hepatic arteries, 
and in the endothelial cells of the sinusoids (Fig. 2). Variation in DPP4 signal and 
localization were occasionally observed between animals within the same species. 
In one common pipistrelle bat, the paranasal sinus and pharynx were examined and 
showed a limited number of DPP4 positive epithelial cells. The results of the DPP4 
immunohistochemistry staining were scored qualitatively and summarized in Table 1.
In general, our results showed that DP-P4 was prominently expressed in the intestine 
and the respiratory tract tissues of the frugivorous bats, i.e. the Gambian and the 
Egyptian fruit bat. However, it is limitedly expressed in the respiratory tract tissues 
of the insectivorous bats, i.e. the common pipistrelle bat and the serotine bat. In 
the common pipistrelle bat, DPP4 was not detected in the nasal respiratory, nasal 
olfactory, bronchiolar, or alveolar epithelium, but was abundant on the apical surface 
of the epithelium lining the small and large intestine. We compared these findings to 
our previous results on dromedary camel and human tissues4. In dromedary camels, 
DPP4 is strongly detected in the nasal respiratory, tracheal, and bronchial epithelium, 
while there is limited expression in the alveolar epithelium (Fig. 3). In humans, it is 
not found in the nasal epithelium and is present mainly in the alveolar epithelium. 
Additionally, we performed DPP4 staining on intestinal tissues of dromedary camels 
obtained from a previous study26. We found that DPP4 was expressed mainly on the 
apical surface of the small intestinal epithelium (data not shown), similar to what has 
been reported for humans32-35(Fig. 3).
Discussion
The tissue distribution of the MERS-CoV receptor, DPP4, has previously been studied 
in humans, dromedary camels, and other livestock animals4,11. Here, we show that 
DPP4 is differentially expressed among bat species, especially between insectivorous 
and frugivorous bats. It is strongly detected in the intestine of the common pipistrelle bat, 
the serotine bat, the Gambian fruit bat and the Egyptian fruit bat. It is also prominent in 
the respiratory tract epithelium of the Gambian and Egyptian fruit bat, but expression 
is limited in that of the common pipistrelle and serotine bat. Given the essential role of 
DPP4 in the entry of MERS-CoV into cells, these results suggest that MERS-like-CoVs 
are not likely able to replicate in the respiratory tract in these two insectivorous bats. 
This is in line with our previous report on MERS-CoV infection experiment in sheep, 
showing that the lack of DPP4 in the respiratory tract of the sheep was associated 
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with restricted MERS-CoV replication in these animals upon intranasal inoculation11. 
Rather, in these two insectivorous bats, MERS-like-CoVs may preferentially replicate 
in the gastrointestinal tract. This is partly supported by the fact that viral genomes of 
MERS-like-CoVs were mainly obtained from faecal and intestinal tissue samples of 
insectivorous bats14-20,36. This intestinal tropism indicates that these viruses transmit 
mainly through the fecal-oral route. Therefore, future screening of MERS-like-CoVs 
from insectivorous bats, particularly the common pipistrelle bat, might focus on fecal 
material, rectal swabs, or intestinal tissues, rather than throat or nasal swabs.
Table 1. Overview of DPP4 expression in the tissues of the common pipistrelle bat, serotine bat, Gambian epauletted fruit bat 
and Egyptian fruit bat. 
Common 






	Nasal respiratory epithelial cells - +/- +/- +
	Nasal olfactory epithelial cells - - - -
	Submucosal glands + +/- +/- +
Lung
	Bronchiolar epithelial cells - - +/- +
	Alveolar epithelial cells - - +/- +
	Endothelial cells of the capillaries and 
small blood vessels +/- +/- + +
Intestine
	Small intestinal epithelial cells + + + +
	Large intestinal epithelial cells + + + +
Kidney
	Glomerular cells + + + +
	Parietal squamous epithelial cells of the 
bowman capsule + + + +
	Proximal tubular epithelial cells + + + +
Salivary gland 
	Glandular epithelial cells - +/- +/- +
	Ductular epithelial cells + - + +
Liver
	Hepatocytes - - - -
	Bile ductular epithelial cells - - + +
	Endothelial cells of the hepatic vein - - - -
	Endothelial cells of the hepatic artery - - + +
	Endothelial cells of the sinusoids - +/- + +
+, positive detection; +/-, only expressed in a limited number of cells; -, undetected.
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Figure 3.  Different distribution of DPP4 expression in the lining respiratory tract and intestinal epithelium of the common 
pipistrelle bat, serotine bat, Gambian fruit bat, Egyptian fruit bat, dromedary camel, and human. In the common pipistrelle bat and 
serotine bat, DPP4 is limitedly detected in the respiratory tract and mainly expressed in the intestinal epithelium. In the Gambian 
and Egyptian fruit bat, DPP4 is found both in the respiratory tract and in the intestinal epithelium. In the dromedary camel, it is 
expressed in the upper respiratory tract and small intestine epithelium. In the human, it is predominantly expressed in the lower 
respiratory tract and small intestine epithelium.
Prominent DPP4 expression in both respiratory tract and intestinal epithelium of 
the Gambian fruit bat and the Egyptian fruit bat suggests that MERS-CoV is able to 
replicate in both the respiratory tract and intestine of the fruit bats. These results are 
in line with the fact that MERS-CoV was able to replicate in the lungs of Jamaican 
fruit bat (Artibeus jamaicensis) upon intranasal and intraperitoneal inoculation37. 
Interestingly, viral RNA could be detected in the rectal swabs of these animals up to 
day 9 p.i. and infectious virus was also isolated in the duodenum of one of the bats 
at day 28 p.i.37. These data suggest that MERS-CoV infects and replicates in the 
intestine of these bats, not only in the respiratory tract. MERS-CoV infection in these 
bats is likely mediated by DPP4, since hamster BHK cells, a non-susceptible cell 
line, could be infected by MERS-CoV when modified to express Jamaican fruit bat’s 
DPP437. DPP4 expression in the intestine and respiratory tract of these Jamaican fruit 
bats, however, was not investigated. Since the Jamaican fruit bat is a new world fruit 
bat, unlike the Gambian fruit bat and the Egyptian fruit bat, which are old world fruit 
bats, their genetic difference might influence the variation in DPP4 expression among 
these species. In contrast to the fruit bats, where DPP4 is expressed throughout the 
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respiratory tract, DPP4 is rarely detected in the respiratory tract tissues of insectivorous 
bats. This limited DPP4 expression in insectivorous bats might significantly restrict 
the replication of MERS-like-CoVs in these tissues and minimize the possibility of 
transmission of these viruses from the respiratory tract.
The limited DPP4 expression in the respiratory tract of the two insectivorous bat 
species, particularly the common pipistrelle bat, is different from what has been 
reported for dromedary camels and humans. In humans, DPP4 is merely expressed 
in the lower respiratory tract, while in the dromedary camels, it is detected in the 
upper respiratory tract epithelium4. This renders humans to develop pneumonia upon 
MERS-CoV infection, while camels develop upper respiratory tract infection26,38,39. In 
the intestine of both dromedary camels and humans, DPP4 is mainly present in the 
apical surface of the small intestine epithelium32-35. MERS-CoV has been isolated from 
faecal samples of a naturally infected dromedary camel, which suggests that this 
virus is able to replicate in the intestinal tract of this species40. However, in dromedary 
camels, the chance of detecting MERS-CoV RNA in faecal samples is much lower than 
from nasal swabs40. We also observed that low amounts of viral RNA are detectable in 
rectal swabs taken from MERS-CoV- inoculated dromedary camels26. While MERS-
CoV has not yet been isolated from human faecal samples, low amounts of viral RNA 
could be detected in stool samples of MERS patients41, and several MERS patients 
have also been reported to suffer from diarrhoea42-44. These observations suggest 
that MERS-CoV replicates in the intestine of both dromedary camels and humans 
although only to a limited extent. It is currently unclear what factors restrain MERS-
CoV replication in the intestinal tract of dromedary camels and humans. The human 
intestinal tract is protected by a mucus layer, commensal microorganisms, multiple 
innate and adaptive immune cells45. Also, adenosine deaminase (ADA), a natural 
antagonist of DPP4 that can inhibit MERS-CoV infection in vitro9, has also been found 
in the human intestine. The amount of ADA in the human intestine is four times higher 
compared to that in the lung46. The presence of DPP4 in the intestinal tract of bats 
suggests an intestinal tropism of MERS-like-CoVs. We also detected DPP4 in the 
salivary glands and kidneys in all of the bats. In vitro, MERS-CoV has also been 
shown to replicate in primary kidney cell culture derived from common pipistrelle bat13. 
However, there has been no further evidence supporting the susceptibility of these 
two tissues in vivo, nor have there been any reports of MERS-like-CoVs isolated from 
these two tissues or from bat urine samples. Whether these viruses are transmitted 
through bat saliva or urine, therefore, is currently unclear.
In general, our study describes the variation in DPP4 distribution among four bat 
species, with notable differences between insectivorous and frugivorous bats. More 
importantly, the tissue distribution of DPP4 in insectivorous bats, believed to be one 
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of the natural hosts for MERS-like-CoVs, is different to that in dromedary camels and 
humans. Our results indicate intestinal tropism of MERS-like-CoVs in the insectivorous 
bats we examined. The existence of a co-receptor that might influence MERS-like-
CoVs tropism and replication in these bats, however, could not be disregarded. 
CEACAM5 is recently reported as an attachment factor that facilitates entry of MERS-
CoV in vitro47. Whether CEACAM5 plays an important role in vivo, particularly in bats, 
remains to be investigated. In vivo infection experiments are necessary to confirm 
our findings, but such studies are ethically and technically challenging. Nevertheless, 
our data are relevant for future monitoring and surveillance of MERS-like-CoVs in 
insectivorous bats, particularly in the common pipistrelle bat14,18, as well as for future 




Common pipistrelle and serotine bats were found stranded and severely wounded on 
different occasions, and admitted to an official local bat shelter in the Netherlands. 
The animals were euthanized by veterinarians due to ethical reasons using officially 
approved methods. The Gambian fruit bats and three of four Egyptian fruit bats 
used in this study originated from free-ranging populations in Ghana. The bats were 
sampled for an unrelated study and this study was approved by the Ethics Committee 
of the Zoological Society of London (ref. WLE715) and the council for scientific and 
industrial research in Accra, Ghana. One of the Egyptian fruit bats was obtained from 
the captive colony at the Friederich Loeffler Institute, Riems, Germany. It had been 
euthanized due to reasons not related to this study. All methods were performed in 
accordance with the relevant guidelines and regulations.
After euthanasia, the bats were necropsied and tissues were collected. Parts of the 
lung, intestine, salivary gland, liver, and kidney were obtained from nine common 
pipistrelle bats, seven serotine bats, three Gambian fruit bats, and four Egyptian 
fruit bats. Parts of the noses were obtained from five common pipistrelle bats, six 
serotine bats, three Gambian fruit bats, and three Egyptian fruit bats. These tissues 
were all fixed in 10% formalin and embedded in paraffin. The noses were decalcified 
in 10% EDTA for 9 days before being embedded in paraffin. The formalin fixed 
paraffin embedded tissues were sectioned (4 μm), deparaffinized, and subsequently 
hydrated. Citric acid buffer 10 mM pH 6 was used to retrieve antigens. Blocking with 
normal rabbit serum 5% was performed prior to staining with polyclonal goat IgG anti-
DPP4 (R&D systems, Abingdon, UK) in 5 µg/ml concentration. Normal goat serum 
(MP Biomedicals, Santa Ana, CA, USA) in equal concentration was used as negative 
control. DPP4 staining was performed at 4 °C overnight. Secondary antibody rabbit 
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anti-goat IgG labeled with peroxidase were applied subsequently in 1:200 dilution for 
1 hour at room temperature (Dako, Glostrup, Denmark). The red signal was revealed 
with 3-amino-9-ethyl-carbazole (Sigma-Aldrich, St. Louis, Missouri, USA) before 
counterstaining with hematoxylin.
Dromedary camel intestinal tissues were obtained from three different animals 
sacrificed at day 14 post infection with MERS-CoV in a previous MERS-CoV 
vaccination experiment26. Two of these animals were vaccinated beforehand, while 
one was not. MERS-CoV was not detected in the intestinal tissues of these animals 
using PCR, virus titration or immunohistochemistry detecting nucleoprotein of MERS-
CoV. Information on DPP4 expression in human respiratory and intestinal tissues was 
derived from the previous studies4,32-34.
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Middle East respiratory syndrome (MERS) cases continue to be reported, predominantly 
in Saudi Arabia and occasionally other countries. Although dromedaries are the main 
reservoir, other animal species might be susceptible to MERS coronavirus (MERS-
CoV) infection and potentially serve as reservoirs. To determine whether other animals 
are potential reservoirs, we inoculated MERS-CoV into llamas, pigs, sheep, and 
horses and collected nasal and rectal swab samples at various times. The presence 
of MERS-CoV in the nose of pigs and llamas was confirmed by PCR, titration of 
infectious virus, immunohistochemistry, and in situ hybridization; seroconversion was 
detected in animals of both species. Conversely, in sheep and horses, virus-specific 
antibodies did not develop and no evidence of viral replication in the upper respiratory 
tract was found. These results prove the susceptibility of llamas and pigs to MERS-
CoV infection. Thus, the possibility of MERS-CoV circulation in animals other than 
dromedaries, such as llamas and pigs, is not negligible.
Introduction
Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV) first emerged 
in 2012 in Saudi Arabia and is currently a worldwide concern1. As of September 21, 
2016, the World Health Organization had confirmed ~1,800 MERS cases and 643 
associated deaths2. Although during most reported outbreaks the virus is mainly 
transmitted by human-to-human contact, infection through contact with dromedary 
camels (Camelus dromedarius) plays a major role in the primary cases. In the Middle 
East and some countries from East Africa where MERS is endemic, high prevalence 
of MERS-CoV–specific antibodies in dromedaries has been reported3-7. Moreover, 
a recent surveillance study in Saudi Arabia demonstrated that MERS-CoV strains 
isolated from humans were also detected in the upper respiratory tract of dromedaries 
of several geographic origins, indicating that the virus did not require mutations to 
jump between species8. However, not all index cases can be explained by direct 
contact with dromedaries, and transmission from other domestic livestock or animal 
species to humans cannot yet be ruled out. Recently, evidence that alpacas (Vicugna 
pacos) were also susceptible to MERS-CoV infection was provided and confirmed 
by field studies performed in Qatar9-11. In contrast, despite the ability of the virus to 
infect a plethora of cell lines and tissues from mammals of multiple species in vitro12, 
serologic surveys of ruminants and horses did not conclusively determine circulation 
of MERS-CoV among these domestic animals3,13,14. Sampling design could explain 
negative results, and experimental infections provide, in many instances, a more 
straightforward answer to virus host susceptibility. This knowledge is crucial for 
determining risk factors with regard to possible globalization of the disease.
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Our aim with this study was to address these critical research gaps and to understand 
the potential role that other animals (besides dromedaries and alpacas) could play 
in MERS-CoV dissemination. We experimentally inoculated MERS-CoV into llamas 
(Lama glama), pigs (Sus scrofa), horses (Equus ferus caballus), and sheep (Ovis 
aries). We based our selection of species on epidemiologic interest and on sequence 





All experiments with MERS-CoV were performed at Biosafety Level 3 (BSL-3) facilities 
of the Biocontainment Unit of the Institut de Recerca i Tecnologia Agroalimentàries 
(IRTA) Centre de Recerca en Sanitat Animal (CReSA) in Barcelona, Spain. The study 
was approved by the Ethical and Animal Welfare Committee of IRTA and the Ethical 
Commission of Animal Experimentation of the Autonomous Government of Catalonia.
Cells and MERS-CoV
Vero cells were cultured in Dulbecco modified Eagle medium (DMEM; Lonza, Basel, 
Switzerland) supplemented with 1% fetal calf serum (EuroClone, Pero, Italy), 100 U/
mL penicillin, 100 mg/mL streptomycin, and 2 mmol/L glutamine. Passage 7 human 
isolate MERS-CoV stock (HCoV-EMC/2012) was propagated in Vero cells at 37°C 
in a CO2 incubator for 3 days. The infectious virus titer was determined in Vero cells 
and calculated by determining the dilution that caused cytopathic effect in 50% of the 
inoculated cell cultures (50% tissue culture infectious dose endpoint [TCID50]).
Animal Studies
All animals used in this study were obtained from France and Spain by private sale 
and housed at BSL-3 animal facilities (IRTA-CReSA, Barcelona, Spain). We obtained 
8 llamas (6–8 months of age), 8 horses (6–8 months), 14 sheep (2–3 months), and 14 
pigs (2 months). We intranasally inoculated a 107 TCID50 dose in 3 mL saline solution 
into each animal (1.5 mL in each nostril) by using a mucosal atomization device 
(LMA; North-America, Inc., San Diego, CA, USA) and monitored the animals daily for 
clinical signs (sneezing, coughing, nasal discharge, dyspnea). Rectal temperatures 
were recorded with a fast display digital thermometer (Digi-Temp; Kruuse Veterinary 
Products, Langeskov, Denmark) until postinoculation day 10. Nasal and rectal swabs 
were obtained on postinoculation days 1, 2, 3, 4, 7, 10, 14, and 24 in phosphate-
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buffered saline (PBS) (for PCR analysis) and DMEM (for virus isolation and titration) 
containing antimicrobial drugs (100 U/mL penicillin and 0.1 mg/mL streptomycin). All 
samples were stored at −80°C until tested. Serum samples were obtained before 
challenge and at postinoculation days 14 and 24 and were subsequently used to 
detect MERS-CoV–specific antibodies.
Virus Titration
Nasal swabs collected at different times after inoculation were evaluated for infectious 
virus by titration in Vero cells. We prepared 10-fold dilutions, starting with a dilution 
of 1:10, and transferred the dilutions to Vero cells. Plates were monitored daily 
under a light microscope, and wells were evaluated for cytopathic effect. The final 
determination was conducted on postinoculation day 5. The amount of infectious virus 
in swab samples was calculated by determining the TCID50.
Pathology Studies
On postinoculation day 2, we euthanized 4 pigs and 4 sheep with an overdose of 
pentobarbital followed by exsanguination; using the same procedure, on postinoculation 
day 4, we euthanized 4 animals of each species (including llamas and horses) and on 
postinoculation day 24, the remaining animals. We performed complete necropsies 
and collected respiratory tissues (frontal, medial, and caudal turbinates; proximal, 
medial and distal trachea; large and small bronchi; and right cranial, mediodorsal, and 
caudal lung parenchyma) for virologic, histopathologic, immunohistochemical (IHC), 
and in situ hybridization (ISH) examination.
Tissues for pathology studies were fixed by immersion in 10% neutral-buffered 
formalin, embedded in paraffin, and sectioned at 3 μm for slides. Sequential 
slides were either stained with hematoxylin and eosin or used to detect the DPP4 
receptor and MERS-CoV antigen by IHC and viral genome by ISH15,16. In brief, we 
performed DPP4 IHC staining by using 5 μg/mL of polyclonal goat IgG anti-human 
DPP4 antibody (R&D Systems, Abingdon, UK) and peroxidase-labeled rabbit anti-
goat IgG (1:200; DAKO; Agilent Technologies Company, Santa Clara, CA, USA) as a 
secondary antibody. To detect MERS-CoV antigen, we used a monoclonal antibody 
to the nucleocapsid protein (SinoBiological Inc., Beijing, China) as described15. We 
performed ISH according to the manufacturer’s instructions by using probes targeting 
the nucleocapsid gene of MERS-CoV (Advanced Cell Diagnostics, Hayward, CA, 
USA). ISH staining was detected by using the Fast Red substrate as previously 
reported17. For detection of mucous substances, we stained selected slides (from 
animals euthanized on postinoculation day 24) with periodic acid–Schiff (PAS) 
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according to standard methods.
Viral RNA Detection by Reverse Transcription PCR
We collected tissues (0.2–0.5 g) for viral RNA quantification and placed them in 
cryotubes containing beads and 500 µL DMEM supplemented with 100 U/mL 
penicillin, 100 mg/mL streptomycin, and 2 mmol/L glutamine. In brief, samples were 
homogenized at 30 Hz for 2 min by using a TissueLyser II (QIAGEN, Hilden, Germany) 
and stored at −70°C until use. We extracted viral RNA from nasal swabs, rectal swabs, 
and tissue homogenates by using a NucleoSpin RNA virus kit (Macherey-Nagel, 
Düren, Germany) according to the manufacturer’s instructions. The RNA extracts 
were tested by UpE PCR18. We conducted reverse transcription quantitative PCR (RT-
qPCR) by using AgPath-ID One-Step RT-PCR reagents (Applied Biosystems, Foster 
City, CA, USA) and performed amplification by using a 7500 Fast Real-Time PCR 
System (Applied Biosystems) programmed as follows: 5 min at 50°C, 20 s at 95°C, 
and 45 cycles of 3 s at 95°C and 30 s at 60°C. We considered samples with a cycle 
threshold <40 positive for MERS-CoV RNA.
MERS-CoV S1 ELISA
We determined specific S1 antibodies in serum samples from postinoculation days 
0, 14, and 24 by a MERS-CoV S1 ELISA as previously described15, with some 
modifications. In brief, 96-well high-binding plates (Sigma-Aldrich, St. Louis, MO, 
USA) were coated with 100 μL of S1 protein at 1 μg/mL in PBS overnight at 4°C. 
After blocking with 1% bovine serum albumin/PBS/0.5% Tween20 for 1 h at 37°C, 
individual serum samples were added at 1:100, followed by 1 h incubation at 37°C. 
Plates were washed 4 times with PBS, and the species-specific secondary antibody 
was added. We used the following conjugates: anti-llama IgG:horseradish peroxidase 
(HRP) (diluted 1:60,000; no. A160–100P, Bethyl Laboratories, Montgomery, TX, USA); 
anti-pig IgG:HRP (diluted 1:20,000; no. A5670, Sigma-Aldrich); anti-horse IgG:HRP 
(diluted 1: 10,000; no. AAI38P, Bio-Rad, Hercules, CA, USA); and anti-sheep IgG:HRP 
(diluted 1:10,000; no. 5184–2504, Bio-Rad). After 1 h of incubation at 37°C, wells were 
washed 4 times with PBS, and TMB (3,3′,5,5′-tetramethylbenzidine) substrate solution 
was added and allowed to develop for 8–10 min at room temperature, protected from 
light. We measured optical density at 450 nm.
MERS-CoV Neutralization Assay
We also tested serum samples collected on postinoculation days 0, 14, and 24 by 
a specific virus neutralization assay. First, the samples were inactivated at 56°C for 
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30 min. Following a previous protocol15, we mixed 400 PFU of MERS-CoV (HCoV-
EMC/2012) with serial 2-fold dilutions of heat-inactivated serum, incubated the 
mixture 1 h at 37°C, and inoculated it onto Huh7 cells. The presence of viral antigen 
was assessed 8 h after inoculation. Cells were fixed with formaldehyde and stained by 
using rabbit anti–MERS-CoV antibodies and fluorescein isothiocyanate–conjugated 
swine anti-rabbit immunoglobulins as secondary antibodies. We calculated 90% 
plaque-reduction neutralization test values for the MERS-CoV neutralization assay.
Results
Clinical Signs
After challenge, 3 of 8 llamas showed clinical signs (moderate mucus secretion in 1 
nostril) at postinoculation days 4–18 (Technical Appendix, Figure 1, panel A). Soon 
after inoculation, mild excretion of white mucus from the nose was noted for 3 pigs. 
Minimal mucus excretion in the nose was noted at variable times (postinoculation 
days 2–16) for 3 horses. We did not detect nasal discharge in any of the sheep during 
the experiment. No animal of any species showed a significant increase in body 
temperature after MERS-CoV inoculation (Technical Appendix, Figure 1, panel B).
MERS-CoV RNA and Infectious Virus in Nasal Swab Samples and Viral RNA in 
Respiratory Tissues
Pigs and llamas excreted virus in the nose, as evidenced by RT-qPCR of nasal swab 
samples from postinoculation days 1–10; in 1 llama, viral RNA was detected until 
postinoculation day 15 (Figure 1, panel A). At postinoculation day 7, the amount of 
MERS-CoV RNA was still high in all llamas, but a decrease in RNA level was noted at 
postinoculation day 10. In pigs, high levels of MERS-CoV RNA were demonstrated until 
postinoculation day 4 and started decreasing at postinoculation day 7; only 1 animal 
remained positive at postinoculation day 10 (Figure 1, panel A). We subsequently 
tested positive nasal swab samples for the presence of infectious virus. During the 
experiment, 7 of 8 llamas and 7 of 14 pigs excreted infectious virus during at least 1 
day from postinoculation day 2 on. We detected infectious virus until postinoculation 
day 4 in pigs and postinoculation day 7 in llamas (Figure 1, panel B). Relatively low 
levels of viral RNA were detected only until postinoculation day 2 in 5 of 8 inoculated 
horses and only at postinoculation day 1 in 7 of 14 sheep, suggesting the presence of 
residual inoculum in these animals (data not shown). We did not detect virus in rectal 
swab samples from any animal.
To determine the presence of viral RNA in tissues, we euthanized representative 
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numbers of animals on postinoculation days 2 (pigs), 4 (llamas and pigs), and 24 
(llamas and pigs) and tested tissue homogenates by RT-qPCR. Early after infection, 
virus RNA transcripts were detected mainly in the nose, trachea, and small and 
large bronchi of llamas and pigs (Figure 2). At postinoculation day 24, viral RNA was 
detected only in some tissues (caudal nose and trachea) in 2 llamas (Figure 2).
Figure 1. Viral shedding of llamas and pigs after experimental inoculation with MERS-CoV. A) Viral RNA and B) infectious 
MERS-CoV from nasal swab samples collected from llamas (top) and pigs (bottom) at different times after challenge. Each bar 
represents an individual animal. Dashed lines depict the detection limit of the assays. Ct, cycle threshold; MERS-CoV, Middle 
East respiratory syndrome coronavirus; TCID50, 50% tissue culture infective dose. 
Figure 2. MERS-CoV viral RNA in respiratory tissues of llamas (A) and pigs (B). Viral RNA was determined in tissue 
homogenates at postinoculation days 4 and 24. Error bars indicate SDs when results were positive in >1 animal. Dashed lines 
depict the detection limit of the assays (Ct ≤40). Ct, cycle threshold; MERS-CoV, Middle East respiratory syndrome coronavirus; 
PI, postinoculation. 
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Pathology, IHC, and ISH
We observed no substantial macroscopic changes attributable to MERS-CoV 
infection in any animals. All horses exhibited purulent inflammation of the guttural 
pouch (empyema), which was most likely of bacterial origin.
At postinoculation day 4, IHC and ISH demonstrated virus antigen and nucleic acid in 
a few nasal respiratory epithelial cells in 3 of 4 llamas and in 2 of 4 pigs (Figure 3). At 
postinoculation day 2, occasional alveolar epithelial cells were positive for antigen and 
nucleic acid in 1 of 4 pigs. Also at postinoculation day 2, occasional bronchiolar cells 
from 1 of 4 sheep were positive for MERS-CoV (Technical Appendix, Figure 2). MERS-
CoV antigen was absent in the rest of the respiratory tissues of animals of all species 
collected on any of the days. Associated with the presence of virus antigen and nucleic 
acid, llamas and pigs demonstrated a mild to moderate rhinitis characterized by mild 
to moderate epithelial necrosis with infiltration of variable numbers of neutrophils in 
the epithelium (exocytosis) and in the lumen and mild to severe infiltration of the 
lamina propria with variable numbers of macrophages, lymphocytes, neutrophils, and 
plasma cells and multifocal mild edema. We also observed mild to moderate multifocal 
epithelial hypertrophy consistent with regeneration (Figure 3). We observed no other 
relevant microscopic lesions in horses (besides the evidence of purulent empyema) 
and sheep.
Figure 3. Histology and expression of viral antigen (IHC) and viral RNA (ISH) at postinoculation day 4 in the nasal respiratory 
epithelium of sheep, pigs, llamas, and horses inoculated with MERS-CoV. A mild to severe rhinitis with epithelial necrosis and 
hypertrophy and inflammation of the epithelium and lamina propria was observed in the nasal respiratory tissue of pigs and 
llamas. Associated with these was presence of virus antigen (IHC) and RNA (ISH). No substantial lesions, virus antigen, or 
virus RNA were detected in the nasal respiratory tissues of sheep and horses (HE, IHC, ISH). Original magnification ×200 for all 
images. HE, hematoxylin and eosin; IHC, immunohistochemistry; ISH, in situ hybridization; MERS-CoV, Middle East respiratory 
syndrome coronavirus. 
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DPP4 Receptor Distribution and Presence of Mucosubstances in Respiratory 
Tissues
Figure 4. Presence of MERS-CoV receptor DPP4 (IHC) and of mucosubstances (PAS) in upper and lower respiratory tract 
tissues from sheep, pigs, llamas, and horses. A) In the nose, DPP4 (red cytoplasmic or membrane staining) was present on 
the lining epithelium of pigs, llamas, and horses but not sheep. PAS staining (magenta) demonstrated more mucous cells in the 
lining epithelium of sheep and horses and a layer of mucus on the lining epithelium of the horses. B) DPP4 (red cytoplasmic or 
membrane staining) was present on the lining epithelium of the trachea, bronchus/bronchioles, and alveoli in the pigs, llamas and 
horses but not in the sheep. Original magnification ×400 for all images. DPP4, dipeptidyl peptidase-4; IHC, immunohistochemistry; 
MERS-CoV, Middle East respiratory syndrome coronavirus; PAS, periodic acid–Schiff; term., terminal. 
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Figure 5. Antibody responses after ex-
perimental inoculation of MERS-CoV 
into llamas and pigs. A) MERS-CoV S1 
antibody responses were analyzed in 
serum from all animals at postinocula-
tion days 0, 14, and 24. An ELISA with 
recombinant MERS-CoV S1 protein 
was used, and results are represent-
ed individually. B) Individual MERS-
CoV neutralization titers from llamas 
and pigs as determined from serum. 
Dashed lines depict the detection limit 
of the assays. MERS-CoV, Middle East 
respiratory syndrome coronavirus; OD, 
optical density; PRNT90, 90% plaque 
reduction neutralization test.
DPP4 IHC staining of upper and lower respiratory tract tissues collected on 
postinoculation day 24 found DPP4 expression on the respiratory epithelium of the 
nose of llamas, pigs, and horses but only to a very limited extent on that of sheep 
(Figure 4, panel A). We also detected DPP4 expression in the lower respiratory tract 
(but restricted to tracheal and bronchial epithelia) of horses, llamas, and pigs (Figure 
4, panel B). PAS staining demonstrated the presence of mucosubstances in the nose 
of llamas, pigs, horses, and sheep, with a relatively higher number of mucous (goblet) 
cells in the lining epithelium of sheep and horses. In the horses only, there was also a 
layer of mucus covering lining epithelium with a multifocal distribution.
Specific Humoral Immune Response
ELISA results showed antibodies against the S1 protein in all llamas and pigs from 
postinoculation day 14 on, although the response in pigs was weaker than that in 
llamas (Figure 5, panel A). We confirmed the specificity of the response by virus 
neutralization assay (Figure 5, panel B). In all llamas, serum neutralizing MERS-
CoV-specific antibody titers (1:80 to 1:320) were detected at postinoculation days 14 
and 24. In addition, 14 days after challenge, in 5 of 6 pigs, MERS-CoV neutralizing 
antibodies were detected (1:80 to 1:160). However, 10 days later, these virus 
neutralizing antibodies decreased (1:20 to 1:40) (Figure 5, panel B). We detected no 
MERS-CoV–specific antibodies in serum of sheep and horses.
Discussion
Our study results indicate that pigs and llamas are susceptible to MERS-CoV infection. 
These animals shed infectious virus until postinoculation days 4 (pigs) and 7 (llamas), 
although titers were lower among pigs. In pigs and llamas, as well as dromedary 
camels15 and alpacas11, we detected virus predominantly in the nasal respiratory 
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epithelium by IHC, ISH, or both. Accordingly, we mainly detected viral RNA, as 
assessed by RT-qPCR, in the nose, trachea, and bronchi of those animals. We 
also detected viral RNA in lung tissue from 2 of 4 pigs euthanized at postinoculation 
day 2. Virus shedding in dromedary camels and alpacas for longer periods, up to 
14 days after experimental inoculation, has been reported11,15,19. Of note, the level of 
MERS-CoV excreted in the nose of dromedaries seems to be much higher15,19 than 
that of other animal species described so far, suggesting a more prominent role of 
dromedaries in transmission of MERS-CoV to humans.
Differences in virus susceptibility and pathogenicity between animals of different 
species could be explained by a distinct tissue distribution of DPP4, the MERS-CoV 
receptor. In our study, DPP4 distribution in the respiratory tract was similar among 
llamas and pigs but differed from that of dromedary camels16. In contrast, DPP4 was 
barely detected in the respiratory tract of sheep, probably accounting for the lack 
of infection reported here. These results are in concordance with those reported by 
Adney et al., that MERS-CoV experimentally inoculated sheep showed no clinical 
disease and that only small amounts of virus were detected in nasal swab samples20. 
Differences in susceptibility to MERS-CoV infection and level of virus excretion might 
also result from host factors associated with innate immunity. Surprisingly, horses 
were not susceptible to MERS-CoV despite high expression and wide distribution of 
the virus receptor along the respiratory tract. Moreover, the receptor binding domain, 
and in particular key amino acids on the docking site, are identical in horses and 
humans21. Although human, camel, and horse DPP4 served as potent and nearly 
equally effective MERS virus receptors22, horses were not productively infected by 
the strain of MERS-CoV used in this study. Detection of low levels of viral RNA in 
nasal swab samples until postinoculation day 2 can be attributed to residual inoculum. 
Similarly, a recent study with horses also showed low levels of MERS-CoV excretion 
and no virus neutralizing antibodies20.
These results highlight that other mechanisms, such as epithelial cell permissibility 
or strong innate immune responses, may influence the establishment of infection. In 
that respect, PAS staining revealed differences in the number of goblet cells in the 
lining epithelium and mucus covering epithelial surfaces, which may have impeded 
the binding of the virus to the respiratory epithelium of horses. Also, virus tends to 
bind more to ciliated or nonciliated non–mucus-producing cells and, in proportion, 
these cells may be fewer in horses than in llamas and pigs. However, it is possible 
that the guttural pouch empyema, which most likely was of bacterial origin (probably 
Streptococcus spp.), may have influenced mucus production in the horses. Although 
these observations are in line with those from studies in the field indicating the absence 
of antibodies to MERS-CoV in equids14, this aspect should be studied further.
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Epidemiologic studies have provided evidence of endemic MERS-CoV infection 
among dromedaries in the Greater Horn of Africa as far back as 19835,23 and in Saudi 
Arabia as far back as 1992–199324. To implement optimal serologic surveillance in 
countries where MERS is and is not endemic, identifying which animal species might 
be potential reservoirs for MERS-CoV, besides dromedaries, is crucial. The finding 
that pigs can be infected with MERS-CoV suggests that other members of the family 
Suidae could be susceptible to the virus, such as common warthogs (Phacochoerus 
africanus), bushpigs (Potamochoerus larvatus), and wild boars (Sus scrofa scrofa). 
Indeed, these animals are commonly found in the Greater Horn of Africa or the Middle 
East, sharing territories and water sources with dromedaries. Thus, members of the 
family Suidae might merit inclusion in MERS surveillance programs. Further studies 
need to be done to investigate MERS-CoV transmission within and among species to 
provide a better understanding of the role of potential reservoirs during an outbreak. 
Moreover, studies comparing the innate immunity of horses with susceptibility of other 
animal species (i.e., dromedary camels, alpacas, llamas, or pigs) are needed.
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Technical Appendix Figure 1. Clinical signs after MERS-CoV inoculation in llamas, pigs, horses, and sheep. A) Presence of 
mucus excretion in a llama at 4 days postinoculation. B) Rectal body temperatures in llamas, pigs, sheep, and horses at different 
times postinoculation.
Technical Appendix Figure 2. Histology, IHC, and ISH in the lung of a sheep 2 days postinoculation with MERS-CoV. Few 
bronchiolar cells stained positive for MERS-CoV antigen in 1 out of 4 sheep (HE, IHC, ISH x200 magnification).
CHAPTER 5
Middle East Respiratory Syndrome Coronavirus 
Transmission in Rabbits
Viruses 2019, 11(4), 381
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Middle East respiratory syndrome coronavirus (MERS-CoV) transmission from 
dromedaries to humans has resulted in major outbreaks in the Middle East. Other 
livestock such as sheep, horses, rabbits and goats, potentially could contribute to 
zoonotic transmission - evidenced by the susceptibility of their cells in vitro - but it is 
not fully understood why this has not been observed in the field. We used rabbits to 
further characterize the transmission potential of MERS-CoV. In line with the presence 
of MERS-CoV receptor in the nasal epithelium, high levels of viral RNA were shed 
following virus inoculation. However, no transmission by contact or airborne routes 
was observed in rabbits, consistent with limited shedding of infectious virus from the 
nose. Our data reveal that the relatively low levels of infectious virus compared to viral 
RNA produced - possibly through host-mediated restriction - limit viral transmission in 
rabbits and possibly other host species. 
Background
Middle East respiratory syndrome coronavirus (MERS-CoV) is a novel pathogen 
isolated late 2012 1. Seroepidemiological studies indicate that this virus has been 
circulating in dromedary camels in the Arabian Peninsula and Africa for decades 
2-4. MERS-CoV sequences obtained from these camels are largely similar to those 
obtained from human MERS cases in corresponding regions, thus providing evidence 
that dromedary camels act as the zoonotic source of this virus 5,6. However, many 
primary human MERS cases do not have a history of direct contact with these animals 
7. This suggests the presence of unidentified routes of human-to-human transmission 
or the involvement of other animal species in spreading the virus to humans. Besides 
dromedary camels, other animals, i.e. llamas, alpacas, and pigs have been shown 
to be susceptible and develop upper respiratory tract infection upon experimental 
intranasal MERS-CoV inoculation 8-10. This is in line with the expression of the MERS-
CoV receptor, dipeptidyl peptidase-4 (DPP4), in their nasal epithelium 8. MERS-CoV-
seropositive llamas and alpacas have been reported in the field, and MERS-CoV-
experimentally-inoculated alpacas have also been shown to transmit the virus via 
contact 11-13. 
To further understand the zoonotic potential of MERS-CoV, it is crucial to delineate 
the factors involved in the spread of the virus among dromedaries as well as other 
animal species. In order to gain insight on these factors, we performed MERS-
CoV transmission experiments in rabbits. We have previously shown that rabbits 
are susceptible to MERS-CoV and develop both upper and lower respiratory tract 
infection upon virus inoculation 14,15. Naïve recipient rabbits were housed with MERS-
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CoV-inoculated donor rabbits either in the same or in adjacent cages to determine 
whether MERS-CoV can be transmitted via contact or airborne routes, respectively 
16. Donor rabbits were found to shed high levels of viral RNA but a limited amount of 
infectious virus thus potentially restricting MERS-CoV transmission in these animals. 
Methods
Virus stocks
In vivo experiments in this study were performed using Passage 7 human isolate 
MERS-CoV (HCoV-EMC/2012) and passage 3 isolate MERS-CoV (Qatar15/2015; 
GenBank Acc. No. MK280984) that were propagated in Vero cells as described 
earlier 8. Qatar15 was isolated from a 69 years old Qatari man that developed severe 
pneumonia and was PCR confirmed to have a MERS-CoV infection 17. 
Animal experiments
Animal experiments were approved and performed according to the guidelines 
from the Institutional Animal Welfare Committee (no. 201300121, 122-17-01, and 
AVD277002015283-WP01). The studies were performed under biosafety level 3 
(BSL3) conditions. To compare whether different routes of MERS-CoV inoculation 
generate similar clinical outcomes, twelve 6-month-old New Zealand rabbits 
(Oryctolagus cuniculus), specific pathogen free, and seronegative for MERS-CoV 
were divided into four groups. Animals were inoculated under ketamine-medetomidine 
anesthesia either (a) intranasally with 200 µl of 1x106 TCID50/ml MERS-CoV; (b) 
intranasally with 1 ml 1x106 TCID50/ml MERS-CoV; (c) intranasally with 200 µl of 
1x106 TCID50/ml MERS-CoV and intratracheally with 3 ml 4x106 TCID50/ml MERS-
CoV; or (d) intranasally with 1ml PBS. The intranasal inoculums were divided equally 
over both nostrils. Nasal and throat swabs were obtained daily from day 1 up to day 
4 post inoculation. These animals were then sacrificed on day 4 and respiratory tract 
tissues were collected. To compare the clinical outcomes of the MERS-CoV EMC 
strain and the Qatar15 strain, ten New Zealand rabbits were divided into two groups 
and inoculated with 1 ml of 1x106 TCID50/ml of each MERS-CoV strain intranasally. 
Nasal and throat swabs were obtained from day 1 up to day 4 post inoculation and 
these animals were sacrificed on day 4. 
To study MERS-CoV transmission, a modified version of the previously described 
influenza A virus ferret transmission set-up was used. This set-up consists of two clear 
polymethyl methacrylate cages of different sizes. Donor rabbits and direct contact 
recipients were housed in a cage of 35 cm x 30 cm x 65 cm (W x H x L), whereas 
56
PART 1 | Chapter 5






airborne recipients were housed in a cage of 30 cm x 30 cm x 55 cm (W x H x 
L). These cages are separated by two stainless steel grids 10 cm apart to prevent 
direct contact, but still allow airflow from the donor rabbit to the airborne recipient 
rabbit. These transmission cages allow the experiment to be conducted in negatively 
pressured isolators in the BSL3 facility, with HEPA-filtered airflow <0.1 m/sec 18. Since 
these cages were too small for New Zealand rabbits, we chose a smaller-sized breed, 
the Netherland dwarf rabbits (Oryctolagus cuniculus), for the MERS-CoV transmission 
experiment. We used both male and female rabbits with an age range of 6 months 
– 3 years in these experiments. First, three MERS-CoV seronegative Netherland 
dwarf rabbits were inoculated intranasally with 1 ml of 1x106 TCID50/ml MERS-CoV 
(500 µl per nostril) to show that they are equally susceptible to MERS-CoV as the 
New Zealand rabbits. Nasal and throat swabs were obtained daily up to 4 days post 
inoculation. These animals were then sacrificed on day 4 and their respiratory tract 
tissues were collected. For the virus transmission experiment, twelve Netherland 
dwarf rabbits were randomly distributed into four individually housed groups. One 
naïve rabbit from each group was inoculated intranasally with 1 ml of 1x106 TCID50/
ml MERS-CoV (500 µl per nostril). Six hours post inoculation, naïve direct contact 
recipients were co-housed in the same cage with the donor rabbits. Donor and direct 
contact animals were of the same sex. The next day, naïve airborne recipients were 
placed in the adjacent cage. Nasal and throat swabs were obtained every other day 
from day 1 until day 7 or 9 post inoculation from the donor and direct contact rabbits, 
respectively, and from day 1 until day 9 post exposure from the airborne recipients. All 
animals were sacrificed at 14 days post exposure and blood was collected to assess 
seroconversion. 
Virological analysis
Nasal swabs, throat swabs, and respiratory tract tissue samples were evaluated for the 
presence of infectious virus by virus titration, and for viral RNA by RT-qPCR against 
the UpE gene as previously described 8. Samples with a cycle threshold less than 
forty were considered as positive for MERS-CoV RNA. Virus titration was performed 
in serial 10-fold dilutions on Vero cells. Cells were monitored under a light microscope 
at day 6 for cytopathic effect. The amount of infectious virus in swab samples was 
calculated by determining the TCID50. Statistical analysis was performed using the 
GraphPad Prism program (La Jolla, CA, USA). Kruskal wallis test was applied due to 
the non-normal distribution of our data as priorly determined by Saphiro-Wilk test. The 
significant difference between groups was determined at a P-value <0.05. 
Histopathology and histochemistry analysis
Respiratory tract tissue samples were collected in formalin and embedded in 
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paraffin for pathological analysis. Hematoxylin-eosin staining was performed 
for histopathological analysis. The presence of MERS-CoV nucleoprotein and 
MERS-CoV RNA was detected by immunohistochemistry and in-situ hybridization, 
respectively, using previously published protocols 15. The localization of DPP4 in the 
respiratory tract of non-infected New Zealand rabbits was analyzed using an optimized 
immunohistochemical assay 15,19. 
Serological analysis 
Collected serum samples were tested for MERS-CoV neutralizing antibodies using 
a virus neutralization assay and for MERS-CoV S1-specific antibodies using MERS-
CoV S1 ELISA according to the previously published protocols 8. Goat anti-rabbit IgG 
conjugated with HRP (1:2000, DAKO, Glostrup, Denmark) was used as a secondary 
antibody in the ELISA.  
Results
DPP4 is expressed in the upper and lower respiratory tract of rabbits 
Rabbits are the smallest animal species that can be infected by MERS-CoV. We 
previously reported that they develop both upper and lower respiratory tract infection 
upon MERS-CoV inoculation 15, suggesting the expression of the viral receptor at 
these locations. Using immunohistochemistry, we analyzed the DPP4 expression 
in rabbit respiratory tract tissues. In the upper respiratory tract, DPP4 is strongly 
expressed at the apical surface of both nasal respiratory and olfactory epithelium 
(Figure 1). In the lower respiratory tract, DPP4 is present in both bronchiolar and 
alveolar epithelial cells, although some variation in DPP4 expression was observed 
throughout the lungs. DPP4 is either absent, limitedly expressed on alveolar type II 
cells, or expressed on both alveolar type I and II cells (Figure 1). Thus, these data 
highlight a broad DPP4 expression in the respiratory tract tissues of rabbits. Our 
results show that rabbits express DPP4 in both the upper and lower respiratory tract 
epithelium, in line with MERS-CoV tropism in this species 8,19. 
MERS-CoV infects both upper and lower respiratory tract of rabbits upon 
intranasal inoculation 
In our previous study, we inoculated rabbits both intranasally and intratracheally 
15. Intratracheal inoculation is quite invasive thus requires a skillful operator to 
minimize procedure-related damage in the respiratory tract. We then investigated 
whether intranasal MERS-CoV inoculation is sufficient to induce both upper and 
lower respiratory tract infection in rabbits. Three New Zealand rabbits (Oryctolagus 
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of viral RNA in their nasal and throat 
swabs (Figure 3). Following this result 
the MERS-CoV transmission experiment 
was performed using the Qatar15 strain, 
the more recent strain of these two. 
Figure 1. DPP4 expression in the respiratory tract tissues 
of rabbits. DPP4, indicated in red, is detected in the epithelial 
cells lining the respiratory tract of rabbits and the nasal 
olfactory ensheating cells. The DPP4 expression is varied 
throughout the lungs, either limited in the type II cells (arrow) 
or expressed in both type II and type I cells (arrowhead). Nasal 
epithelium and bronchiolar epithelium pictures were taken in 
400x magnification, while alveolar epithelium in 1000x. The 
isotype control showed no background signal in our assay. 
cuniculus) were inoculated with MERS-
CoV EMC strain either intranasally with 
200 µl of 1 x 106 TCID50/ml (group a); 
intranasally with 1 ml of 1 x 106 TCID50/
ml (group b); intranasally with 200 µl of 
1 x 106 TCID50/ml and intratracheally with 
3 ml of 4 x 106 TCID50/ml (group c); or 
intranasally with 1ml of PBS as a negative 
control (group d). All three groups of 
MERS-CoV inoculated rabbits developed 
minimal clinical mani-festations and 
histopathological lesions. The amount 
of viral RNA shed in the nasal and throat 
swabs did not vary among the inoculated 
groups (Figure 2A, B). However, in the 
lungs of the rabbits, the amount of viral 
RNA was significantly lower in group a 
than in groups b and c (Figure 2C). In line 
with these observations, fewer MERS-
CoV-infected cells were observed in 
the lungs of group a animals compared 
to groups b and c (Figure 2D). Based 
on these results, we decided to use 
intranasal inoculation with 1 ml of 1 x 106 
TCID50/ml MERS-CoV for our subsequent 
experiments. 
Different human MERS-CoV strains have 
been isolated since the EMC/2012 strain 
was first characterized 20,21. However, 
studies that evaluate phenotypic differ-
ences between these strains in animals 
are currently lacking. We investigated 
whether a more recent MERS-CoV strain 
(Qatar15/2015) rep-licates differently in 
rabbits in comparison to the EMC strain. 
We found that rabbits inoculated with the 
MERS-CoV EMC strain and those with 
the Qatar15 strain developed an equally 
mild infection and shed similar levels 
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Figure 2. MERS-CoV inoculation in rabbits with different routes and volumes. Three New Zealand 
rabbits were each infected either with (a) 200 µl of 1x106 TCID50/ml MERS-CoV intranasal (I.N.); (b) 1 ml of 1x106 TCID50/ml 
MERS-CoV I.N.; (c) 200 µl of 1x106 TCID50/ml MERS-CoV I.N. combined with 3 ml of 4x106 TCID50/ml MERS-CoV intratracheal 
(I.T.); or (d) 1ml of PBS I.N as negative control. These animals were sacrificed at day 4 post inoculation. Viral RNA shed by the 
MERS-CoV-inoculated rabbits in the nasal swabs (A) and throat swabs (B) are reported in genome equivalents per ml (GE/
ml). Viral RNA detected in the lungs of these rabbits are reported in genome equivalents per gram tissues (GE/g). Dashed 
lines depict the detection limit of the assays. All error bars represent standard deviations. Statistical analysis is performed using 
Kruskal wallis test (**, p value <0.01; ***, p value <0.001). Representative figures of immunohistochemistry detecting MERS-CoV 
nucleoprotein (displayed in red) in the lungs of these rabbits were taken at a 200x magnification (D).
Figure 3. MERS-CoV EMC strain and Qatar strain replicate equally in the upper respiratory tract of rabbits. Five New 
Zealand rabbits were each intranasally inoculated either with 1 ml of 1x106 TCID50/ml MERS-CoV EMC strain or Qatar strain. 
Nasal and throat swabs were obtained from day 0 (before inoculation) until day 4 post inoculation. There is no difference in the 
viral RNA being shed between the rabbits inoculated with EMC strain and Qatar strain. The amount of viral RNA is displayed 
in genome equivalent per ml (GE/ml). Dashed lines depict the detection limit of the assay. All errorbars represent standard 
deviations.
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Unlike MERS-CoV-inoculated rabbits, both contact and airborne-exposed 
rabbits did not develop an infection
 
To study MERS-CoV transmis-sion, an experimental set up previously used to 
investigate influenza A virus transmission between ferrets was used. This set up 
consists of two polymethyl methacrylate cages and separated with two steel grids, 
10 cm apart 16. Because this set-up was too small to house New Zealand rabbits; 
we used a smaller-sized breed, the Netherland dwarf rabbits. Prior to the virus 
transmission experiment, Netherland dwarf rabbits were inoculated with MERS-CoV 
to determine their susceptibility to the virus. Similar to the New Zealand rabbits 15, 
Netherland dwarf rabbits shed viral RNA in the nasal and throat swabs as well as in 
the respiratory tract tissues upon intranasal inoculation (Figure 4A, B). Identical to the 
New Zealand rabbits 15, the MERS-CoV-inoculated Netherland dwarf rabbits did not 
develop any clinical signs and showed minimal histopathological lesions and immune 
cell infiltration in the respiratory tract. 
Figure 4. MERS-CoV infects the upper and lower respi-
ratory tract of Netherland dwarf rabbits. Upon intranasal 
inoculation, viral RNA can be detected in the nasal and throat 
swabs (A) as well as in the respiratory tract tissues obtained 
at day 4 post inoculation (B). The amount of viral RNA in the 
nasal and throat swabs as well as in the respiratory tract tis-
sues are displayed in genome equivalent per ml (GE/ml) and 
genome equivalent per gram tissues (GE/g), respectively. 
Dashed lines depict the detection limit of the assays. All error 
bars represent standard error of means. 
To study MERS-CoV transmission, four 
Netherland dwarf rabbits were intranasal-
ly inoculated with 1 ml of 1 x 106 TCID50/
ml MERS-CoV. Six-hours later, each of 
them was co-housed with one naïve rab-
bit in the same cage, and 24 hours later 
another one was co-housed in an adja-
cent cage to determine whether MERS-
CoV could be transmitted through contact 
and/or airborne routes. Nasal and throat 
swabs were collected every other day up 
to day 7 or 9 post inoculation/exposure 
for the donor and direct contact rabbits, 
respectively, and day 9 post exposure 
for the airborne recipient ones. Both viral 
RNA and infectious virus were quantified 
in these samples. We found that all do-
nor rabbits shed relatively high loads of 
viral RNA in both the nasal swabs (~105 
– 106 TCID50 GE/ml) and the throat swabs 
(~103 – 104 TCID50 GE/ml). The amount of 
viral RNA shed by the inoculated rabbits 
remained high until day 7 post inocula-
tion. On the other hand, recipient rabbits 
housed in the same cage (direct contact 
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recipients), or adjacent cage (airborne 
recipients), shed limited amounts of viral 
RNA (~10 TCID50 GE/ml) in both nasal 
and throat swabs. Among four animals 
in each group, only two direct contact 
recipient and two airborne recipient rab-
bits had detectable viral RNA up to day 5 
post inoculation in the nasal swabs, while 
in the throat swabs, viral RNA was only 
detected in one direct contact recipient 
and one airborne recipient rabbit at day 1 
post inoculation (Figure 5A, B). Infectious 
virus was detected at low level (~102 
TCID50/ml) both in the nasal and throat 
swabs of the donor rabbits. Infectious vi-
rus was detected in the nasal swabs of all 
donor rabbits at day 1 post inoculation, 
and in one of the donors up to day 7. In 
the throat swabs, infectious virus was 
only detected in two donors on day 1, but 
up to day 5 in one of them. In contrast, 
none of the swabs from recipient rabbits 
was positive for virus titration (Figure 5C, 
D). Serological analysis of samples col-
lected 14 days after exposure showed 
that only the donor rabbits seroconverted 
and developed neutralizing antibodies 
(Figure 6A, B). This indicates that these 
rabbits developed MERS-CoV infection 
while the contact and airborne-exposed 
rabbits did not, supporting the results of 
the virus titration. 
Figure 5. Shedding of MERS-CoV RNA and infectious virus in inoculated, contact-exposed and airborne-exposed rab-
bits. MERS-CoV RNA and infectious virus were measured in the nasal (A, B) and throat swabs (C, D). In the inoculated rabbits, 
both MERS-CoV RNA and infectious virus were detected. Meanwhile, in the contact and airborne-exposed rabbits, only MERS-
CoV RNA was detected. The amount of viral RNA is displayed in genome equivalent per ml (GE/ml), while infectious virus in 50% 
tissue culture infective dose per ml (TCID50/ml). Dashed lines depict the detection limit of each assay. 
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Figure 6. MERS-CoV-specific antibody response in rabbits. Inoculated rabbits developed S1-specific MERS-CoV antibody 
(A) and MERS-CoV neutralizing antibodies (B), while contact and airborne-exposed developed none. S1-specific MERS-CoV 
antibody was measured with ELISA and displayed in optical density (OD) value, while MERS-CoV neutralizing antibodies was 
measured with the virus neutralization test (VNT) and displayed in titers. Dashed lines depict the detection limit of the assay. 
Discussion
Current data indicate that MERS-CoV is highly endemic in dromedary camels in the 
Arabian Peninsula and Africa and has been circulating in these animals for decades 
2-4,22. This suggests that this virus is easily transmitted between dromedary camels. 
From an epidemiological point of view, it is important to know whether other animal 
species in the region may also spread the virus to humans or other animal species. In 
vitro, MERS-CoV has been found to infect cells from a broad range of animal species 
including Old and New World camelids as well as primates, bats, cows, sheep, goats, 
pigs, horses, and rabbits 15,23,24. The DPP4 of these species, especially rabbits, has 
high similarity to that of humans and dromedary camels, especially in the region that 
interacts with the spike protein, thus can facilitate MERS-CoV infection 23-25. The New 
World camelids, i.e. llamas and alpacas, have been shown to seroconvert to MERS-
CoV when present in regions where MERS-CoV is circulating and may transmit the 
virus 11-13. It is currently unclear why, besides camelids, other livestock animals do not 
seem to transmit the virus to humans  22,26-28. To further understand the transmission 
potential of MERS-CoV, we performed virus transmission experiments using rabbits 
as animal model. 
To perform the virus transmission experiments, we housed MERS-CoV-inoculated 
rabbits together with naïve contact rabbits either in the same or adjacent cages. 
Rabbits developed both upper and lower respiratory tract infection upon MERS-CoV 
inoculation 15, either via intranasal or combined intranasal and intratracheal routes, in 
line with the localization of DPP4 in their respiratory tract epithelium. The amount of viral 
RNA being shed by the inoculated rabbits during the first three days post inoculation is 
almost as high as that of the MERS-CoV-inoculated dromedary camels 29,30. However, 
none of the direct contact and airborne-exposed rabbits developed infection. They 
hardly shed viral RNA, did not shed infectious virus nor did they seroconvert. One 
PART 1 | Chapter 5





possible reason for this lack of transmission is the limited amount of infectious virus 
being shed by the inoculated rabbits. Similar to rabbits, MERS-CoV-infected pigs and 
goats shed a limited amount of infectious virus, and  hardly spread the virus to  naïve 
animals 26,31. In humans, levels of infectious virus shed by MERS-CoV patients have 
rarely been reported. However, MERS-CoV patients that transmit the virus have been 
shown to shed a higher amount of viral RNA in their swabs compared to those that do 
not, supporting the quantity of virus shed as an important factor in the transmission 
of MERS-CoV between humans 32. For influenza A viruses, infectious virus shedding 
has been documented as one of the main determinants of airborne virus transmission. 
Using ferrets as an animal model, it has been reported that a reduction in infectious 
virus shedding in the nasal swabs can subsequently limit virus transmission 33-35. 
Our results show that despite the presence of DPP4 in the upper respiratory tract, 
accompanied by MERS-CoV replication at this site, a limited amount of infectious 
virus was shed. Similarly, titration of rabbit lung homogenates, that show high levels 
of viral RNA and presence of nucleoprotein (Fig. 2 C and D), resulted in only low 
levels of infectious virus (not shown), in line with earlier observations 15. At this stage 
it is not clear which host mediated mechanisms limit the production of infectious virus 
while allowing viral RNA to still be shed at high levels. Since restriction of infectious 
virus shedding in the rabbits already occurred one day post inoculation, activation 
of host innate immune responses, including type I interferon induction, may be 
relevant. In vitro studies have shown that MERS-CoV is relatively sensitive to type 
I interferon-mediated antiviral activities 36,37. In human plasmacytoid dendritic cells, 
MERS-CoV inoculation leads to secretion of large amount of type I and III interferons 
and production of viral RNA, but hardly any infectious virus is being produced 38. 
Further studies are needed to elucidate the mechanisms that restrict MERS-CoV 
replication in rabbits compared to dromedary camels. Potentially, some of the MERS-
CoV accessory proteins shown to antagonize immune responses including production 
of interferon, may not work efficiently in  some MERS-CoV susceptible species, 
including rabbits. It is intriguing to investigate whether a similar phenomenon occurs 
in some human MERS-CoV infections and whether this is linked to the development 
of asymptomatic to mild clinical manifestations 39. This might partly explain why 
MERS-CoV transmission in humans is rather inefficient in comparison to dromedary 
camels 40,41, and why camelids that secrete high levels of infectious virus are the 
only known zoonotic source of MERS-CoV 6,13,29,42. Deciphering these mechanisms 
could potentially offer insight into understanding MERS-CoV transmission as well as 
developing novel treatments to tackle the ongoing outbreaks.
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MERS-CoV uses the S1B domain of its spike protein to bind to dipeptidyl peptidase-4 
(DPP4), its functional receptor, and its S1A domain to bind to sialic acids. The tissue 
localization of DPP4 in humans, bats, camelids, pigs, and rabbits generally correlates 
with MERS-CoV tropism, highlighting the role of DPP4 in virus pathogenesis and 
transmission. However, MERS-CoV S1A does not indiscriminately bind to all α2,3-
sialic acids and the species-specific binding and tissue distribution of these sialic 
acids in different MERS-CoV susceptible species has not been investigated. We 
established a novel method to detect these sialic acids on tissue sections of various 
organs of different susceptible species by using nanoparticles displaying multivalent 
MERS-CoV S1A. We found that the nanoparticles specifically bound to the nasal 
epithelial cells of dromedary camels, type II pneumocytes in human lungs, and the 
intestinal epithelial cells of common pipistrelle bats. Desialylation by neuraminidase 
abolished nanoparticle binding and significantly reduced MERS-CoV infection in 
primary susceptible cells. In contrast, S1A nanoparticles did not bind to the intestinal 
epithelium of serotine bats and frugivorous bat species, nor to the nasal epithelium of 
pigs and rabbits. Both pigs and rabbits have been shown to shed less infectious virus 
than dromedary camels and do not transmit the virus, neither via contact nor airborne 
routes. Our results depict species specific co-localization of MERS-CoV entry and 
attachment receptors which may be relevant in the transmission and pathogenesis of 
MERS-CoV. 
Introduction
Coronaviruses use their spike (S) protein to attach to host cell surface molecules and 
enter  target cells. The N-terminal part of this S protein, known as S1, is responsible for 
attachment to host cells, while the C-terminal part mediates virus fusion to host cells 
post-attachment 1. For Middle East respiratory syndrome coronavirus (MERS-CoV), 
the S1 protein comprises four individually folded domains, designated S1A through 
S1D 2,3. Two of these domains, S1A and S1B, are involved in binding to host cell surface 
molecules during the attachment phase. The S1A domain preferentially binds to 
several glycotopes of α2,3-sialic acids, while the S1B recognizes a host exopeptidase 
named dipeptidyl peptidase-4 (DPP4), the viral receptor 4,5. The absence of DPP4 
renders cells insusceptible to MERS-CoV4. Meanwhile, elimination of sialic acids 
in susceptible cell lines significantly reduces MERS-CoV infection 5. These findings 
indicated that besides DPP4, the functional entry receptor of MERS-CoV, α2,3-sialic 
acids acts as attachment receptor 4,5. 
DPP4 expression has been mapped in tissues of different susceptible species. It is 
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expressed in the nasal epithelium of camelids, pigs, and rabbits, in which MERS-
CoV causes upper respiratory tract infection 6-12. In the human respiratory tract, it is 
mainly expressed in the type II pneumocytes in the lungs 8,13, in line with clinical data 
showing that in humans MERS-CoV mainly replicates in the lower respiratory tract 
14-16. In insectivorous bats, a potential reservoir for MERS-CoV-like viruses, DPP4 
is scarcely detected in the respiratory tract but abundantly present in the intestinal 
tract 17. Accordingly, MERS-CoV-like viruses are detected mostly in fecal samples of 
these species of bats 18-20. Sheep, on the other hand, do not seem to express DPP4 in 
their respiratory tract, thus hardly shed infectious virus and did not seroconvert upon 
intranasal MERS-CoV inoculation 7,21. Altogether, these data support the role of DPP4 
in determining the host range and tissue tropism of MERS-CoV.  
The localization of α2,3-sialic acids in the respiratory tract of both humans and 
dromedary camels has been mapped using lectin histochemistry (5). These molecules 
are mainly present in the lower respiratory tract epithelium of humans and the upper 
respiratory tract epithelium of dromedary camels, in line with the localization of DPP4 
5,22. However, it is important to note that MERS-CoV S1A does not indiscriminately 
bind to all α2,3-sialic acids. It does not recognize those with 5-N-glycosylation nor 
9-O-acetylation, but preferentially binds 5-N-acetyl modified sialic acids 5. Among 
these α2,3-linked, N-acetyl modified sialic acids, MERS-CoV S1A predominantly 
binds to short, sulfated, α2,3-linked mono-sialosaccharides; and to long, branched, 
di- and triantennary α2,3-linked sialic acids with a minimum extension of 3 N-Acetyl-
D-Lactosamine tandem repeats 5. These glycotopes were previously identified by 
glycan array analysis using nanoparticles displaying multivalent MERS-CoV S1A 5. 
Here, using these nanoparticles, we developed a histochemistry-based technique 
to map the MERS-CoV-recognized glycotopes in the tissues of different susceptible 
species. The results of our study offer further insight into the importance of these 
glycotopes in MERS-CoV host range, tropism, and transmission. 
Results
MERS-CoV S1A binds specifically to the nasal epithelium of dromedary camels
The nasal epithelia of dromedary camels express DPP4 and are susceptible to 
MERS-CoV upon experimental inoculation 8,23. Recent studies revealed that these 
tissues also express α2,3-sialic acids based on Maackia Amurensis Lectin II binding 
5. However, this lectin binds to a broad range of modified α2,3-sialic acids, and thus 
may not represent a specific marker for glycotopes recognized by the MERS-CoV S1A 
24. In order to map these glycotopes, we displayed MERS-CoV S1A in a multivalent 
manner using 60-meric self-assembled nanoparticles generated from the lumazine 
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synthase protein of the Aquifex aeolicus bacterium (np-S1A) 5 and subsequently used 
these nanoparticles to set up a histochemistry assay. We previously showed that both 
np-S1A and MERS-CoV virions can agglutinate human erythrocytes while dimeric 
MERS-CoV S1A cannot, indicating that multivalent presentation is necessary for the 
hemagglutination phenotype of the MERS-CoV S1A. Similarly, the np-S1A, but not 
the dimeric MERS-CoV S1A, can bind to tissues in our assay. As shown in Figure 
1, the np-S1A binds specifically to the nasal epithelium of dromedary camels. We 
found that these glycotopes are expressed in clusters of ciliated and goblet cells in 
the nasal epithelium in a random multifocal pattern (Fig. 1A). Goblet cells, however, 
are DPP4 negative thus are not susceptible to MERS-CoV despite expressing these 
glycotopes (Fig. S1). We determined the binding specificity of the np-S1A by using 
blank nanoparticles and tissues pre-treated with neuraminidase as negative controls 
(Fig. 1A). 
Figure 1. MERS-CoV S1A binds specifically to the nasal epithelium of dromedary camels. The binding of nanoparticles 
displaying multivalent MERS-CoV S1A protein (np-S1A) to camel nasal ciliated epithelial cells (red) is abrogated by prior 
neuraminidase treatment and nanobodies against S1A protein (Nb anti-S1A), but not by those against S1B protein (Nb anti-S1B) 
(A). The tissues used in this experiment were sequentially cut. All pictures are taken in 400x magnification. Nb anti-S1A and anti-
S1B bind to both S1A and S1B proteins respectively and to S1 protein as revealed by ELISA. The control Nb does not bind to S1, 
S1A, and S1B proteins (B). Nb binding is measured in OD values with ELISA.
In a previous study, we generated a nanobody library from the bone marrow of 
dromedary camels vaccinated with Modified Vaccinia virus Ankara (MVA) expressing 
the MERS-CoV spike protein and identified S1B-reactive nanobodies 25. We 
rescreened this library using S1A protein and identified an S1A-reactive nanobody. 
We confirmed its specific binding to S1A domain through S1, S1B, and S1A ELISAs. 
While the control nanobody 25 was negative in all three ELISAs, each of the anti-
S1A and anti-S1B nanobodies reacted specifically to its corresponding domain and 
to S1 in a dose-dependent manner (Fig. 1B). The identified S1A nanobody inhibited 
np-S1A binding to nasal epithelial cells, whereas the S1B reactive nanobody did not, 
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acids further supports the fine specificity 
of the A domain binding. 
Figure 2. Detection of MERS-CoV N protein, DPP4, α2,3-sialic 
acids, and MERS-CoV S1A binding in the nasal epithelium of 
dromedary camels, pigs, and rabbits. MERS-CoV N protein, 
DPP4, α2,3-sialic acids, and MERS-CoV S1A binding are all 
indicated in red. MERS-CoV N protein is detected on the nasal 
epithelium tissues of MERS-CoV-infected dromedary camels, 
pigs, and rabbits. DPP4, α2,3-sialic acids, and MERS-CoV 
S1A binding are evaluated on the tissues of non-infected 
animals. MERS-CoV N protein and DPP4 are detected in the 
nasal epithelium of dromedary camel, pig, and rabbit. α2,3-
sialic acids are detected in the nasal epithelium of dromedary 
camel and rabbit but not in that of pig. Meanwhile, MERS-CoV 
S1A merely binds to the nasal epithelium of dromedary camel. 
All pictures are taken in 400x magnification.   
further confirming the np-S1A binding specificity and the potential role of S1A specific 
antibodies in blocking MERS-CoV attachment (Fig. 1A). 
MERS-CoV S1A does not bind to the nasal epithelium of pigs and rabbits
Similar to dromedary camels, pigs and 
rabbits also develop upper respiratory tract 
infection upon MERS-CoV inoculation. 
However, both pigs and rabbits shed less 
infectious virus than dromedary camels 
and do not transmit the virus, neither via 
contact nor airborne routes 6,7,9-11,23,26. In 
line with these findings, there were fewer 
numbers of MERS-CoV-infected cells in 
the nasal epithelium of pigs and rabbits 
compared to that of dromedary camels 
at day 4 post-inoculation (Fig. 2), while 
DPP4 was highly expressed in the nasal 
epithelium of these three species (Fig. 2). 
Subsequent screening for the presence 
of α2,3-sialic acids in these tissues using 
lectin histochemistry revealed that the 
nasal epithelium of pigs does not express 
these sialic acids, in accordance with 
the results of previous studies 27,28. In 
contrast, these sialic acids were detected 
in the nasal epithelium of dromedary 
camels and rabbits (Fig. 2). We then used 
the np-S1A to test for the presence of 
MERS-CoV-recognized glycotopes in the 
nasal epithelium of pigs and rabbits and 
found that unlike dromedary camels, both 
species do not express these glycotopes 
(Fig. 2). The absence of these glycotopes 
in the nasal epithelium of rabbits, despite 
the abundant presence of α2,3-sialic 
MERS-CoV S1A binds specifically to the intestinal epithelium of Pipistrelle bats 
DPP4 has been reported to mediate MERS-CoV infection in various bat cell lines 
derived from different bat species 29,30. It has also been shown to mediate entry of 
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pseudotyped viruses expressing spike proteins of two MERS-CoV-like-viruses, i.e. 
HKU4 and Hp-BatCoV HKU25, in target cells 31-33. DPP4 has also been shown to 
be abundantly expressed in the intestinal epithelium of both insectivorous and 
frugivorous bats 17. Altogether, these studies suggest the susceptibility of various bat 
species to MERS-CoV-like-viruses. However, not all susceptible bat species may 
act as hosts for these viruses, as they were preferentially detected in insectivorous 
bats 18-20. One study conducted a large screening of over 5000 insectivorous bats, 
from Ghana, Ukraine, Romania, Germany, and the Netherlands, showing that these 
viruses were mainly detected in Nycteris bats and Pipistrelle bats 20. Using the np-
S1A, we investigated whether MERS-CoV-recognized glycotopes were differentially 
expressed in the intestinal epithelium of insectivorous bats, i.e. common pipistrelle 
(Pipistrellus pipistrellus) and serotine bats (Eptesicus serotinus); and frugivorous 
bats, i.e. Gambian epauletted (Epomophorus gambianus) and Egyptian fruit bats 
(Rousettus aegyptiacus). We observed that np-S1A bind to the apical surface of the 
intestinal epithelium of common pipistrelle bat both in villi and crypts, while in others, 
np-S1A only bind to the intestinal crypts (Fig. 3). 
Figure 3. DPP4 expression and 
MERS-CoV S1A binding in the intes-
tinal tissues of common pipistrelle 
bat, serotine bat, Gambian epaulet-
ted fruit bat, and Egyptian fruit bat. 
DPP4 expression and MERS-CoV S1A 
binding are indicated in red. DPP4 is 
expressed at the apical surface of the 
intestinal epithelial cells of these four 
bat species. MERS-CoV S1A binds to 
the apical surface of the intestinal epi-
thelial cells of common pipistrelle bats 
both in villi and crypts, while in other bat 
species, it binding is mostly to intestinal 
epithelial cells within the crypts. All pic-
tures are taken in 400x magnification.
MERS-CoV S1A binds specifically to cells in the human lower respiratory tract
Since lower respiratory tract samples of MERS human cases have higher levels of 
virus and the virus is detected by immunohistochemistry in the lungs of some cases, 
it is concluded that MERS-CoV mainly replicates in the human lower respiratory tract 
14-16. In line with these observations, DPP4 is expressed in the lower airway epithelium 
but not in the upper airway epithelium. It is detected in bronchiolar and alveolar 
epithelial cells, but primarily in the type II pneumocytes (Fig. 4A), consistent with 
previous studies 8,13. Our lectin histochemistry staining showed that both bronchiolar 
epithelial cells and type II pneumocytes express α2,3-sialic acids 22. Both cell types 
also express MERS-CoV-recognized glycotopes as indicated by the binding of np-S1A 
(Fig. 4B). The expression of these glycotopes in bronchial epithelial cells allowed us to 
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confirm their function as an attachment factor using primary well-differentiated normal 
human bronchiolar epithelial (wd-NHBE) cell cultures. These cells were obtained from 
healthy human bronchial epithelial cells and cultured at air-liquid interface to mimic 
the human airway environment. These cells have been shown to express DPP4 and 
are susceptible to MERS-CoV 34-36. Thus far, the function of MERS-CoV-recognized 
glycotopes as an attachment factor has only been observed in Calu3 cells, which is 
a cell line originating from a human lung adenocarcinoma. These cells express both 
DPP4 and the glycotopes of α2,3-sialic acids recognized by MERS-CoV. Removal 
of sialic acids on these cells using neuraminidase prior to MERS-CoV infection 
significantly reduced the number of infected cells 5. In contrast, neuraminidase 
treatment on Vero cells, that do not express MERS-CoV-recognized glycotopes, had 
no effect on the number of infected cells 5. Neuraminidase treatment of wd-NHBE 
cells prior to MERS-CoV infection significantly reduced the number of infected cells 
(Fig. 4C), similar to our previous findings in Calu3 cells 5. Thus, our results concur with 
the importance of MERS-CoV-recognized glycotopes as an attachment factor during 
infection of human airway epithelial cells. 
Figure 4. MERS-CoV receptor and attachment factor in the human lower respiratory tract epithelium. The MERS-CoV 
receptor, DPP4, is expressed in the nasal epithelium of dromedary camels, while in the lungs it is mainly expressed in the 
endothelial cells. In the human respiratory tract, DPP4 is expressed in the bronchiolar epithelial cells (arrowhead) and type II 
pneumocytes (arrow) in the lungs, but not in the nasal epithelium (A). α2,3-sialic acids expression and MERS-CoV S1A binding 
are also detected in human bronchiolar epithelial cells (arrowhead) and type II pneumocytes (arrow) (B). DPP4 expression, 
α2,3-sialic acids presence, and MERS-CoV S1A binding are indicated in red. Pictures of the nasal epithelium are taken in 400x 
magnification, while the alveoli in 1000x magnification. MERS-CoV infection in the primary normal human bronchial epithelial 
cells is inhibited up to 50% upon prior removal of sialic acids using neuraminidase treatment (B). MERS-CoV N protein is 
indicated in red, while nuclei are in blue.
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The S1 domain of the spike protein is an important determinant for the host range 
and tissue tropism of coronaviruses. This domain initiates infection by binding to host 
cell surface molecules, either proteinaceous, sialoglycans-based, or both 37. The S1 
protein of feline coronavirus, transmissible gastroenterovirus, and MERS-CoV has 
been demonstrated to have dual-binding specificity, allowing them to engage both 
sialoglycans and proteinaceous molecules 5,34,37-41. We have previously reported that 
for MERS-CoV, this dual-binding is facilitated by distinct domains of its S1 protein, i.e. 
S1A and S1B 4,5. The S1B domain binds DPP4, the functional receptor of MERS-CoV 
34. DPP4 has been demonstrated to have a major influence on the viral host range 
and tropism since its tissue localization varies between species 7,8,13,17,29,34,42-44. It is 
detected in the nasal epithelium of camelids, pigs, and rabbits 7,8. In bats, it is mainly 
expressed in the small intestinal epithelium of common pipistrelle and serotine bats 
– and in both the respiratory and intestinal epithelium of Gambian epauletted and 
Egyptian fruit bats 17. Meanwhile, in the human airways, it is merely present in the lower 
respiratory tract epithelium, particularly in the type II pneumocytes 8,13. Besides DPP4, 
MERS-CoV preferentially binds α2,3-linked sialic acids via its S1A domain and uses 
these sialic acids as an attachment factor 5. Using nanoparticles displaying multivalent 
S1A domain, we show that the tissue localization of these glycotopes varies between 
various tissues in susceptible species. The S1A protein bound to the nasal epithelium 
of dromedary camels and the type II pneumocytes in human lungs, but not the nasal 
epithelium of pigs and rabbits. 
Previous studies have shown that MERS-CoV-inoculated pigs and rabbits shed 
less infectious virus in comparison to dromedary camels 6,7,10,11,23. In addition, these 
animals did not transmit the virus, neither via contact nor airborne routes 45 (W. 
Widagdo, N.M.A. Okba, et al, submitted for publication). In contrast, MERS-CoV 
is easily transmitted among dromedary camels 12,46-49. The absence of MERS-CoV-
recognized glycotopes in the nasal epithelium of pigs and rabbits might render them 
less permissive to MERS-CoV, thus shed less infectious virus which subsequently 
limited virus transmission. This is supported by our finding that the loss of these 
glycotopes, e.g. through desialylation, could significantly reduce MERS-CoV infection 
5. However, it is important to note that expression of other factors such as proteases 
and interferons may also influence MERS-CoV replication and transmission. MERS-
CoV has been reported to use host cell proteases, such as TMPRSS2, furin, and 
cathepsins to mediate fusion to host cells 50-52. The virus has been shown to be 
sensitive towards type I interferon, an essential host innate immune cytokine 5,50-54. The 
importance of glycotopes in MERS-CoV transmission, either solely or in combination 
with other factors, remains to be further elucidated. These studies would likely require 
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experimental infection of camelids, particularly dromedary camels 46,47,55,56. 
Our data also show that besides its presence in the respiratory tract of dromedary 
camels and humans, MERS-CoV-recognized glycotopes are expressed at the apical 
surface of the villi and crypts of intestinal epithelium of common pipistrelle bats. 
Interestingly, in serotine bats and both Gambian epaulleted and Egyptian fruit bats, 
these glycotopes are merely detected in the intestinal crypts. This finding further 
supports the belief that insectivorous bats are one of the natural hosts of MERS-CoV-
like-viruses 18-20 and also suggests that not all insectivorous bats express the α2,3-
sialic acid glycotopes recognized by MERS-CoV in their intestines. Whether these 
glycotopes influence the permissiveness of different bat species towards MERS-CoV, 
still remains to be elucidated and would need the availability of primary bat intestinal 
cell culture or bat intestinal organoids. However, experiments in insectivorous bats 
may be difficult to perform due to legal restrictions. 
In general, our results showed that the tissue localization of α2,3-sialic acid 
glycotopes recognized by MERS-CoV S1A varies between susceptible species. 
These glycotopes and DPP4 are both expressed in the nasal ciliated epithelial cells 
of dromedary camels, type II pneumocytes of humans, and intestinal epithelial cells 
of common pipistrelle bats, providing further evidence that these tissues are the main 
replication site of MERS-CoV in the respective species. This study corroborates 
α2,3-sialic acids glycotopes as an important attachment factor for MERS-CoV 5, and 
highlights the necessity to further understand their role in MERS-CoV pathogenesis 
and transmission. Importantly, our results also imply that the MERS-CoV S1A domain 
should be considered a target for vaccines 57,58. 
Materials and Methods
Tissue samples
Human formalin fixed paraffin embedded (FFPE) lung tissues were obtained from 
the Erasmus MC Tissue Bank and had been used in a previous study 8. These tissue 
samples were residual human biomaterials taken either from healthy donors or from 
patients with nonmalignant lung tumors that were collected, stored, and issued by the 
Erasmus MC Tissue Bank under ISO 15189:2007 standard operating procedures. 
Use of these materials for research purposes is regulated according to human tissue 
and medical research: code of conduct for responsible use (2011). Dromedary camel, 
pig, and rabbit FFPE nasal tissues, both MERS-CoV-infected and mock-infected were 
obtained from previous studies. Infected animals were all sacrificed at day 4 post-
inoculation 6,7,23. Bat FFPE intestinal tissues were also obtained from a previous study 
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17. All of these samples were obtained in accordance with the relevant guidelines and 
regulations.
Histochemistry and immunofluorescence analysis
MERS-CoV nucleoprotein was detected with 5 µg/ml mouse anti-MERS nucleoprotein 
(Sino-Biological, Beijing, China), while DPP4 expression with 5 µg/ml goat anti-
human DPP4 (R&D, Minneapolis, Minnesota, USA) using the protocol described in 
previous studies 7,8,17. Periodic acid-Schiff staining was also performed according 
to the protocol described in a previous study 7. Expression of α2,3-sialic acids was 
detected using biotinylated Maackia Amurensis Lectin II (Vector Labs, Burlingame, 
California, USA) in 1:800 dilution and streptavidin-HRP in 1:300 dilution, both diluted 
in 1x Tris buffered saline containing 0.1M MnCl2, 1M MgCl2, and 0.1M CaCl2, then 
subsequently visualized using 3-Amino-9-ethylcarbazole and counterstained with 
Hematoxylin. S1A protein binding on the tissues was performed using nanoparticles 
displaying multivalent S1A protein (np-S1A) and a strep-tag generated in a previous 
study 5. The tissues were boiled in citric acid buffer 10 mM pH 6 for 15 minutes and 
blocked with 5% normal goat serum (DAKO, Glostrup, Denmark) before staining with 3 
µg/ml np-S1A overnight at 4°C. Tissues that were stained with an equal concentration 
(3 µg/ml) of blank nanoparticles and those that were pre-treated with 800 mU/ml 
neuraminidase from Vibrio cholerae (Sigma-Aldrich, St. Louis, Missouri, USA) for 4 
hours at 37°C were used as negative controls. Additional controls were performed by 
staining tissues with np-S1A priorly incubated for 1 hour at 37°C with either anti-S1A, 
anti-S1B or control nanobodies in 15 µg/ml concentration. These nanobodies were 
obtained from a nanobody library generated in a previous study 25. These tissues 
were subsequently stained with rabbit anti-strep-tag sera generated in-house and 
goat anti rabbit-IgG-HRP (DAKO, Glostrup, Denmark), each in 1:100 dilution for 1 
hour at room temperature, and then visualized with 3-amino-9-ethylcarbazole and 
counterstained with Hematoxylin. For immunofluorescence staining, fluorescence 
conjugated secondary antibody was applied in the experiment, i.e. goat anti-rabbit 
IgG conjugated with Alexa Fluor 488 and goat anti-mouse IgG conjugated with Alexa 
Fluor 594 (Life technologies, Carlsbad, California, USA), both in 1:250 dilution and 1 
hour incubation at room temperature.
MERS-CoV S1, S1B, and S1A ELISAs 
The specificity of anti-S1A, anti-S1B and control nanobodies to MERS-CoV S1, S1A, 
and S1B proteins was determined using ELISA as previously described 25. In brief, 
96-well ELISA plates were coated with 1 μg/ml MERS-CoV S1 (amino acid 1-751), 
S1A (amino acids 1-357), or S1B (amino acids 358-588) proteins in PBS (pH 7.4) and 
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incubated overnight at 4°C. Wells were then washed with PBS, and blocked with 1% 
bovine serum albumin in PBS/0.5% Tween-20 for 1 hour at 37°C. Nanobodies were 
two-fold serially diluted in blocking buffer starting at a 1 µg/ml concentration, 100 μl of 
each dilution was added per well, and plates were incubated at 37°C for 1 hour. Next, 
plates were washed three times in PBS/0.05% Tween-20 (PBST), after which they 
were incubated with mouse anti-his tag antibodies (1:2000, Thermo Fisher Scientific) 
at 37°C for 1 hour. Following incubation, the plates were washed and further incubated 
with goat anti-mouse HRP (1:2000, Dako) at 37°C for 1 hour. After this incubation, 
plates were washed three times in PBST and 3,3′,5,5′-tetramethylbenzidine substrate 
(eBioscience) was added and incubated for 10 min. The reaction was stopped with 
0.5N H2SO4 (Sigma). The absorbance of each sample was read at 450 nm with an 
ELISA reader (Tecan Infinite F200).
MERS-CoV infection in well-differentiated primary normal human bronchial 
epithelial (wd-NHBE) cells 
Primary NHBE cells (Lonza, Basel, Switzerland) were cultured on Transwell® 
permeable support (Costar) according to the protocol suggested by the manufacturer 
(CloneticsTM Airway Epithelial Cell Systems, Lonza, Basel, Switzerland). The cells 
were differentiated at the air-liquid interface for 6 weeks to promote mucociliary 
differentiation, resulting in the presence of multilayered epithelium, ciliated cells, and 
goblet cells 59. These cells were subsequently either mock-treated or pre-treated with 
a mixture of 40U of Arthrobacter urefaciens neuraminidase (Sigma-Aldrich, St. Louis, 
Missouri, USA) and 50U of Clostridium perfringens neuraminidase (NEB, Ipswich, 
Massachusetts, USA) for 1 hour before infection. Each well was inoculated with 
MERS-CoV EMC/2012 strain 6,7 106 TCID50/ml (MOI 5), incubated for 36 hours and 
fixed in formalin 10%. MERS-CoV infected cells were visualized with 5 µg/ml mouse 
anti-MERS nucleoprotein (Sino-Biological, Beijing, China) and 1:250 goat anti-mouse 
IgG conjugated with Alexa Fluor 594 (Life technologies, Carlsbad, California, USA). 
Experiments were performed in triplicates. The number of infected cells was counted 
for each well and the percentage of infected cells was determined, as performed in 
our previous study 5. Statistical analysis was performed using student’s t-test and then 
presented in mean ± standard deviation for each group. 
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Supplementary figure 1. Periodic 
acid-Schiff staining, DPP4 expres-
sion, MERS-CoV S1A binding, and 
MERS-CoV N protein detection in the 
nasal epithelium of dromedary camel. 
Goblet cells (arrows), visualized in 
purple by periodic acid-Schiff stain, are 
DPP4 negative unlike the nasal ciliated 
columnar epithelial cells (arrowheads). 
The DPP4 expression is indicated in 
red. MERS-CoV S1A binding to these 
goblet cells (red) can be abrogated by 
neuraminidase treatment. In MERS-
CoV-infected camels, MERS-CoV S1A 
(green) binds to both nasal ciliated 
columnar epithelial cells and goblet 
cells, while MERS-CoV N protein (red) 
is only detected in the nasal ciliated 
columnar epithelial cells. All pictures 
are taken in 400x magnification.
CHAPTER 7
DPP4, the Middle East Respiratory Syndrome 
Coronavirus Receptor, is Upregulated in Lungs 
of Smokers and Chronic Obstructive Pulmonary 
Disease Patients
Clin Infect Dis. 2018 Jan 6;66(1):45-53
82
Part 2 | Chapter 7







Background: Middle East respiratory syndrome coronavirus (MERS-CoV) causes 
pneumonia with a relatively high case fatality rate in humans. Smokers and chronic 
obstructive pulmonary disease (COPD) patients have been reported to be more 
susceptible to MERS-CoV infection. Here, we determined the expression of MERS-
CoV receptor, dipeptidyl peptidase IV (DPP4), in lung tissues of smokers without 
airflow limitation and COPD patients in comparison to nonsmoking individuals (never-
smokers). Methods: DPP4 expression was measured in lung tissue of lung resection 
specimens of never-smokers, smokers without airflow limitation, COPD GOLD stage 
II patients and in lung explants of end-stage COPD patients. Both control subjects 
and COPD patients were well phenotyped and age-matched. The mRNA expression 
was determined using qRT-PCR and protein expression was quantified using 
immunohistochemistry. Results: In smokers and subjects with COPD, both DPP4 
mRNA and protein expression were significantly higher compared to never-smokers. 
Additionally, we found that both DPP4 mRNA and protein expression were inversely 
correlated with lung function and diffusing capacity parameters. Conclusions: We 
provide evidence that DPP4 is upregulated in the lungs of smokers and COPD 
patients, which could partially explain why these individuals are more susceptible to 
MERS-CoV infection. These data also highlight a possible role of DPP4 in COPD 
pathogenesis.
Introduction
Middle East Respiratory Syndrome coronavirus (MERS-CoV) is a newly emerging 
pathogen that mainly causes pneumonia with a relatively high case-fatality rate1,2. 
Since 2012, ~2000 laboratory-confirmed cases have been reported to the World Health 
Organization (WHO)2. The majority of cases occurred in familial or hospital-related 
clusters through human-to-human transmission3-5. The clinical course of MERS-CoV 
infection ranges from asymptomatic to acute respiratory distress syndrome with need 
for ventilatory support4-7. To infect its host, MERS-CoV attaches to its receptor, an 
exopeptidase called dipeptidyl peptidase 4 (DPP4), also known as CD268.
DPP4 is a type II transmembrane glycoprotein that is expressed in many cell types 
and organs in the body. It serves multiple functions among which post-translational 
cleavage of hormones and chemokines, T-cell activation, cell adhesion, and 
apoptosis9-11. In lungs, however, DPP4 is expressed at a minimum level12, mainly in 
alveolar epithelial cells and endothelial cells, and to a lesser extent in bronchiolar 
epithelial cells, airway submucosal glands, alveolar macrophages, lymphocytes, and 
plasmacytoid dendritic cells13-16. Importantly, the alveolar epithelial cells are the main 
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Several underlying comorbidities, including chronic lung diseases, have been reported 
to increase the risk of acquiring MERS-CoV infection18. Chronic obstructive pulmonary 
disease (COPD) is a highly prevalent chronic lung disease in older subjects and is 
currently the leading cause of death worldwide19,20. The most common cause of COPD 
is chronic cigarette smoking. The inflammatory response to cigarette smoke results 
in an excessive release of chemokines and cytokines with a subsequent high influx 
of immune cells19. Because smoking has also been reported to increase susceptibility 
to MERS-CoV infection18, we aimed to investigate the expression of the MERS-CoV 
receptor, DPP4, in a large well-phenotyped cohort of smokers, with and without 
airflow limitation, in comparison to age-matched individuals that never smoked (never-
smokers).
Methods
Human Lung Tissue Samples 
Table 1. Characteristics of study population (n=117)
Never-smokers Smokersa COPD IIb COPD III–-IVc 
Number 21 32 37 27 
Sex (M/F) 6/15d 23/9d 34/3d 12/14d 
Age (years) 65 (58–71) 64.5 (55–71) 65 (58–69) 56.5 (54–60)e,f,g 
Current- / ex-smoker - 19/13d 24/13d 0/27d 
Smoking history (PY) 0 (0–0) 33 (14–51)e 45 (40–60)e,f 30 (25–36)e,g 
FEV1 post (L) 2,4 (2,1–3) 2,7 (2,3–3,3) 2,1 (1,8–2,4)
e,f 0,7 (0,5–1)e,f,g 
FEV1 post (% predicted) 103 (92–117) 95 (92–112) 69 (61–75)
e,f 27 (21–33)e,f,g 
FEV1 / FVC post (%) 78 (74–83) 76 (72–79) 56 (51–61)
e,f 30 (27–35)e,f,g 
DLCO (% predicted) 88 (81–103) 83 (65–104) 67 (51–86)e,f 34 (32–37)e,f,g 
KCO (% predicted) 95 (86–121) 93 (78–106) 85 (65–107)e 52 (46–59)e,f,g 
ICS (yes/no) 1/19d 2/30d 16/21d 25/1d 
Abbreviations: COPD, chronic obstructive pulmonary disease; DLCO, diffusing capacity of the lung for carbon monoxide; FEV1 
forced expiratory volume in 1 second; FVC, forced vital capacity; IQR, interquartile range; KCO, transfer of carbon monoxide 
coefficient, ICS, inhaled corticosteroids; PY, pack years.
aSmokers without airflow limitation; bsubjects with COPD stage II as defined by the Global initiative for Obstructive Lung Disease 
(GOLD). Data are presented as median (IQR), Mann-Whitney U test:cSubjects with COPD stage III–IV as defined by GOLD. 
Fisher’s exact test:dP < .001. eP < .05 versus never smokers; fP < .05 versus smokers without COPD; gP < .05 versus COPD 
GOLD I–-II.
Lung resection specimens were obtained from patients diagnosed with solitary 
pulmonary tumors at Ghent University Hospital (Ghent, Belgium) or from explant 
lungs from end-stage COPD patients (UZ Gasthuisberg, Leuven, Belgium). Based 
on preoperative spirometry, diffusion capacity tests and questionnaires, patients were 
categorized as never-smokers with normal lung function, smokers without airflow 
limitation or patients with COPD. COPD severity was defined according to the Global 
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Initiative for Chronic Obstructive Lung Disease (GOLD) classification20. None of the 
patients were treated with neo-adjuvants chemotherapy. Lung tissue of patients 
diagnosed with solitary pulmonary tumor was obtained at a maximum distance from 
the pulmonary lesions and without signs of retro-obstructive pneumonia or tumor 
invasion and collected by a pathologist. Lung tissue of patients with COPD GOLD 
III-IV was obtained from lung explants of end-stage COPD patients undergoing lung 
transplantation. Written informed consent was obtained from all subjects. This study 
was approved by the medical ethical committees of the Ghent University Hospital 
(2011/114) and the University Hospital Gasthuisberg Leuven (S51577). Patient 
characteristics are listed in Table 1. Detailed patient characteristics per read-out are 
provided in supplementary Tables S1 and S2.
Human Proximal Bronchi Samples
Table 2. Characteristics of the Patients in Which Proximal Bronchi Biopsy Samples Were Obtained
Mean ± SD Median Range 
Age, years 56.3 ± 8.9 60 42–46 
Actual smoking, cigarettes/day 15.4 ± 7.4 13 6–30 
Pack-years 25.3 ± 11.2 21 5–50 
FEV1, % predicted 62.5 ± 12.9 65 34–93 
Reversibility, % predicted 5.3 ± 3.1 5 0–9.0 
PC20, mg/ml 
For histamine 1.7 ± 2.1 0.87 0.11–8 
For methacholine 4.6 ± 5.5 1.72 0.6–17.4 
Abbreviations: FEV1, forced expiratory volume in 1 second; SD, standard deviation; PC20, provocative concentration causing 
a 20% fall in FEV1. 
Table 3. Overview of the Cohorts and Samples Used in This Study
90 patients (21 never-smokers, 32 smokers without airflow limitation and 37 patients with COPD GOLD stage II) who under-
went lobectomia or pneumectomia due to lung cancer.
73/90 patients: samples for both qRT-PCR and IHC analyses.
5/90 patients: samples only for qRT-PCR analysis.
12/90 patients: samples only for IHC analysis.
27 patients with COPD GOLD stage III–IV who underwent lung transplantation due to end-stage COPD.
14/27 patients: samples for qRT-PCR analysis.
13/27 patients: samples for IHC analysis.
37 patients who underwent bronchial biopsies.
21/37 patients with moderate-to-severe COPD (ref): samples used for IHC staining.
16/37 control patients with airflow limitation (ref): samples used for IHC staining.
In this study we used resection lung tissue of 90 patients who underwent lobectomia/pneumectomia due to lung cancer, explant 
lung tissue of 27 end-stage COPD patients and bronchial biopsy tissue of 37 patients.
Abbreviations: COPD, chronic obstructive pulmonary disease; GOLD, global initiative for chronic obstructive lung disease; IHC, 
immunohistochemistry; qRT-PCR, quantitative reverse-transcription polymerase chain reaction.   
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Biopsy samples of proximal bronchi were obtained from 21 patients (17 male and 4 
female) with moderate-to-severe COPD previously recruited for a separate study21. 
Inclusion criteria were the following: chronic productive cough, age between 40 and 
70 years, current smokers, negative skin tests for inhalation allergens, FEV1 < 70% 
of predicted normal value or FEV1/VC < 0.70, reversibility of FEV1 < 10% pred after 
750 µg terbutaline inhalation, and suffering from moderate-to-severe bronchial hyper-
responsiveness, as determined by PC20 value upon challenge with histamine and 
methacholine. Exclusion criteria were a history of asthma, complaints of wheezing, 
recent respiratory tract infection, and recent or concurrent usage of anti-inflammatory 
drugs. Oral anti-inflammatory medication was discontinued for at least 3 months and 
inhaled glucocorticoids at least 6 weeks before the start of the study. Bronchoscopy 
was performed with an Olympus BF 1T10. At least 6 biopsies were taken from the 
bronchi of the right and the left upper and lower lobes using a fenestrated forceps 
(FB-18C or FB-20C). All was according to published guidelines22. The study was 
approved by the Medical Ethics Committee of the Erasmus University Medical Center 
Rotterdam, and written informed consent was obtained from all participants. Patient 
characteristics are listed in Table 2. Proximal bronchi biopsy samples of 16 healthy 
individuals (8 male and 8 female), previously described in the earlier study23, were 
used as negative control.
Purification of Human Lung Dendritic Cell-subsets
Lung dendritic cells (DC) were isolated from single cell suspensions of lung tissue 
of 3 patients, as described previously24. Lung tissues were rinsed, cut into small 
fragments, and incubated in digestion medium. Next, the samples were resuspended 
in Ca2+ and Mg2+–free PBS containing 10 mM EDTA and passed through a 40 µm 
filter. Subsequently, pulmonary mononuclear cells were separated on a Ficoll density 
gradient. The cells were labeled with anti-CD3-FITC, anti-CD19-FITC, anti-CD207-
PE, anti-CD209-PerCp-Cy5 and anti-BDCA2-APC and sorted on a FACSAria (BD 
Biosciences).
RNA Extraction and Real-Time Polymerase Chain Reaction Analysis
RNA extraction and polymerase chain reaction (PCR) analysis of lung tissue were 
performed as described previously25. RNA extraction from lung tissue blocks of 92 
subjects (18 never-smokers, 26 smokers without airflow limitation, 34 patients with 
COPD GOLD II, 14 patients with COPD GOLD IV) was performed with the miRNeasy 
Mini kit (Qiagen, Hilden, Germany), following manufacturer’s instructions. Next, 
complementary DNA (cDNA) was prepared with the iScript™ Advanced cDNA 
Synthesis Kit for RT-qPCR (Bio-Rad, Hercules, California). Taqman Gene Expression 
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Assays (Applied Biosystems, Forster City, California) were used to measure 
the expression of DPP4 and the reference genes Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH), Hypoxanthine phosphoribosyltransferase-1 (HPRT-1) 
and Succinate Dehydrogenase complex flavoprotein subunit A (SDHA). Data were 
analyzed using the standard curve method, and expression of DPP4 was calculated 
relative to the expression of the 3 reference genes, using the geNorm applet according 
to the guidelines and theoretical framework previously described25,26.
For human lung DC subsets, RNA extraction was performed with miRNeasy Mini 
kit (Qiagen, Hilden, Germany), whereas RNA amplification was with the Qiagen 
QuantiTect Whole Transcriptome kit, both following manufacturer’s instructions. DPP4 
expression in the DC subsets was calculated relative to the expression of GAPDH, 
HPRT1 and peptidylprolyl isomerase A (PPIA) as described previously25.
DPP4 Immunohistochemistry and Analyses
Sections obtained from formalin-fixed paraffin-embedded lung tissue blocks of 98 
subjects (19 never-smokers, 30 smokers without COPD, 36 subjects with COPD 
GOLD II, and 13 subjects with COPD GOLD III-IV) were incubated with anti-DPP4 
antibody (polyclonal goat-anti-human, R&D Systems, AF1180)16 after antigen 
retrieval with citrate buffer (Klinipath, Olen, Belgium). Next, slides were colored with 
diaminobenzidine (Dako, Carpinteria, California) and counterstained with Mayer’s 
hematoxylin (Sigma-Aldrich, St-Louis, Missouri). The isotype control was goat 
immunoglobulin G (IgG) from R&D Systems (Abingdon, UK) (AB-108-C). To co-
stain DPP4 with alveolar epithelial cells, anti-aquaporin 5 (Abcam, Cambridge, UK) 
(ab92320) and pro-surfactant C (Abcam) (ab90716) were used to detect, respectively, 
type I and type II alveolar cells and subsequently colored with Vector Blue (Vector, 
Peterborough, UK).
Quantitative scoring of the amount of DPP4-positive scoring in alveolar tissue and 
airway epithelium was performed using the Axiovision software (Zeiss, Oberkochen, 
Germany). In order to measure the area of DPP4-positive signal in alveolar tissue, 
15 images of alveolar tissue were recorded from an average of 3 tissue blocks per 
patient. The intensity of brown staining we wished to score was selected by means 
of selecting specific hue, lightness, and saturation values. The hue, saturation, and 
lightness values were identical for all images, therefore restricting our scoring to a 
specific signal. In every image the alveolar tissue was selected and the DPP4-positive 
signal was calculated only within the alveolar tissue and normalized to the area of 
alveolar tissue present in each image. The final score of each patient was the average 
ratio of DPP4-positive signal of the 15 images. In the airway epithelium, the amount 
of DPP4 signal was normalized to the length of the basement membrane (Pbm). The 
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final score of each patient was the average DPP4 staining in all airways present in all 
tissue blocks available of that patient. The number of airways per patient was between 
3 and 20.
DPP4 detection in the frozen samples of proximal bronchi was performed with 1 
µg/mL mouse anti-DPP4 monoclonal antibody (Santa Cruz Biotechnology, Dallas, 
Texas)16, after previously fixed with acetone and incubated with 10% normal goat 
serum (Dako, Glostrup, Denmark) for 1 hour at room temperature. These slides were 
subsequently stained with biotinylated goat antimouse Ig serum (1:50 in PBS/BSA 
plus 10% human serum) and with streptavidin alkaline phosphatase (1:50 in PBS/
BSA plus 10% human serum; Biogenex, Klinipath, Duiven, The Netherlands) for 30 
minutes each. A positive signal was revealed with New Fuchsin substrate (Chroma, 
Kongen, Germany). Counterstaining was performed with Gill’s hematoxylin. Negative 
control staining was performed by the substitution of the primary monoclonal antibody 
with an isotype antibody.
Statistical Analysis
Statistical analysis was per-formed with Sigma Stat software (SPSS 23.0, Chicago, 
Illinois), using Kruskal-Wallis, Mann-Whitney U, Fisher exact test, and Spearman 
correlation analysis. In addition, one-way analysis of variance (ANOVA) and T-tests 
were used for statistical analyses of the DC subsets. Characteristics of the study 
population are presented as a median and interquartile range. Differences at P-values 
< .05 were considered to be significant (*P < .05, **P < .01, and *** P < .001).
Results
DPP4 mRNA Expression is Upregulated in Lungs of Smokers and COPD Patients
Messenger RNA (mRNA) expression of DPP4 was analyzed in lung tissue of 92 
subjects. Lung tissue was derived from either resection tissue of lobectomy (never 
smokers, smokers without airflow limitation and patients with COPD GOLD stage II) or 
explant lungs of lung transplantation (patients with COPD GOLD stage III–IV). Patient 
characteristics are described in supplementary Table 1.
Compared to never-smokers, mRNA expression of DPP4 in lung tissue of smokers 
without airflow limitation and patients with COPD was significantly increased (Figure 
1A). Moreover, DPP4 mRNA expression in lung tissue of patients with COPD GOLD 
stage III–IV was significantly higher than in lung tissue of smokers without airflow 
limitation and patients with COPD GOLD stage II (Figure 1A). Quantification according 
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to smoking status (ex- vs. current smokers) is shown in Supplementary Figure S1. 
Furthermore, DPP4 mRNA expression was inversely correlated with the severity of 
airflow limitation: FEV1 (R = −0.376, P < .001) and FEV1/FVC ratio (R = −0.527, P < 
.001) (Figure 1B–C). In addition, the mRNA expression of DPP4 was also correlated 
inversely with the diffusing capacity of the lung, DLCO (R = −0.402, P < .001) and 
KCO (R = −0.408, P < .001) (Figure 1D–E). Linear regression analysis revealed that 
the association of DPP4 mRNA expression with the presence of COPD was significant 
even when corrected for age, sex, pack-years, and use of inhaled corticosteroids 
(Supplementary Table S3).
Figure 1. DPP4 mRNA expression 
in the lung tissues of smokers and 
COPD patients. A, DPP4 mRNA 
expression was measured by qRT-
PCR and normalized to three reference 
genes (GAPDH, HPRT-1, SDHA). 
DPP4 mRNA expression in the lungs 
of smokers and COPD patients is 
significantly higher in comparison to 
that of never smokers. B, Correlation 
of DPP4 mRNA expression with 
post-bronchodilator FEV1 values. C, 
Correlation of DPP4 mRNA expression 
with post-bronchodilator Tiffeneau index 
(FEV1/FVC). D, Correlation of DPP4 
mRNA expression with DLCO (diffusing 
capacity or transfer factor of the lung 
for carbon monoxide). E, Correlation 
of DPP4 mRNA expression with KCO 
(carbon monoxide transfer coefficient). 
**P < .01, ***P < .001. Abbreviations: 
COPD, chronic obstructive pulmonary 
disease; DLCO, diffusing capacity of the 
lung for carbon monoxide; FEV/FVC, 
forced expiratory volume in 1 second/
forced vital capacity; GOLD, global 
initiative for obstructive lung disease; 
KCO, transfer of carbon monoxide 
coefficient; mRNA, messenger RNA; 
qRT-PCR, quantitative reverse-tran-
scription polymerase chain reaction. 
Additionally, because dendritic cells (DCs) play a crucial role in antiviral immunity, we 
investigated whether DPP4 mRNA expression differs between DC subsets. Three DC 
subsets were sorted: langerin-positive DCs, DC-SIGN-positive DCs, and plasmacytoid 
DCs (pDCs). DPP4 mRNA was merely detected in pDCs (Supplementary Figure S2).
DPP4 Protein Expression is Upregulated in Lungs of Smokers and COPD 
Patients
DPP4 protein expression was studied in lung tissue of never-smokers, smokers 
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without airflow limitation, and COPD patients by using immunohistochemistry (IHC) 
staining. DPP4 was detected on the apical surface of bronchiolar epithelium and in the 
alveolar epithelial cells. In the alveoli, we observed that DPP4 protein was gradually 
increased from never-smokers to COPD GOLD stage III–IV (Figure 2). Additionally, we 
performed immunohistochemical staining of DPP4 with both aquaporin 5 (marker of 
type I alveolar epithelial cells) and pro-surfactant C (marker of type II alveolar epithelial 
cells), confirming that the upregulation of DPP4 protein can mainly be contributed to the 
alveolar epithelial cells (Figure 2I–L). In contrast, this increment was not observed in 
the bronchiolar epithelium (Figure 2A), as well as in the proximal bronchial epithelium 
(Figure 3). Furthermore, DPP4 was also detected in the endothelial cells, alveolar 
macrophages, immune cells in the submucosal region of airway epithelium, and 
lymphoid aggregates (Supplementary Figure S3). We further quantified DPP4 signals 
in the lung tissues of 98 subjects using the Axiovision software (Zeiss). Characteristics 
of these patients are presented in supplementary Table 2.
Figure 2. DPP4 protein expression in the bronchiolar epithelium and the alveolar tissues of never smoker, smoker, and COPD 
patients. Representative images of DPP4 staining in the bronchiolar epithelium (top row) and alveoli (middle and bottom row) of 
A,E,I, never-smoker, B,F,J, smoker without airflow limitation, C,G,K, subject with COPD GOLD stage II and D,H,L, subject with 
COPD GOLD stage III–IV. I–-L, are immunohistochemical stainings of DPP4 (brown) and aquaporin 5 (marker of type I alveolar 
epithelial cells) and pro-surfactant C (marker of type II alveolar epithelial cells) (both in blue). Co-staining of DPP4 with either 
one of the alveolar epithelial cell types results in a dark brown stain. DPP4 was mainly expressed in the alveolar epithelial cells 
and expressed the most intense in the COPD GOLD stage III–IV group. A 400× magnification was used for all photomicrographs 
in this figure. Abbreviation: COPD, chronic obstructive pulmonary disease; GOLD, global initiative for chronic obstructive lung 
disease.
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Figure 3. DPP4 staining in the proximal bronchi epithelium. 
Representative images of DPP4 staining in proximal bronchial 
epithelium and submucosal glands of the healthy control sub-
ject with COPD GOLD stage II. DPP4 was hardly detected in 
the apical surface of the proximal bronchi epithelium of both 
healthy control and COPD patients. Submucosal glands here 
served as  positive control for DPP4 staining. Abbreviation: 
COPD, chronic obstructive pulmonary disease.
Compared to the never-smokers, DPP4 
protein expression was significantly in-
creased in the alveolar epithelial cells 
of smokers and patients with COPD. 
DPP4 protein expression was the high-
est in patients with COPD GOLD stage 
III–IV (Figure 4A). Quantification of DPP4 
protein expression according to smoking 
status (ex- vs. current smoking) is shown 
in Supplementary Figure S4. Similar to 
DPP4 mRNA expression, DPP4 protein 
was also inversely correlated with lung 
function parameters FEV1 (R = −0.567, P 
< .001) and FEV1/FVC ratio (R = −0.689, 
P < .001); as well as diffusing capacity 
parameters DLCO (R = −0.603, P < .001) 
and KCO (R = −0.563, P < .001). Linear 
regression analysis revealed that the as-
sociation of alveolar DPP4 expression 
with the presence of COPD was signifi-
cant even when corrected for age, gen-
der, pack-years, and use of inhaled corti-
costeroids (Supplementary Table S4).
Figure 4. DPP4 protein expression in the lung tissues of 
smokers and COPD patients. , DPP4 protein expression was 
analyzed by using Axiovision software (Zeiss). The area of 
DPP4 positive signal was normalized to the total area of cells 
present in each analyzed image. DPP4 protein expression in 
the lungs of smokers and COPD patients is significantly high-
er in comparison to that of never smokers. B, Correlation of 
alveolar DPP4 protein expression with post-bronchodilator 
FEV1 values. C, Correlation of alveolar DPP4 protein expres-
sion with post-bronchodilator Tiffeneau index (FEV1/FVC). D, 
Correlation of alveolar DPP4 protein expression with DLCO 
(diffusing capacity or transfer factor of the lung for carbon 
monoxide). E, Correlation of alveolar DPP4 protein expres-
sion with KCO (carbon monoxide transfer coefficient). **P 
< .01, ***P < .001. Abbreviation: COPD, chronic obstructive 
pulmonary disease.
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Our study investigated the expression of the MERS-CoV receptor, DPP4, in lung 
tissues of smokers without airflow limitation and COPD patients in comparison to 
never-smokers. As previously reported, DPP4 is mainly detected in the alveolar 
epithelial cells of the lungs, the main target of MERS-CoV infection13,16. Among the 
dendritic cells, we found that DPP4 mRNA is mainly expressed in pDCs; confirming 
in vitro data showing that among the antigen presenting cells, pDCs produce large 
amounts of type I and III interferon upon contact with MERS-CoV14. Most importantly, 
we provide evidence that DPP4 is upregulated in the lungs, both at mRNA and protein 
level, not only in COPD patients but also in that of smokers. This indicates that these 
individuals may be more susceptible to MERS-CoV, supporting both smoking and 
COPD as risk factors for MERS-CoV infection18. These results are in line with a recent 
study describing a higher DPP4 expression in lungs of 4 COPD patients compared to 
16 control subjects of different ages13.
In this study, we did not find any evidence of DPP4 upregulation in the bronchial and 
bronchiolar epithelium in the lungs of smokers and COPD patients, suggesting that 
DPP4 upregulation in pulmonary epithelia is restricted to the alveolar epithelial cells. 
Previous studies have shown that DPP4 is limitedly expressed in the bronchial and 
bronchiolar epithelium, and even absent at the apical surface of the nasal respiratory 
and olfactory epithelium of humans13,16. Future studies are needed to assess whether 
DPP4 upregulation is specific for the alveolar epithelial cells or also occurs in the upper 
respiratory tract epithelium. Additionally, the importance of alveolar macrophages in 
the pathogenesis of MERS-CoV needs further research as these cells also express 
DPP4 and patrol the alveoli while being in close contact with the alveolar epithelial 
cells.
It is currently unclear how DPP4 is upregulated in the lungs of smokers and COPD 
patients. Several cytokines have been reported to upregulate DPP4 in vitro. TGF-β2, 
for instance, could upregulate DPP4 protein expression and enzymatic activity in 
primary human endothelial cells27, whereas interleukin 13 (IL-13) has been reported 
to increase DPP4 mRNA expression in human primary bronchial epithelial cells28. On 
the other hand, in COPD pathogenesis, several cytokines—such as IL-6, IL-8, and the 
TGF-β superfamily—have been described to play important roles29,30. Further studies 
are needed to identify cytokines that could both upregulate DPP4 in the lung and 
influence COPD pathogenesis.
We also showed that DPP4 mRNA and protein expression were inversely correlated 
with lung function and diffusing capacity parameters. These data suggest a possible 
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role of DPP4 in COPD pathogenesis. DPP4 is an exopeptidase responsible for 
cleaving chemokines and this alters the biological function. Moreover, DPP4 is able 
to activate T cells and induce production of pro-inflammatory cytokines, which later 
could affect the development of COPD19,31-33. Furthermore, DPP4 is also capable of 
influencing migration of immune cells by activating or deactivating chemokines in an 
inflammatory or tumor environment9,11. Interestingly, soluble DPP4 in the serum of 
COPD patients has been reported to be significantly lower compared to that of non-
COPD controls34,35. It remains possible that in COPD patients, DPP4 concentration is 
low in the serum and high in the lungs to facilitate migration of certain immune cells 
into or out of the lungs.
Our study has several strengths; first, we included a large number of patients which 
have been thoroughly characterized. Second, to eliminate the possible interference 
of the presence of malignancy in our patients, we also included lung tissue derived 
from explant lungs of end-stage COPD patients, devoid of malignancy. A possible 
limitation of our study might be the sex imbalance in the groups with, respectively, a 
male predominance in the COPD groups and a female predominance in the never-
smokers. However, it should be noted that linear regression analyses indicated that sex 
does not significantly contribute to the differences in expression of membrane-bound 
DPP4. Our data are in line with recent analyses of soluble DPP4 in serum in patients 
with COPD versus non-COPD controls indicating that there is no relationship between 
sex and DPP4 levels34. It is also important to acknowledge that there are other factors 
related to COPD that could contribute to the increased MERS-CoV susceptibility 
independent of DPP4. For instance, COPD patients are mostly in advanced age and 
more prone to many other pulmonary infections during hospitalization36. Besides that, 
COPD is associated with systemic inflammation, which might also cause insufficient 
host immune response against pathogens19,37.
In conclusion, because smoking is the most common etiology of COPD20, our data 
highlight the association between chronic exposure to cigarette smoking and DPP4 
upregulation in the lungs, as well as partially explain the increased susceptibility of 
smokers and COPD patients to MERS-CoV infection18. It is imperative to try replicating 
this observation in an animal model in order to further dissect the molecular pathway 
of DPP4 upregulation in the lungs.
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Supplementary table S1. Characteristics of study population (RT-PCR study) (n = 92)
 Never-smokers Smokersç COPD II%     COPD III-IV$
 Number 18 26 34 14
Gender ratio (M/F) 6/12 # 19/7 # 31/3 # 8/6 #
Age (years) 65 (56-70) 63 (55-70) 66 (58-69)§ 56 (54-60)*§†
Current- / ex-smoker - 16/10 22/12 0/14
Smoking history (PY) 0 (0-0) 28 (15-45)* 45 (40-60)*§ 30 (25-30)*†
FEV1 post (L) 2,7 (2,3-3,2) 2,7 (2,3-3,3) 2,0 (1,8-2,4)*§ 0,7 (0,7-0,9)*§†
FEV1 post (% predicted) 102 (92-116) 95 (93-112) 68 (61-75)*§ 26 (20-32)*§†
FEV1 / FVC post (%) 78 (75-83) 75 (71-79)* 56 (53-60)*§ 32 (27-35)*§†
DLCO (% predicted) 90 (80-105) 80 (61-102) 67 (51-87)* 35 (33-41)*§†
KCO (% predicted) 103 (88-123) 91 (68-107)* 87 (62-108)* 59 (50-65)*§†
ICS (yes/no) 0/18 # 1/25 # 15/19 # 13/1 #
Footnote:
M/F (male/female); PY (pack years); FEV1 (forced expiratory volume in 1 second); FVC (forced vital capacity); DLCO (diffusing 
capacity of the lung for carbon monoxide); KCO (transfer of carbon monoxide coefficient), ICS (inhaled corticosteroids), çsmokers 
without airflow limitation, %subjects with COPD stage II as defined by the Global initiative for Obstructive Lung Disease (GOLD), 
$subjects with COPD stage III-IV as defined by GOLD
Data are presented as median (IQR), Mann-Whitney U test: * P < 0,05 versus never smokers; § P < 0,05 versus smokers without 
COPD; † P < 0,05 versus COPD GOLD I-II
Fisher’s exact test: # P < 0,001
Supplementary table S2. Characteristics of study population (IHC study) (n = 98)
 Never-smokers Smokersç COPD II%     COPD III-IV$
Number 19 30 36 13
Gender ratio (male/female) 5/14 # 22/8 # 34/2 # 5/8 #
Age (years) 64 (57-69) 64 (55-70) 65 (59-69)§ 59 (56-62)*§†
Current- / ex-smoker - 18/12 23/13 0/13
Smoking history (PY) 0 (0-0) 34 (16-58)* 46 (39-60)*§ 36 (30-45)*†
FEV1 post (L) 2,6 (2,3-3,0) 3.1 (2,4-3,4) 2,0 (1,8-2,4)*§ 0,6 (0,5-1)*§†
FEV1 post (% predicted) 103 (91-115) 95 (93-114) 69 (60-75)*§ 29 (21-35)*§†
FEV1 / FVC post (%) 78 (74-83) 74 (71-78) 56 (50-58)*§ 27 (25-36)*§†
DLCO (% predicted) 88 (80-103) 83 (59-105) 70 (54-87)*§ 33 (28-36)*§†
KCO (% predicted) 95 (86-121) 90 (70-98) 89 (69-107)* 46 (25-55)*§†
ICS (yes/no) 1/18 # 2/28 # 15/21 # 13/0 #
Footnote:
M/F (male/female); PY (pack years); FEV1 (forced expiratory volume in 1 second); FVC (forced vital capacity); DLCO (diffusing 
capacity of the lung for carbon monoxide); KCO (transfer of carbon monoxide coefficient), ICS (inhaled corticosteroids), ç smok-
ers without airflow limitation,      %subjects with COPD stage II as defined by the Global initiative for Obstructive Lung Disease 
(GOLD), $subjects with COPD stage III-IV as defined by GOLD
Data are presented as median (IQR), Mann-Whitney U test: * P < 0,05 versus never smokers; § P < 0,05 versus smokers without 
COPD; † P < 0,05 versus COPD GOLD I-II
Fisher’s exact test: # P < 0,001
Supplementary table S3. Linear regression model with DPP4 mRNA expression as the dependent variable
Parameter B Std. Error t Sig. 95% Confidence IntervalLower Bound Upper Bound
Intercept -,261 ,270 -,965 ,337 -,798 ,277
COPD GOLD III-IV ,837 ,165 5,059 ,000 ,508 1,166
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COPD GOLD II ,328 ,164 1,995 ,049 ,001 ,656
Smoker* ,252 ,131 1,916 ,059 -,010 ,514
Never-smoker 0a . . . . .
Male gender ,032 ,085 ,380 ,705 -,137 ,202
Female gender 0a . . . . .
ICS yes -,115 ,110 -1,046 ,299 -,334 ,104
ICS no 0a . . . . .
Pack-years ,001 ,002 ,271 ,787 -,004 ,006
Age -,001 ,004 -,195 ,846 -,009 ,008
Footnote:
a. This parameter is set to zero because it is redundant. COPD stage III-IV : severe and very severe COPD according to the 
guidelines of the Global initiative for Obstructive Lung Disease (GOLD). COPD stage II: moderate COPD according to the 
guidelines of GOLD. *Smoker without airflow limitation. ICS: inhaled corticosteroids.
Supplementary table S4. Linear regression model with alveolar DPP4 protein expression as the dependent variable.
Parameter B Std. Error t Sig. 95% Confidence IntervalLower Bound Upper Bound
Intercept -3,203 ,644 -4,977 ,000 -4,487 -1,920
COPD GOLD III-IV 1,652 ,392 4,213 ,000 ,870 2,435
COPD GOLD II 1,036 ,342 3,032 ,003 ,354 1,717
Smoker* ,413 ,293 1,410 ,163 -,171 ,998
Never-smoker 0a . . . . .
Male gender -,156 ,209 -,744 ,459 -,572 ,261
Female gender 0a . . . . .
ICS yes -,153 ,241 -,632 ,529 -,634 ,329
ICS no 0a . . . . .
Pack-years ,002 ,004 ,409 ,684 -,007 ,011
Age ,004 ,010 ,427 ,671 -,016 ,024
Footnote:
a. This parameter is set to zero because it is redundant. COPD stage III-IV : severe and very severe COPD according to the 
guidelines of the Global initiative for Obstructive Lung Disease (GOLD). COPD stage II: moderate COPD according to the 
guidelines of GOLD. *Smoker without airflow limitation. ICS: inhaled corticosteroids.
Supplementary Figure 1. mRNA expression of DPP4 in 
lung tissue of 92 subjects according to smoking status. DPP4 
mRNA expression measured by qRT-PCR and normalized 
to 3 reference genes (GAPDH, HPRT-1, SDHA). *p<0.05, 
**p<0.01, ***p<0.001. 
Supplementary figure S2. mRNA expression of DPP4 in 
dendritic cell subsets. DPP4 mRNA expression measured 
by qRT-PCR and normalized to 3 reference genes (GAPDH, 
HPRT-1, PPIA). **p<0.01.
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Supplementary figure S3. Localisation of DPP4 expression in the human lungs. DPP4 was detected with anti-DPP4 polyclonal 
goat anti-human antibody and visualized in brown with diaminobenzidine. DPP4 was found in the immune cells located in the 
submucosal region of the airway (A), the apical surface of bronchiolar epithelium (A, B), the endothelium and the lymphoid ag-
gregate (D), as well as the lymphoid follicle (E). Negative controls were stained with isotype antibody (goat IgG). Negative control 
staining on bronchiolar epithelium and lymphoid follicle were presented here as a representative (C, F).
Supplementary figure S4. DPP4 protein expression in alveolar tissue of 98 subjects according to smoking status. Analyses of 
DPP4 protein expression in the lung sections was performed with the Axiovision software (Zeiss). The amount of DPP4 positive 
cells was normalized to the total amount of cells present in the analysed image.
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Background: MERS-coronavirus (MERS-CoV) causes lower respiratory disease 
in humans that may be fatal in some. The pathogenesis of MERS-CoV in humans, 
however, is ill-defined, partly due to the lack of autopsies performed. Here we aimed to 
gain insight into MERS-CoV pathogenesis using the lungs obtained from a fatal human 
MERS-CoV case and experiments in non-human primates. Methods : We analyzed 
histopathological lesions and the expression of MERS-CoV receptor, dipeptidyl 
peptidase-4 (DPP4), in the lungs of a fatal human case. We then investigated DPP4 
expression in different non-human primate species infected with MERS-CoV or other 
viruses. Results: MERS-CoV was detected in the type I and II pneumocytes in the 
lungs of a fatal human MERS-CoV case, consistent with DPP4 expression in these 
cells. In contrast, in healthy human lungs, DPP4 is almost exclusively expressed in 
type II pneumocytes. In cynomolgus macaques, we observed a similar restricted DPP4 
localization, consistent with virus replication in type II pneumocytes. Virus replication 
in the lungs was mainly detected at day 1 post inoculation but no upregulation of 
DPP4 in type I cells was observed. Instead, DPP4-expressing type I pneumocytes 
were found in cynomolgous macaques that developed severe pneumonia due to 
influenza A pH1N1, H5N1, and SARS-CoV. Conclusions: DPP4-expressing type 
I pneumocytes are present in the lungs of a fatal MERS-CoV case and in that of 
influenza A pH1N1, H5N1, and SARS-CoV infected macaques, but almost absent in 
the lungs of healthy humans and macaques. These cells may broaden the tropism of 
MERS-CoV in the lungs.
Introduction
Coronaviruses (CoVs) are known to cause respiratory and enteric infections in diverse 
animal species and humans 1-3. Among six CoVs known to infect humans, four of them, 
i.e. HKU1, 229E, OC43, and NL63-CoV, mainly cause mild upper respiratory tract 
infection. The other two, i.e. severe acute respiratory syndrome coronavirus (SARS-
CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV), result in 
lower respiratory tract infection, ranging in clinical manifestations from asymptomatic 
to severe 3-5. Severe SARS-CoV and MERS-CoV infections are often characterized 
by diffuse alveolar damage (DAD) lesions in the lungs, acute respiratory distress 
syndrome and fatal outcome 6,7. 
Studies on SARS-CoV pathogenesis have revealed that DAD is a multifactorial 
phenomenon requiring interplay between viral and host factors. Adaptations within 
the S protein seen during the outbreak, have been shown to result in increased affinity 
of this virus to its receptor, angiotensin converting enzyme 2 (ACE2) – and may have 
101
Part 2 | Chapter 8 




improved replication of this virus as well as contributed to the unusual severity of 
SARS 8,9. Since ACE2 is expressed in both type I and II pneumocytes in the lung, 
SARS-CoV is able to replicate efficiently in both cell types 10-14. Studies in macaques 
indicated that especially type I cells may be an important target during SARS, and 
protecting these cells from infection could reduce DAD as well as improve clinical 
outcome 10. Another crucial factor in the pathogenesis of SARS-CoV-associated DAD 
is the delay in type I interferon (IFN) response. Inability to rapidly mount sufficient type 
I IFN upon SARS-CoV infection, for example due to aging, promotes the accumulation 
of pathogenic inflammatory monocyte-macrophages and induces DAD 13,15-17. 
Unlike SARS-CoV, no major changes have been observed in the receptor binding 
domain of the MERS-CoV spike protein that interacts with dipeptidyl peptidase-4 
(DPP4) after zoonotic transmission from dromedaries to humans  18. In addition, 
different from SARS, MERS-CoV infection may cause asymptomatic to mild clinical 
manifestations in a substantial fraction of individuals infected 19-21. This suggests that 
host factors rather than viral factors may have a determining role in the clinical outcome 
of MERS-CoV infection. Partly due to the limited number of autopsy reports on fatal 
MERS-CoV cases, there is currently a gap in our understanding of the pathogenesis 
of MERS-CoV in humans 22,23. Our study aimed to gain insight in the host factors-
associated with MERS-CoV pathogenesis by using post-mortem lung samples 
obtained from a fatal human MERS-CoV case 24, and by performing experimental 
MERS-CoV infection in cynomolgus macaques.
Methods
Lung tissue samples from a fatal human MERS-CoV case and healthy controls 
This case was once briefly reported in PROMED mail 24. Family consent was granted 
for limited postmortem tissue retrieval, consisting of a 20-cm-long midline incision in 
the lower chest and upper abdomen, from which tissue samples were collected from 
both lungs. These tissues were then fixated in 10% formalin and embedded in paraffin 
for further analysis (see Supplementary Methods). As healthy controls, we used lung 
tissue samples with minimal histopathological lesions obtained from healthy donors or 
patients with nonmalignant tumors, as described previously 25.
Tissues samples of different non-human primate species
Respiratory tract tissues from cynomolgus macaques, both young-adult (3-5 years old) 
and aged (10-19 years old), three animals each, were obtained from mock-infected 
animals from previous experiments 13,14. Lung tissues of three rhesus macaques were 
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acquired from simian varicella virus-infected macaques that were sacrificed at day 21 
post inoculation (pi). These rhesus macaques developed an asymptomatic infection 
and no virus detected in bronchial alveolar lavage samples. Lung tissues of two mock-
infected African green monkeys were taken from past experiment 12. Three common 
marmoset’s lung tissues were received from Biomedical Primate Research Center 
in Rijswijk, the Netherlands. One was a newborn baby, another one was 2 years old 
female marmoset, and the last one was 4 years old male marmoset. Lung tissues from 
cynomolgus macaques infected with SARS-CoV, influenza A H5N1 virus, seasonal 
influenza A H1N1 virus, and pandemic influenza A H1N1 virus were obtained from 
previous studies 6,12,13,26,27. These tissues were analyzed with immunohistochemistry 
and immunofluorescence-based techniques (see Supplementary Methods). 
In vivo and ex vivo infection experiment in cynomolgus macaques
In vivo MERS-CoV infection experiments were performed under BSL 3 conditions 
at the Erasmus Medical Centre in Rotterdam using an animal research protocol 
approved by the Institutional Animal Welfare Committee (EMC2808, nr 122-12-32). 
Ten immunocompetent young-adult cynomolgus macaques were inoculated with 
MERS-CoV (EMC/2012 isolate) 7 through intranasal and intratracheal inoculation. 
Four animals were sacrificed at day 1 pi, four at day 4, and two at day 14. Nasal 
and throat swabs were collected at multiple time points. Various tissue samples were 
collected upon necropsy. Presence of viral RNA, virus nucleoprotein, and infectious 
virions were analyzed in these samples. IFN-β, IL-6, IL-8, CCL3, and CCL20 mRNA 
expression in the lungs were measured. As a contrast to understand MERS-CoV 
pathogenesis, we performed experimental NL63-CoV infection in four macaques 
(EMC1519, nr 122-08-17) and ex vivo MERS-CoV infection on nasal and lung tissues 
of young-adult cynomolgus macaques, as well as reanalyzed samples obtained from 
previous SARS-CoV (HKU-39849 strain) infection experiment in similar animal models 
sacrificed at day 4 pi 12. Details are described in supplementary methods. 
Results
Histopathological analysis of postmortem lung tissue samples from a fatal 
human MERS-CoV case
This human case was once briefly reported earlier in a PROMED mail [24]. A 56-year-
old male was admitted to the hospital due to acute respiratory illness. The patient was 
continuously deteriorating thus required assisted ventilation. Nose and throat swabs 
were positive for influenza A subtype H1N1pdm09 upon admission. MERS-CoV viral 
RNA was detected starting at day 14 post onset. The patient developed multi-organ 
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failure and succumbed to a fatal outcome. Complete history of this patient is described 
in the supplementary information. 
Figure 1. Histopathology and histochemistry analysis on the lungs of a fatal MERS-CoV case. Hyaline membrane (A, arrow-
heads), hypertrophy and hyperplasia of type II pneumocytes (B, arrows), and syncytia (C) are observed. MERS-CoV nucleocap-
sid protein is detected in both type I (arrow) and type II pneumocytes (arrowhead) (D). MERS-CoV RNA is detected in epithelial 
cells (E).  MERS-CoV is also detected in alveolar macrophages (F). In healthy human lungs, DPP4 is expressed in type II pneu-
mocytes (arrow) and hardly detected in type I pneumocytes (arrowhead) (G). While in the lungs of the fatal MERS-CoV case, 
DPP4 is expressed in both type II (H, arrow) and type I cells (I, arrowhead). ACE2 is expressed abundantly in the healthy lungs 
(J) and the lungs of the fatal MERS-CoV case (K). Isotype control for all antibodies used in this analysis were clean (represented 
in L). DPP4 and ACE2 are indicated in red. Figure A is taken in 100x magnification; figure B, D-L in 400x; while figure C in 1000x.
Upon histopathological analysis, we found marked alveolar haemorrhage, thickened 
fibrillar alveolar walls missing epithelial lining, the presence of hyaline membranes, 
and flooding of alveolar lumina by neutrophils, macrophages, and sloughed epithelial 
cells, mixed with oedema fluid and fibrin. There was hypertrophy and hyperplasia 
of type II pneumocytes and bronchiolar epithelial cells. Both cell types occasionally 
formed syncytial cells pathognomonic for virus infection (Figure 1A-C). MERS-CoV 
nucleocapsid protein was detected in both type I pneumocytes, the thin squamous 
epithelial cells, and type II pneumocytes, the larger and more cuboidal epithelial cells 
(Figure 1D). MERS-CoV RNA was also detected in these keratin positive pneumocytes 
(Figure 1E, supplementary figure S1A). Besides pneumocytes, MERS-CoV was also 
detected in CD68 positive alveolar macrophages (Figure 1F, supplementary figure 
S1B), likely due to phagocytosis of infected cellular debris based on the granular 
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cytoplasmic expression of virus antigen and the advanced stage of the pathological 
changes. These results support diffuse alveolar damage as the main histopathology 
finding in severe MERS-CoV infection and pneumocytes as the replication site of this 
virus. 
We subsequently analyzed DPP4 expression in the lungs of this patient. In healthy 
human lungs, DPP4 is almost exclusively expressed in type II pneumocytes (Figure 
1G), in line with previous reports 25,28. In contrast, in the lungs of the fatal MERS-
CoV case, we observed that DPP4 is expressed both in type I and II pneumocytes 
(Figure 1H,I). Unlike DPP4, ACE2 is abundantly expressed in healthy lungs (Figure 
1J) as well as in the lungs of the fatal human MERS-CoV case (Figure 1K), consistent 
with previous studies 11,29. The isotype controls for each of the staining showed no 
background signal as represented in figure 1L. 
DPP4 expression in the lungs of different non-human primate species
Figure 2. DPP4 expression in the lungs of different non-human primates. DPP4 is expressed in both type I and II pneumocytes 
in the lungs of common marmosets, while in other non-human primate species, it is almost exclusively expressed in type II 
pneumocytes. DPP4 is indicated in red. Pictures are made in 400x magnification.. 
We further studied DPP4 expression in more detail by investigating lungs of different 
non-human primate species. We found that DPP4 is expressed in both type I and II 
pneumocytes in the lungs of common marmosets, while in that of other non-human 
primate species, DPP4-expressing type I pneumocytes were hardly detected (Figure 
2). In rhesus macaques, MERS-CoV causes mild-to-moderate pneumonia 30,31, while 
in common marmosets this virus may induce severe-to-fatal pneumonia 32,33. We did 
not find a distinct difference in DPP4 protein expression between the lungs of young-
adult and advanced-age cynomolgus macaques (Figure 2), but DPP4 mRNA level in 
the lungs of advanced-age cynomolgus macaques was significantly higher compared 
to the young-adults (Supplementary figure S2). 
MERS-CoV infection hardly causes clinical manifestations in cynomolgus 
macaques
We then performed a MERS-CoV infection experiment in young-adult cynomolgus 
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macaques to better understand MERS-CoV tropism and replication in the lungs. 
All animals developed a mild increase in body temperature during the experiment 
(Supplementary Figure S3A). Upon autopsy, the macroscopic lung lesions were found 
to be mild, except for one macaque sacrificed at day 4 pi that developed severe 
suppurative bronchopneumonia due to Escherichia coli coinfection (Supplementary 
Figure S3B). The bronchial lymph nodes and tonsils were enlarged in all animals. 
Seroconversion and neutralizing antibodies were detected in the animals sacrificed 
at day 14 pi.
MERS-CoV does not replicate in the DPP4 negative upper respiratory tract 
epithelium
Figure 3. MERS-CoV replication and 
DPP4 expression in the upper respira-
tory tract. MERS-CoV RNA is detected 
in the nasal and throat swabs of all ma-
caques up to day 11 pi (A,B). None of 
the samples showed detectable infec-
tious virus titres, except for one throat 
swab (*) taken from the macaque that 
developed bacterial co-infection. Dot-
ted lines indicated detection limit of 
the assays. Data from each sample is 
indicated by black circles and the hor-
izontal line represents the median val-
ue. Neither MERS-CoV nucleocapsid 
protein nor MERS-CoV receptor, DPP4, 
are detected in the nasal epithelium of 
cynomolgus macaques (C). In contrast, 
NL63-CoV nucleocapsid pro-tein is 
detected in the nasal olfactory epithe-
lium, while NL63-CoV receptor, ACE2, 
is detected in both nasal olfactory and 
respiratory epithelium (C). In the ex 
vivo MERS-CoV infection experiment, 
MERS-CoV nucleocapsid protein is de-
tected in the pneumocytes but not in the 
nasal epithelial cells (D). Non-infected 
tissues (mock) are used as negative 
control. Figures C and D are taken at 
400x. DPP4 is mainly detected in the 
type II pneumocytes (arrows) and grad-
ually became unde-tected from lower to 
the upper part of the respiratory tract 
(E). The kidney is used as a control 
tissue due to its high DPP4 expression. 
Pictures of the terminal bronchioles and 
alveolus are taken at 400x magnifica-
tion, while the othersat 200x. 
In the nasal and throat swab samples, MERS-CoV RNA was detected from day 1 pi, 
but the levels were generally low (Fig 3A,B). No infectious virus was detected, except 
in one throat swab sample from the macaque with bacterial co-infection (10 TCID50/ml, 
labelled with an asterisk in Figure 3B). We detected no MERS-CoV antigen in the upper 
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respiratory tract tissues even at day 1 pi, supporting the virus titration result. Unlike 
MERS-CoV, NL63-CoV that uses ACE2 as its receptor 34, can infect nasal epithelium. 
NL63-CoV-infected macaques developed mild clinical signs and did seroconvert (virus 
neutralization titres of 40-80), mimicking clinical manifestations in humans 35. NL63-
CoV preference to infect nasal olfactory epithelium is currently unclear. However, 
NL63-CoV has been described to use heparan sulfate as attachment factor; and in 
mice this polysaccharide is selectively expressed at the apical surface of  the olfactory 
but not the respiratory epithelium 36,37. In contrast to ACE2, DPP4 is not expressed in 
the nasal epithelium (Figure 3C). Using ex vivo infection of respiratory tract tissues 
we also observed that  nasal epithelium is not susceptible to MERS-CoV infection 
(Figure 3D).
MERS-CoV replication is confined to type II pneumocytes that express DPP4 
Figure 4. MERS-CoV replication and DPP4 expression in the lungs. In the lung, large amounts of MERS-CoV RNA were 
detected at day 1 and 4 pi, but infectious MERS-CoV is only largely detected at day 1 pi (A). Three out of four lung homogenate 
samples from day 4 pi are negative in virus titration. Dotted lines indicated detection limit of the assays. The data is presented 
in median ± interquartile range, while data from each sample is shown as black circles. MERS-CoV nucleoprotein, MERS-CoV 
RNA, and double-stranded RNA are detected mainly in the type II pneumocytes at day 1 pi (B). HE staining showed hardly any 
histopathological changes in the lungs of these macaques. DPP4 is mainly expressed in type II pneumocytes (arrows) at both 
time points (B). All these pictures are taken at 400x. The percentage of MERS-CoV nucleoprotein positive cells in the lungs of 
macaques sacrificed at day 1 pi is scored qualitatively. The percentage is generally low since most of the areas are uninfected 
(D).
In the respiratory tract of cynomolgus macaques, DPP4 is absent in the nasal epithelium 
but predominantly expressed in type II pneumocytes (Figure 3E). Its expression in the 
lungs is relatively low compared to that in the kidney and small intestine (Figure 3E 
and Supplementary Figure S4). This DPP4 distribution is comparable to humans, in 
which DPP4 is absent in the nasal epithelium, while its expression in the lungs, liver, 
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and colon are lower compared to that in kidney and small intestine 25,38.
Upon MERS-CoV inoculation, both viral RNA and infectious virus were detected in the 
lungs of cynomolgus macaques at day 1 pi, but infectious virus was hardly detected 
at day 4 pi (Figure 4A). No infectious virus was found in other respiratory and extra-
respiratory tissues, while virus RNA was detected in the urine, large intestines, and 
kidneys of only one macaque sacrificed at day 1 pi. MERS-CoV nucleoprotein was 
detected in the lungs at day 4 pi in very few cells, supporting rapid clearance of the 
virus. At day 1 pi, MERS-CoV nucleoprotein, MERS-CoV RNA, and double-stranded 
RNA were mainly found in the type II pneumocytes. Histopathological lesions and 
immune cell infiltration were minimal in these lungs (Figure 4B). DPP4 was still mainly 
expressed in type II pneumocytes both at day 1 and day 4 pi (Figure 4B). Together, 
these data indicate that MERS-CoV replication is confined to type II pneumocytes 
where DPP4 is predominantly expressed and upregulation of DPP4 on type I cells 
was not observed during the infection.  
Type I interferon is locally expressed in the lungs of MERS-CoV-infected 
macaques 
We subsequently investigated the extent of MERS-CoV infection in the lungs of these 
macaques at day 1 pi. We found relatively few MERS-CoV infected cells in the lungs, 
with two out of four macaques, having almost no MERS-CoV-infected cells (Figure 
4C). These data may indicate that MERS-CoV replication is already restricted at day 
1 pi, possibly due to early innate immune response. In line with confined MERS-
CoV replication, IFN-β, IL8, IL6, CCL3, and CCL20 mRNA expression was detected 
in several lung samples at day 1 pi (Figure 5A). We have previously reported that 
MERS-CoV is sensitive towards type I IFN and does not block pSTAT1 translocation, 
a crucial step for host cells to initiate IFN production via JAK-STAT signaling 
pathway 39. In the lungs of MERS-CoV-infected macaques at day 1 pi, pSTAT1 was 
expressed in pneumocytes and alveolar macrophages, in areas surrounding virus-
infected pneumocytes and blood vessels. Similar findings were observed in the 
lungs of SARS-CoV-infected macaques obtained from previous experiment 14, but 
not in the lungs of mock-infected macaques and MERS-CoV-infected lung explants 
(Figure 5B). This suggests that type I IFN is initially produced by infiltrating rather 
than residential immune cells. pSTAT1 colocalized with MERS-CoV nucleoprotein in 
several pneumocytes, but not with SARS-CoV nucleoprotein (Figure 5B), supporting 
that SARS-CoV is more resistant to type I IFN compared to SARS-CoV 39,40. Upon 
reanalyzing past SARS-CoV infection samples 12,13, we found that at day 4 pi, viral 
RNA levels, IFN-β, IL-6, and CCL3expression were significantly higher in the lungs of 
SARS-CoV-infected macaques compared to that of MERS-CoV-infected macaques 
(Figure 5C, Supplementary figure S5). SARS-CoV infectious virions were also still 
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abundantly detected at day 4 pi 12, supporting the ongoing SARS-CoV replication in 
the lungs at this time point, while MERS-CoV is more rapidly contained. 
Figure 5. Cytokine expression in the lungs of MERS-CoV-infected macaques. IFN-β, IL8, IL6, CCL3, and CCL20 mRNA 
expression were relatively high in some of the lung tissues at day 1 pi (A). Data are presented in fold change unit as described 
in the supplementary methods and displayed based on their data distribution, i.e. IFN-β, IL8, IL6, and CCL20 are presented in 
median ± interquartile range, while CCL3 in mean ± standard  error. pSTAT1 is detected in the lungs of MERS-CoV and SARS-
CoV infected macaques at day 1 pi, but not in the lungs mock-infected macaques and MERS-CoV infected lung explants (B). 
pSTAT1 colocalizes with MERS-CoV nucleoprotein (arrows) in some of the pneumocytes, but not with SARS-CoV nucleoprotein 
(arrowheads) (B). Pictures in first row are taken in 400x magnification, while those in second row in 1000x magnification. Viral 
RNA and IFNβ expression in the lungs of SARS-CoV infected macaques are significantly higher compared to MERS-CoV at day 
4 pi (C). Both are displayed in median ± interquartile range and analyzed with Mann-Whitney test. Significant difference was 
marked with asterisks (***p value ≤ 0,001).
Differential DPP4 expression in the lungs of cynomolgus macaques 
Our data revealed that in the respiratory tract of cynomolgus macaques, DPP4 ex-
pression and MERS-CoV replication were confined mainly to type II pneumocytes, 
unlike the lungs of a fatal MERS-CoV case that was positive for influenza A subtype 
H1N1pdm09 upon admission. Next, we investigated whether other viruses that induce 
severe respiratory infection in the lungs  upregulate DPP4 in type I pneumocytes. We 
found that DPP4-expressing type I pneumocytes were readily detected in several 
areas of the lungs of cynomolgus macaques that developed diffuse alveolar damage 
due to influenza A pH1N1, H5N1, and SARS-CoV (Figure 6A). These DPP4-express-
ing type I pneumocytes were mostly located nearby actively proliferating type II pneu-
mocytes, as indicated by Ki67 staining (Figure 6B). Likely, these DPP4 positive type I 
pneumocytes recently differentiated from proliferating type II pneumocytes.
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Figure 6. DPP4 expression in the lungs of cynomolgus macaques infected with different viruses. DPP4 is almost exclusively de-
tected in type II pneumocytes in the lungs of cynomolgus macaques infected with influenza A sH1N1. However, it is prominently 
detected in type I and II pneumocytes in the lungs with diffuse alveolar damage, obtained from cynomolgus macaques infected 
with either influenza A pH1N1, influenza A H5N1 or SARS-CoV (A). Colocalization between DPP4 (red) and Ki67 (green), a cell 
proliferation marker, was detected in the type II pneumocytes within the lungs of H5N1-infected cynomolgus macaques (B). 
Nuclei were stained with Hoechst and visualized in blue. All pictures are taken at 400x magnification.
Discussion
Both MERS-CoV and SARS-CoV are known to cause severe pneumonia in humans 5. 
The severe cases develop DAD-associated lesions in the lungs and have a high risk to 
succumb to fatal outcome 6,7,22. For SARS-CoV, three factors have been suggested to 
be essential for inducing DAD and severe clinical outcome, i.e. SARS-CoV adaptation 
to increase its affinity to its receptor in humans, viral tropism for type I pneumocytes, 
and a delayed host type I interferon response 9,10,15. Unlike SARS-CoV, MERS-CoV 
from dromedary camels already binds with moderate to high affinity to its receptor, 
DPP4, thus suggesting a difference in pathogenesis between both viruses 18. 
We observed that unlike healthy lung tissues where DPP4 is almost exclusively 
expressed in type II pneumocytes, in the lungs of a fatal MERS-CoV case DPP4 
is prominently expressed in the type I pneumocytes 25,28. These DPP4 positive type 
I pneumocytes are also readily detected in the lungs of smokers and chronic lung 
disease patients, and in that of common marmosets 28,41. Smoking and chronic lung 
diseases are known risk factors for primary and fatal MERS-CoV infection, whereas 
common marmosets have been reported to exhibit severe clinical manifestations upon 
MERS-CoV inoculation 32,33,42,43. In genetically modified susceptible mice, MERS-CoV 
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induces mild infection when DPP4 is exclusively expressed in type II pneumocytes 
44. Severe clinical manifestations are found in these mice when the virus is adapted 
through serial passaging or DPP4 expression is upregulated throughout the airway 
epithelium 44,45. These data suggest that variation in DPP4 expression may influence 
the severity of MERS-CoV infection. 
Our experimental MERS-CoV infection in healthy young-adult cynomolgus macaques, 
which have a similar DPP4 distribution compared to humans 25,28, generally resulted 
in minimal clinical manifestations. MERS-CoV does not replicate in the DPP4 
negative nasal epithelium and mainly targets type II pneumocytes where DPP4 is 
predominantly expressed. However, only a few cells were infected and infectious virus 
was rapidly eliminated within four days, similar to what has been observed in the lungs 
of MERS-CoV-infected rhesus macaques 30. Limited DPP4 expression in the lungs, 
MERS-CoV sensitivity towards type I IFN, and MERS-CoV inability to block pSTAT1 
translocation are several possible factors that limit MERS-CoV replication in these 
animals 38,39. DPP4-expressing type I pneumocytes were not detected in the lungs of 
our macaques. In contrast, these were prominently found in the lungs of macaques 
that developed DAD due to other viral infections such as SARS-CoV, influenza A 
pH1N1 and H5N1 viruses 6,12,13,26,27. We further showed that these DPP4-expressing 
type I pneumocytes are most likely those that are recently differentiated from type II 
cells, linking DPP4 upregulation with pneumocyte regeneration and differentiation. 
Interestingly, the fatal MERS-CoV case was originally admitted due to influenza A 
pH1N1 infection suggesting coinfection in this patient. 
In general, our experimental infection study in macaques may indicate that MERS-
CoV infection in healthy young individuals also results in limited replication and 
asymptomatic to mild clinical manifestations. In contrast, SARS-CoV-infected young-
adult macaques shed infectious virus in their nasal swabs up to day 7 pi and can 
productively replicate in the lungs up to day 10 pi 8,12,13,46,47. This suggests that MERS-
CoV has a narrower tropism and replication window in macaques compared to SARS-
CoV, hence is less pathogenic. Thus, DPP4 upregulation in type I pneumocytes 
either due to comorbidities 41 or coinfections might be crucial to enhance MERS-CoV 
replication, induce DAD lesions, and yield a fatal outcome. Further investigations 
to assess the importance of DPP4-expressing type I pneumocytes in MERS-CoV 
pathogenesis are still necessary, yet challenging to perform. These studies would 
for example require a reliable and physiologically representative in vitro model for 
type I pneumocytes. Recent advances in the field of lung organoids seem to offer 
the possibility to develop such model in the near future 48,49. Alternatively, performing 
these studies in vivo would require the generation of a mice model that specifically 
expresses DPP4 in type I pneumocytes. Upregulating DPP4 expression by introducing 
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an underlying comorbidity or by coinfection would likely influence other factors, for 
example host immune response. Further studies remain necessary to understand the 
pathogenesis of fatal MERS-CoV infection and characterize the factors responsible 
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MERS-CoV (EMC/2012 isolate) 1 was passaged six times on Vero E6 cells. NL63-CoV was passaged four times on Vero E6 
cells. All cell cultures were performed at biosafety level 3 facility.
In vivo infection experiment in cynomolgus macaques
Young adult cynomolgus macaques (Macaca fascicularis) seronegative for coronaviruses were purchased from commercial 
breeders (Harlan, Indianapolis, IN, USA), maintained in standard housing and provided with commercial food pellets and water 
ad libitum until the start of the experiment. Two weeks prior to inoculation with MERS-CoV, a telemetric sensor (DST micro-T 
ultra-small temperature logger, Star-Oddi, Reykjavik, Iceland) was placed in the peritoneal cavity of only three macaques in 
the MERS-CoV inoculated group to record body temperature every 15 minutes. Before the inoculation, the macaques were 
examined clinically and determined as healthy by a registered veterinarian and were placed in negatively pressurized glove 
boxes. During the experiment, animals were checked daily for clinical signs, including assessment of appearance, behavior, 
weight, presence of any nasal or ocular secretions, food, and water consumption. 
All inoculations were performed under anesthesia ((ketamine® (Nimatek, Eurovet Animal Health BV, Bladel, the Netherlands) 
and domitor® (Orion Pharma, Espoo, Finland)). Ten macaques were inoculated intratracheally (4.5 ml) and intranasally (0.5 ml) 
with 1 x 106 50% Tissue Culture Infectious Dose (TCID50) MERS-CoV. Prior to infection and at days 1, 2, 4, 8, and 11 pi, animals 
were anesthetized with ketamine, and oral and nasal swabs were taken and placed in 1 ml Dulbecco’s modified Eagle’s medium 
supplemented with 100 IU penicillin/ml and 100 μg streptomycin/ml (virus transport medium). The swabs were frozen at −70°C 
until analysis. Four macaques were euthanized at each of days 1 and 4 pi, while the last two were euthanized at day 21 pi by 
exsanguination under anesthesia. Autopsies were performed according to a standard protocol. One lung from each monkey 
was inflated with 10% neutral-buffered formalin by intrabronchial intubation and suspended in 10% neutral-buffered formalin 
overnight. Samples were collected in a standard manner, embedded in paraffin, cut at 3 μm, and used for immunohistochemistry, 
in situ hybridization, or stained with hematoxylin-eosin for examination by light microscopy. Tissue samples were also collected 
in virus transport medium (Hanks balanced salt solution supplemented with 10% glycerol, 200 U of penicillin per ml, 200 μg 
of streptomycin per ml, 100 U of polymyxin B sulphate per ml, 250 μg of gentamycin per ml, and 50 U of nystatin per ml). 
Tissue samples were weighed prior to homogenization in 2 ml virus transport medium, using Polytron PT2100 tissue grinders 
(Kinematica). After centrifugation, the homogenates were frozen at −70°C until virus titration and RT-qPCR. 
NL63-CoV and SARS-CoV infections were used as a contrast to further understand the pathogenesis of MERS-CoV infection. 
Experimental NL63-CoV infection was performed in four macaques. They were inoculated intratracheally (2.5 ml) and intranasally 
(0.5 ml) with 1 x 105 TCID50 of NL63-CoV. Two animals were euthanized at each of days 4 and 21 pi. All animals were euthanized 
by exsanguination under anesthesia. Meanwhile, the experimental SARS-CoV infection had been previously performed in our 
center also in healthy young adult cynomolgus macaques 2.  They were infected intratracheally with 1 × 106 TCID50 of one of 
the late SARS-CoV strains (HKU-39849) and euthanized at day 4 pi. Leftover lung tissue samples from this experiment were 
analyzed together with lung tissue samples from MERS-CoV experiment.
Ex vivo infection experiment in tissues of cynomolgus macaques
Nasal tissue and one entire lung lobe were harvested from a healthy 8-year-old cynomolgus macaque and transferred immediately 
to ice. Lung tissue was prepared as described previously 3. Nose and lung tissue were sliced and transferred to 24-well plates 
(Corning, Wiesbaden, Germany) containing culture medium and incubated overnight at 37°C in 5% (v/v) CO2. Each tissue was 
prepared in triplicate. Either 3 x 106 TCID50 MERS-CoV or culture medium (mock-infected group) was added to the wells under 
BSL3 conditions. After 1 hour incubation at 37°C, 500 µl fresh medium was added to each well and incubated overnight at 37°C 
in 5% (v/v) CO2. All tissue pieces were then fixed in formalin and embedded in paraffin for further analysis.
Virological analysis
Viral RNA was isolated using viral RNA Mini kit (Qiagen, Hilden, Germany) and subsequently measured for a viral load using 
reverse transcription-quantitative polymerase chain reaction (RT-qPCR) (Roche, Mannheim, Germany). Each MERS-CoV 
samples was only considered positive if both E and N gene were detected 4. Meanwhile, NL63-CoV samples were detected by 
RT-qPCR targeting N gene 5. Samples were also titrated on Vero E6 cells to further confirm the results of RT-qPCR. Ten-fold 
serial dilutions of the homogenates were prepared in Lonza IMDM medium containing 5% fetal bovine serum (FBS) for virus 
titration assay on Vero E6 cells. The amount of infectious virus in lung homogenates was calculated according to the Spearman-
Karber standard equation 6. The limit of viral detection for this assay was 0.5 log10 TCID50/ml. 
Microbiology analysis
One macaque developed severe suppurative bronchopneumonia in our study. Lung tissue samples of this macaque were used 
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to isolate RNA and bacterial typing as described previously 7.
Immunohistochemistry and Immunofluorescence analysis
MERS-CoV antigen was detected either with rabbit-anti-SARS-CoV NSP4, which cross-reacts with MERS-CoV 8 or with mouse 
monoclonal antibodies against MERS-CoV nucleocapsid protein (clone 10, SinoBiological, Beijing, China). Additionally, MERS-
CoV RNA in tissues was detected using in situ hybridisation designed by Advanced Cell Diagnostics (Hayward, CA, USA) with 
procedures suggested by the manufacturer. DPP4 was detected with polyclonal goat anti-human DPP4 (clone AF1180, R&D 
systems, Abingdon, UK). Angiotensin converting enzyme 2 (ACE2) with polyclonal rabbit anti-human ACE2 (clone ab15348, 
Abcam, Cambridge, UK). Pankeratin, an epithelial marker, with mouse monoclonal antibodies (clone AE1/AE3, Neomarkers, 
Fremont, CA, USA). CD68, a macrophage marker, with mouse monoclonal antibodies (clone KP-1, Dako, Glostrup, Denmark). 
The presence of double-stranded RNA was observed with mouse monoclonal antibody J2 (Scicons, English and Scientific 
Consulting, Hungary) 9. SARS-CoV nucleocapsid protein was identified with mouse monoclonal antibody (Imgenex, Littleton, 
USA). NL63-CoV antigen was detected using rabbit serum against its nucleocapsid protein (a kind gift from Lia van den Hoek). 
CEACAM5 was checked using polyclonal rabbit IgG anti-human CEACAM5 (Abcam, Cambridge, UK). pSTAT1 protein was 
detected using rabbit anti-human pSTAT1 (ThermoScientific, Rockford, USA). Normal goat serum (MP Biomedicals, Bruxelles, 
Belgium), rabbit IgG and isotype antibodies (DAKO, Glostrup, Denmark) were used as negative controls. The dark blue signal 
was stained with alkaline phosphatase-labelled secondary antibody and revealed with BCIP/NBT substrate (DAKO, Glostrup, 
Denmark). The red signals were stained with peroxidase-labelled secondary antibody and revealed using 3-amino-9-ethyl-
carbazole and the 3,3′-diaminobenzidine substrate, respectively. All slides were counterstained with hematoxylin. For double-
immunofluorescence staining, each slide was incubated with mouse monoclonal anti-Ki67 (DAKO, Glostrup, Denmark), and 
polyclonal goat IgG anti-human DPP4. Secondary staining was performed with rabbit anti-mouse IgG conjugated with Alexa 
Fluor 488 and rabbit-anti goat IgG conjugated with Alexa Fluor 568, while cell nuclei were detected with Hoechst (all products 
from Life Technologies, Rockford, USA).
In situ hybridization
In situ hybridization was performed according to the RNAScope platform suggested by the manufacturer 10. Probes targeting the 
nucleocapsid gene of MERS-CoV and NL63-CoV were designed by Advanced Cell Diagnostics (Hayward, CA, USA).
Microarray processing
The original experiments and generation of microarray expression data were performed by Smits et al (PMID: 20140198; ref 
9). The array data were quantile normalized and summarized using median polish (i.e., RMA, ref Irizarry et al PMID 12925520). 
Affymetrix rhesus macaque array annotation (available from the Affymetrix website) was used for annotating probesets with 
gene symbols. Statistical analysis was performed using limma [Smythe 2004 PMID: 16646809]. Log2-expressions were plotted 
for selected probesets.
Cytokine measurements
RT-qPCR was performed as described previously to detect cellular gene expression changes for IFN-β, IL-6, IL-8, CCL3, and 
CCL20 [9, 10]. Differences in gene expression are represented as the fold change in gene expression relative to a calibrator 
and normalized to a reference, using the 2−ΔΔCt method 11. GAPDH (glyceraldehyde-3-phosphate dehydrogenase) was used as a 
reference endogenous control. The samples from the mock-infected macaques were used for calibration. Data distribution was 
evaluated with D’Agustino and Pearson omnibus normality test. The data were presented either in mean ± standard error of 
mean or median ± interquartile range. Statistical analysis was performed with unpaired t test or Mann-Whitney test. 
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Supplementary figure S1. Pankeratin and CD68 staining 
on the sequential slides of the fatal MERS-CoV case lungs 
displayed in figure 1. Pankeratin positive epithelial cells are 
found in the sequential slides where MERS-CoV RNA is 
detected (A). CD68 alveolar macrophages are found in the 
sequential slides where MERS-CoV antigen is detected (B). 
Both figures are  taken in 400x magnification.
Supplementary figure S2. DPP4, ACE2, CTSC, PREP, 
GUSB, and GAPDH mRNA expression in the lungs 
of young and advance-age cynomolgus macaques. 
DPP4 was significantly higher in the lungs of advance-
age cynomolgus macaques. ACE2, CTSC, PREP, GUSB 
and GAPDH were not significantly different in the lungs of 
young and advance-age cynomolgus macaques. Data were 
expressed in log2 expression values. Statistical analysis was 
performed using limma (FDR < 0.05). All available probeset 
were shown for DPP4, ACE2, PREP and GUSB; two out of six 
probeset for CTSC were shown (those not known had similar 
expressions and were not signicantly different between young 
and advance-age macaques).  
Supplementary figure S3. Body temperature and gross 
pathology of the MERS-CoV infected macaques’ lungs. 
All animals developed elevated body temperature (body 
temperature >38°C) post MERS-CoV inoculation. One 
macaque (number 3) developed bacterial co-infection 
during the experiment. This macaque developed elevated 
temperature up to 40°C around day 4 pi (A). Gross lesions 
were hardly found in the lungs of MERS-CoV infected 
macaques, except in one macaque that developed bacterial 
coinfection (B, bottom right). Histological examination of the 
gross lesions revealed myriad intralesional small rod-shaped 
bacteria, which later identified as Eschericia coli with bacterial 
typing analysis.
Supplementary figure S4. DPP4 expression in other 
macaque tissues. DPP4 was expressed on the apical surface 
of the nasal submucosal glands (A). It was also found in the 
tracheal submucosal glands and their secretory ducts (B). 
In the tonsils, it was mainly detected in the paracortex and 
medulla, but not inside the lymphoid follicles (C). In the liver, 
it was predominantly found in the endothelium of the hepatic 
sinusoids (D). In the intestine, it was detected on the apical 
surface of the small intestine (E) and colonic crypts (F). Small 
intestine and colon pictures were taken at 100x magnification; 
tonsil and liver at 200x; while the rest at 400x
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Supplementary figure S5. The mRNA expression of IL8, IL6, CCL3, and CCL20 in the lungs of MERS-CoV and SARS-CoV 
infected macaques at day 4 pi. The fold change unit of these markers are displayed in mean ± standard error and analyzed 
with unpaired t-test. Significant difference was marked with asterisks (**p value ≤ 0,01; *p value ≤ 0,05;  n.s. = not significant).
Supplementary Information
Case description of the fatal human MERS-CoV infection
The patient was a 56 year old male with long-standing type 2 diabetes. He travelled to the Kingdom of Saudi Arabia (KSA) 
for ten days and developed acute respiratory illness with malaise, rigors, sore throat, sneezing, and fever at the fifth day of 
his stay, on 24 January 2013. No animal contact or hospital visits were reported within ten days prior to onset of illness. He 
then travelled back to UK and at sixth day post onset he developed breathing difficulty and admitted to the hospital. He was 
referred to the intensive care unit at the same day, where he was intubated and mechanically ventilated using a low tidal 
volume ventilation strategy. Nose and throat swabs were taken within 24 hours from which influenza A subtype H1N1pdm09 was 
detected. Oseltamivir treatment was then started.  
Due to persistent severe refractory hypoxia, the patient was referred to another institution for veno-venous extracorporeal 
membrane oxygenation (ECMO) at the twelfth day post onset. Upon arrival, bronchoschopy revealed purulent and haemorrhagic 
sputum with airway plugging. Chest radiograph revealed almost complete opacification of both lung fields. Upper respiratory tract 
sample was then tested positive for MERS-CoV at the fourteenth day post onset. MERS-CoV RNA was continuously detected in 
respiratory samples up to 49th day post onset. MERS-CoV reactive antibodies were detected starting from 20th day post onset. 
The patient developed multi-organ failure with respiratory, cardiovascular, renal, and hepatic dysfunction at 33rd day post onset. 
Cytomegalovirus (CMV), Epstein-Barr virus, and herpes simplex virus type 2 were repeatedly detected by PCR in blood samples 
afterwards. Over the next ten days, the patient developed sepsis. Klebsiella pneumoniae was grown from respiratory tract 
samples including broncho-alveolar lavage (BAL), and from a central venous line tip. The patient died on 19 March 2013.
CHAPTER 9
Summarizing Discussion










Middle East respiratory syndrome coronavirus (MERS-CoV) is a novel pathogen 
isolated late 2012 1. Since then, the virus has caused multiple outbreaks and infected 
more than 2000 individuals 2 which may develop a respiratory infection ranging in 
severity from asymptomatic to fatal 3,4. The severe-to-fatal MERS-CoV patients have a 
higher chance to transmit this virus since they shed a higher amount of virus progeny 
in comparison to the asymptomatic-to-mild ones 5-8. Identifying and quarantining these 
patients in health care facilities where outbreaks occurred, together with implementing 
proper infection control, has been effective in reducing transmission and containing 
these outbreaks 9,10. However, new MERS-CoV cases are still being reported, 
especially in the Arabian Peninsula 2,11. This is partly due to the continuous zoonotic 
introduction of this virus to the human population in this region by dromedaries 12. 
The dromedary camel is the only animal species that has been reported to transmit 
this virus to humans 13-16. MERS-CoV infection in these animals merely causes mild 
upper respiratory tract infection 17,18, but seroepidemiological studies showed that 
this virus has been circulating in dromedary camels for decades, suggesting efficient 
transmission of MERS-CoV in this species 19-23. 
Although the clinical manifestations, as well as transmission, are remarkably different 
in MERS-CoV-infected humans and dromedary camels, the viruses isolated from 
these two species are highly similar, if not indistinguishable 12,16. This indicates that 
host factors play a significant role in MERS-CoV pathogenesis and transmission. 
However, the identity of these host factors and how they affect the pathogenesis and 
transmission of MERS-CoV are generally not well understood. Dipeptidyl peptidase-4 
(DPP4)–the MERS-CoV receptor, sialic acids, proteases, and interferons, are 
examples of potentially critical host factors that have been shown to affect MERS-CoV 
infection in vitro 24-27. Here we highlight the role of some MERS-CoV-interacting host 
factors, especially DPP4, in the MERS-CoV pathogenesis and transmission. 
MERS-CoV-interacting Host Factors 
MERS-CoV infection of a target cell is initiated by the virus attachment to the cell 
surface 24,28. MERS-CoV uses the N-terminal part of its spike, the so called S1 protein 
(Figure 1A), to bind to two host cell surface molecules, dipeptidyl peptidase-4 (DPP4) 
and α2,3-sialic acids 24,25.  DPP4 is the functional receptor of MERS-CoV; its absence 
renders cells resistant to this virus while its transient expression in cells permits 
viral replication 24. DPP4 is a serine exopeptidase which is either expressed at the 
cell surface or shed in a soluble form. It has the capacity to cleave-off dipeptides 







Accordingly, DPP4 is capable of cutting various substrates, such as hormones, 
cytokines, chemokines, and neuropeptides, allowing it to be involved in multiple 
physiological functions as well as pathophysiological conditions 29. This enzymatic 
activity is mediated by the α/β hydrolase domain of DPP4, while MERS-CoV infection 
is mediated by the binding of S1 protein to the β-propeller domain of this exopeptidase 
(Figure 1B) 29-32. There are eleven critical residues within the β-propeller domain 
that directly interact with the S1 protein 30-32. These residues are quite conserved in 
camelids, primates, and rabbits, species shown to be susceptible to MERS-CoV 17,32-
34. In contrast, ferrets, rats, and mice resist MERS-CoV infection due to  differences in 
some critical DPP4 residues 32,35-37. These data illustrate that DPP4 has the capacity 
to determine the host range of MERS-CoV.
Figure 1. Schematic figure depicting four structural proteins of MERS-CoV, i.e. S, E, M, and N proteins (A); and a cartoon 
representation of MERS-CoV S1 protein binding to DPP4 (PDB code 4L72) (B). The S protein consists of the  S1 and S2 subunit. 
The α/β hydrolase domain of DPP4 is indicated in red, β-propeller domain in green, while part of MERS-CoV S1 protein is shown 
in blue.
Other MERS-CoV-interacting host factors besides DPP4 are less extensively studied 
and mostly have been investigated in vitro. Glycotopes of α2,3-sialic acids coupled 
with 5-N-acetylated neuraminic acid are recognized by the S1 protein of MERS-
CoV during attachment 25. In the absence of these glycotopes, MERS-CoV entry is 
reduced but not abolished, indicating their function as an attachment factor rather 
than a receptor 25. Besides α2,3-sialic acids, CEACAM5 and GRP78 have also been 
suggested to be attachment factors for MERS-CoV, but their roles in vivo during 
MERS-CoV infection are not clear at this moment 38,39. Post attachment, MERS-CoV 
uses the C-terminal part of its S protein, known as S2 (Figure 1A), to interact with host 
proteases, such as furin, TMPRSS2, and cathepsins 40-43. These proteases cleave 
the S protein and induce conformational changes allowing fusion between viral and 
host cellular membranes, resulting in the release of viral RNA into the cell cytoplasm 
28.  TMPRSS2 and DPP4 are hold in one complex at the cell surface by a scaffolding 
protein, the tetraspanin CD9,  leading to a rapid and efficient entry of MERS-CoV into 
the susceptible cells 44. Once fusion with host cell membranes has occurred, MERS-









cell cytoplasm to generate new virus progeny. During this stage, MERS-CoV uses its 
nsp3-4 polyproteins to build its replication organelles, and its accessory proteins such 
as the 4a and 4b proteins to inhibit host anti-viral defense mechanisms 45-55. However, 
the capacity of MERS-CoV accessory proteins to impede several pathways of host 
immune response in the lungs may be limited. MERS-CoV inoculation of macaques 
and genetically modified mice generally results in limited clinical manifestations, thus 
adapting this virus through serial passaging or defecting the type I interferon pathway 
may be needed to enhance viral replication and pathogenesis in these animals 33,56-
59. These observations, together with studies showing type I interferon capacity to 
inhibit MERS-CoV infection in vitro 26,60, highlight the importance of the innate immune 
response, especially type I interferon, as an inhibiting factor for MERS-CoV.  
Host Factors in MERS-CoV Transmission
So far MERS-CoV has been isolated from dromedary camels and humans 1,61. 
Both species are not only susceptible to MERS-CoV infection, but also capable 
of transmitting this virus 7,12-18,23. However, current data indicate that virus spread 
is more efficient in dromedary camels than in humans 5,7,20-22,62. This difference in 
transmissibility could be partially due to the different tropism of MERS-CoV in these 
two species. In dromedaries, MERS-CoV has been shown to replicate in the nasal 
epithelium upon experimental in vivo infection 17, while in humans, MERS-CoV mainly 
replicates in the lower respiratory tract, particularly in the bronchiolar and alveolar 
epithelium 19,24,63-65. Higher viral RNA levels in the sputum and lavage samples of 
MERS-CoV patients compared to nasal and throat swabs are consistent with the 
tropism of MERS-CoV in humans 66-68. In chapter 2 we showed that this different 
MERS-CoV tropism in dromedary camels and humans is in line with the localization of 
DPP4 in the respiratory tract tissues of these two species. In humans, DPP4 is absent 
in the nasal epithelium but present in the lower respiratory tract epithelium, mainly in 
the type II pneumocytes 69,70. In contrast, DPP4 is expressed in the nasal epithelium 
of dromedary camels 69. This difference in DPP4 localization between humans and 
dromedary camels, therefore explains MERS-CoV tropism in these two species and 
highlights DPP4 as an essential determinant for MERS-CoV tropism. 
DPP4 localization has also been investigated in many other MERS-CoV susceptible 
species. In chapter 3 we reported that in Gambian and Egyptian fruit bats, DPP4 is 
expressed in the respiratory tract and intestinal epithelium, suggesting that MERS-
CoV can target both tissues 71. In line with this finding, MERS-CoV inoculation via 
intranasal and intraperitoneal routes in the Jamaican fruit bats led to viral RNA shedding 
both in the respiratory tract and the intestinal tract 72. In contrast to frugivorous bats, 







bats, i.e. common pipistrelle and common serotine bat, but abundant in their intestinal 
epithelium 71. Accordingly, sequences of MERS-like-CoVs were mainly obtained from 
rectal swabs and fecal samples of insectivorous bats 73-80. These findings not only 
support insectivorous bats as the origin host of MERS-CoV 73-80, but also indicate the 
importance of intestinal tropism and fecal-oral transmission of MERS-like-CoVs in 
these insectivorous bats.
Besides bats, humans, and dromedary camels, other animal species have also been 
proposed as potential hosts of MERS-CoV. Remarkably, DPP4 of horses, llamas, 
alpacas, pigs, bovines, goats, sheep, and rabbits has been demonstrated to recognize 
the S protein of MERS-CoV 81,82. In most of these species there is a preferential upper 
respiratory tract expression of DPP4 observed. Rabbits express DPP4 in the upper 
and lower respiratory tract epithelium, thus may allow MERS-CoV to replicate in both 
compartments 34,83. We showed in chapter 4 that horses, llamas, and pigs mainly 
express DPP4 in the upper respiratory tract, particularly the nasal epithelium 84. 
Upon intranasal MERS-CoV inoculation, llamas, alpacas, and pigs developed upper 
respiratory tract infection, while horses did not seroconvert and only shed infectious 
virus in a limited amount 84-88. The reason why horses seem to be less permissive 
to MERS-CoV remains to be investigated, but a chronic co-infection in the guttural 
pouch, a common disease among horses, might be one of the explanations. This 
guttural pouch infection results in an excessive mucus production that might hinder 
MERS-CoV to attach and enter the nasal epithelium 84,89,90. Sheep, on the other hand, 
do not seem to express significant levels of DPP4 in their respiratory tract, thus did 
not seroconvert nor shed infectious virus upon experimental MERS-CoV inoculation 
84,88. Comparable to sheep, goats limitedly shed infectious virus upon experimental 
infection and did not transmit this virus to other naïve goats upon direct contact 88. The 
results of experimental MERS-CoV infection in the livestock animals are in line with 
data from epidemiological studies. MERS-CoV seropositive llamas and alpacas are 
present in the field, while horses, goats, and sheep are generally found seronegative 
23,86,87,91-98. 
Given the fact that experimental in vivo infection studies and DPP4 expression analysis 
in different animal species revealed that dromedary camels are not the only animals 
in which MERS-CoV has an upper respiratory tract tropism 17,18,83,84, it is then relevant 
to question whether other animals potentially can spread MERS-CoV as well. New 
World camelids, i.e. alpacas and llamas, are able to transmit the virus to respective 
naïve animals upon contact 86. Pigs on the other hand hardly transmit the virus 
neither by contact nor airborne routes 99, and so does rabbits as described in chapter 
5 of this thesis. Most likely this is caused by the fact that pigs and rabbits, unlike 









(Figure 2). This difference indicates that other host factors besides DPP4  could cause 
interspecies variation in MERS-CoV infection. Indeed, we reported in chapter 6 that 
several glycotopes of α2,3-sialic acids that function as attachment factor of MERS-
CoV are present in the nasal epithelium of dromedary camels but absent in that of 
rabbits and pigs (Figure 3) 25,100. The lack of these glycotopes in pigs and rabbits might 
limit susceptibility and transmission of MERS-CoV in these animals. Although the role 
of these glycotopes in MERS-CoV transmission still requires further investigations, it 
remains plausible that an efficient transmission of this virus might require the presence 
of both DPP4 and MERS-CoV-recognized glycotopes of α2,3-sialic acids (Figure 3). 
Figure 2. Schematic overview of viral RNA and infectious virus shedding of MERS-CoV-inoculated dromedary camels, pigs, 
and rabbits. Each data point represents the average data from previous experiments [17, 34, 84]. Viral RNA is measured in 
TCID50/ml genome equivalents, while infectious virus is expressed in TCID50/ml.
Besides entry and attachment receptors, MERS-CoV has been demonstrated to 
use both cell surface and lysosomal proteases to enter its target cells 40,41,44,101. The 
preference of MERS-CoV to use certain host proteases is influenced by the type 
of target cells and the cleavage stage of their S protein prior to infection 41. It has 
also been reported that the lysosomal proteases from bat cells support coronavirus 
spike-mediated virus entry more efficiently than their counterparts from human cells 
40. These observations suggest that host proteases from different host species may 
determine species and tissue tropism of MERS-CoV.
Because MERS-CoV has been circulating in dromedary camels for decades before 
emerging in the human population 19-23, it is plausible that this virus more efficiently 
inhibits the immune response of dromedary camels than that of other species, 
including pigs and rabbits. The difference in immune response among MERS-CoV 
susceptible species is therefore another factor that might yield interspecies variation 
in permissiveness to MERS-CoV. Characterizing the difference in host proteases 
and immune responses among MERS-CoV susceptible species, as performed for 
DPP4 and MERS-CoV-recognized α2,3-sialic acid glycotopes (Figure 3), has not yet 
been investigated. These data, however, may further explain interspecies variation in 







Figure 3. Schematic representation of DPP4 expression and MERS-CoV-recognized α2,3-sialic acid glycotopes in the respira-
tory tract of dromedary camel, pig, rabbit, human, and sheep.
Host Factors in MERS-CoV Pathogenesis
Figure 4. MERS-CoV infection in the lungs of asymptomatic-to-mild (left panel) and severe-to-fatal cases (right panel).  Shown 
is a hypothetical model with two critical host determinants, DPP4 and interferon, differentially expressed in asymptomatic-to-mild 
and severe-to-fatal MERS-CoV infection.
MERS-CoV causes respiratory infection in humans ranging from asymptomatic to 
severe pneumonia 3,4, however, it is currently unclear what causes this intraspecies 
variation. Epidemiology data indicate that individuals with certain risk factors are at 
higher risk to develop severe MERS-CoV infection 4,102. This implies that some host 
factors may dictate the outcome of MERS-CoV infection, thus rendering intraspecies 









chronic obstructive pulmonary disease (COPD), could upregulate DPP4 expression 
in the lungs 70,102-104, suggesting DPP4 as a possible reason for intraspecies variation 
observed among MERS-CoV patients. In healthy human lungs, DPP4 is almost 
exclusively expressed in the type II pneumocytes 69,70. In the lungs of smokers and 
COPD patients, on the other hand, DPP4 is prominently expressed in both type I and 
II pneumocytes, indicating upregulated expression on type I pneumocytes 104. Autopsy 
reports from fatal MERS-CoV patients, including the one displayed in chapter 8 of 
this thesis, showed that both type I and II pneumocytes express DPP4 and became 
infected by MERS-CoV, proposing a role of DPP4-expressing type I pneumocytes 
in MERS-CoV pathogenesis 105,106. Damage to type I cells in the lung alveoli during 
viral infection may lead to diffuse alveolar damage 107. In line with observations 
made in human MERS cases, common marmosets, that express DPP4 in both type 
I and II pneumocytes, have been reported to produce more infectious virus upon 
experimental MERS-CoV infection compared to rhesus and cynomolgus macaques 
that merely express DPP4 in type II pneumocytes 59,108-111. Accordingly, these common 
marmosets develop moderate to severe infection 108-110, while macaques generally 
develop mild transient pneumonia 33,59, as we also observed in our study described in 
chapter 8. Similarly, in genetically modified mice that display MERS-CoV tropism for 
type II pneumocytes, only mild clinical manifestations are observed upon MERS-CoV 
infection 57,112. Adapting MERS-CoV through serial passaging or upregulating DPP4 
expression throughout the airway epithelium in mice, however,  will induce severe 
clinical disease 56,57. These data altogether support the role of DPP4-expressing type 
I pneumocytes in the pathogenesis of severe MERS-CoV infection. 
Differential expression of host factors that limit the infection should have also been 
taken into account. DPP4 in soluble form has been demonstrated to protect against 
MERS-CoV infection in vitro and in mice model 24,113, however, its presence in the 
lungs and role in MERS-CoV pathogenesis remain to be investigated. The host 
immune response also has the capacity to inhibit MERS-CoV infection. MERS-
CoV has been shown to replicate to higher levels in immunocompromised rhesus 
macaques 114, consistent with the observation that immunocompromised individuals 
have difficulties clearing MERS-CoV upon infection 68,105,115. The survivors of MERS-
CoV infection have been shown to develop virus specific CD4+ and CD8+ T cell 
responses, implying the role of T cells in virus clearance 116. However, depletion of 
T cells in mice can either lead to failure in MERS-CoV clearance or improvement in 
clinical outcome depending on the type of mouse model used 58,117. Therefore, the role 
of adaptive immune response in MERS-CoV pathogenesis is currently unclear. On the 
other hand, one of the main components of the host innate immune response, type I 
interferon, inhibits MERS-CoV replication in susceptible cells, partly by inhibiting DMV 







in more severe clinical manifestations and histopathological lesions upon MERS-
CoV infection 58. Advance age, that can cause delayed type I interferon response 
upon viral infection, is a well-known risk factor for fatal MERS-CoV infection 4,102,120-122. 
Collectively, these data highlight the role of host innate immune response as a potent 
inhibitor for MERS-CoV infection. 
It is indubitable that severe MERS-CoV infection is not solely driven by the pathogen. 
Additional underlying conditions seem to be detrimental to increase MERS-CoV repli-
cation and induce severe to fatal clinical manifestations 4,11,103,123,124. It is plausible that 
more than one underlying condition is needed to yield a fatal outcome 109. DPP4 up-
regulation in type I pneumocytes and insufficient type I interferon response might be 
crucial determinants for severe MERS-CoV infection (Figure 4). Further investigation 
on the host determinants of MERS-CoV pathogenesis may offer insights for develop-
ing novel therapeutic measures. 
 
Concluding remarks and future perspectives
Although MERS-CoV has been reported to undergo some genotypic changes since 
it emerged in the human population 12,125-128, this did not result in distinct phenotypic 
changes so far 1,64,125. Therefore host factors remain the most significant determinant 
in explaining inter- and intraspecies variations observed in MERS-CoV pathogenesis 
and transmission. DPP4 and MERS-CoV-recognized α2,3-sialic acids might partially 
explain these variations since their localization has been demonstrated to be variable 
between MERS-CoV susceptible species 69,71,84,100. DPP4 expression in the human 
lungs has also been shown to vary due to certain comorbidities 70,96,104. Nevertheless, 
it is undoubted that the inter- and intraspecies variation in MERS-CoV pathogenesis 
and transmission is a complex phenomenon influenced by more than one host factor. 
Current data suggest proteases and interferons as other critical host factors, but 
how they instigate inter- and intraspecies variations, and their role in MERS-CoV 
pathogenesis and transmission still remains to be further elucidated. Characterization 
of the host determinants of MERS-CoV pathogenesis and transmission could 
potentially offer insight into this virus epidemiology and guide novel therapeutic 
development. It may also help  to identify the most vulnerable individuals to protect 
against MERS-CoV infection, for example by using vaccination. 
Current epidemiology observations suggest that MERS-CoV has limited pathogenicity 
and transmissibility in individuals without risk factors 4,5,7, thus a large number of 
vulnerable individuals in one location that could allow this virus to efficiently spread, 
for example in healthcare facilities, particularly in the intensive care units, might be 









for MERS-CoV to cause outbreaks outside these facilities, one could argue that the 
risk of MERS-CoV causing a pandemic is considerably low. However, it is important to 
note that the risk is not negligible, as exemplified by a large MERS-CoV outbreak in 
South Korea 62. Despite increased awareness and implementation of proper infection 
control in the healthcare facilities, new MERS-CoV cases are still being reported 
in the Arabian Peninsula 2. MERS-CoV might also undergo adaptation to be more 
pathogenic and transmissible in humans, as SARS-CoV once did 129-134. Therefore, 
it is still crucial to investigate whether MERS-CoV has been subjected to genotypic 
and phenotypic changes, by maintaining surveillance and performing in vitro and in 
vivo experiments comparing the earlier and the more recent virus strains. MERS-CoV 
transmission and pathogenesis are complex phenomena that are likely influenced by 
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MERS-CoV is a microbe that commonly infects dromedary camels in the Arabian Peninsula 
and Africa. However, since the late 2012s, it is known that MERS-CoV could also cause 
disease in humans ranging from asymptomatic to fatal. It infects the human lungs thus 
render the infected individuals to develop respiratory illness known as pneumonia. During 
the infection, MERS-CoV enters the cells in the human lungs by first attaching to several 
molecules expressed at the cell surface. Two of these molecules are a protein called 
dipeptidyl peptidase-4 (DPP4) and a sugar structure called sialic acids. An absence of DPP4 
renders the cells protected from MERS-CoV infection, while the absence of sialic acids 
reduces the capacity for MERS-CoV to infect the cells but does not fully protect them. Thus, 
DPP4 functions as the receptor for MERS-CoV, while sialic acids as an attachment factor. 
Our studies focused on mapping the localization of these two molecules in various tissues of 
animals and humans as well as get some clues on how DPP4 is regulated, in order to gain 
insights on how MERS-CoV is transmitted and how it causes diseases, especially in humans. 
We found that these two molecules are variably distributed in the tissues of different species. 
In human respiratory tract, DPP4 is merely expressed in the lungs, while in that of dromedary 
camels, it is expressed in the nasal epithelium. This means that MERS-CoV replicates in 
human lungs, while in camels it could replicate in the nose. Thus, it could partially explain 
why MERS-CoV is endemic in dromedary camels, while it is rather inefficiently transmitted 
between humans. We also found that DPP4 expression is relatively low in the healthy human 
lungs, however, chronic lung diseases and coinfections could upregulate its expression, 
suggesting MERS-CoV to infect a higher number of cells under these conditions. This might 
be one of the reasons why MERS-CoV infection causes a wide range of severity in humans, 
i.e. asymptomatic to fatal. Besides dromedary camels and humans, we also investigated 
DPP4 expression in other species as well. In insectivorous bats, that suggested to be the 
original host of MERS-CoV, DPP4 is hardly expressed in the respiratory tract but abundantly 
present in the intestine. This suggests that this virus replicates in the intestine and transmits 
via fecal-oral route between these bats. DPP4 is also detected in the nose of pigs and rabbits, 
in line with MERS-CoV replication site in these animals. However, unlike dromedary camels, 
these animals do not spread this virus, suggesting either the presence of inhibiting factors 
or the lack of supporting factors for MERS-CoV transmission in these animals. Interestingly, 
we also found that both pigs and rabbits are lacking an attachment factor, the sialic acids, in 
their nose. Collectively, the data compiled in this thesis showed that studies on MERS-CoV 
receptor and attachment factor could provide insights into its transmission and pathogenesis. 
Thus, these data are essential to better our understanding of MERS-CoV epidemiology and 










MERS-CoV is een microbe die vaak dromedarissen infecteert in het Arabisch schiereiland 
en Afrika. Sinds 2012, is het ook bekend dat MERS-CoV ook bij de mens ziekte kan 
veroorzaken, variërend van asymptomatisch tot fataal. Het infecteert de longen, waardoor 
geïnfecteerde individuen longontsteking kunnen ontwikkeling. Tijdens het infectieproces 
bij de mens, komt MERS-CoV de cellen in de longen binnen door eerst te hechten aan 
verschillende moleculen die op het celoppervlak voorkomen. Twee van deze moleculen 
zijn de eiwitten dipeptidylpeptidase-4 (DPP-4) en een suikerstructuur genoemd siaalzuur. 
Een afwezigheid van DPP-4 zorgt ervoor dat de cellen beschermd zijn tegen MERS-CoV 
infectie, terwijl de afwezigheid van siaalzuur de infectiecapaciteit van MERS-CoV vermindert, 
maar de cellen niet volledig beschermd. DPP4 functioneert dus als receptor voor MERS-
CoV, terwijl siaalzuur als bindingsfactor functioneert. Onze studies zijn gericht op het in kaart 
brengen van de lokalisatie van deze twee moleculen in verschillende weefsels van dieren 
en mensen. Evenals nog wat aanwijzingen over hoe DPP-4 is gereguleerd, om inzicht te 
krijgen over hoe MERS-CoV wordt overgedragen en hoe het ziekte veroorzaakt, voornamelijk 
in mensen. We vonden dat deze twee moleculen variabel worden verdeeld in de weefsels 
van verschillende soorten. In de menselijke luchtwegen, wordt DPP4 alleen tot expressie 
gebracht in de longen, terwijl bij dromedarissen wordt het uitgedrukt in het nasale epitheel. Dit 
betekent dat MERS-CoV zich repliceert in de menselijke longen, terwijl in kamelen repliceert 
in de neus. Dit verklaart gedeeltelijk waarom MERS-CoV endemisch is in dromedarissen, 
terwijl het nogal inefficiënt overgedragen wordt tussen de mens. We vonden ook dat DPP4 
expressie relatief laag is in gezonde menselijke longen, alhoewel chronische longziekten 
en co-infecties zijn expressie opwaarts kunnen reguleren, wat suggereert MERS-CoV een 
groter aantal cellen  onder deze omstandigheden te infecteerd. Dit is wellicht een van de 
redenen waarom MERS-CoV infectie een breed scala van de ernst bij mensen veroorzaakt, 
dat wil zeggen asymptomatische tot fatale. Naast dromedarissen en mensen, onderzochten 
we ook DPP4 expressie in andere soorten. In insectetende vleermuizen, dat de voorgesteld 
originele gastheren zijn van MERS-CoV, wordt DPP4 nauwelijks tot uitdrukking gebracht in de 
luchtwegen, maar overvloedig aanwezig is in de darm. Dit suggereert dat het virus repliceert 
in de ingewanden en overgebracht wordt via de fecaal-orale route tussen deze vleermuizen. 
DPP4 wordt ook gedetecteerd in de neus van varkens en konijnen, dat in overeenstemming 
komt met MERS-CoV replicatie in deze dieren. In tegenstelling tot dromedarissen, kunnen 
deze dieren dit virus niet verspreiden, wat suggereert naar de aanwezigheid van remmende 
factoren of het gebrek aan ondersteunende factoren voor MERS-CoV transmissie in deze 
dieren. Verder nog, vonden we ook dat zowel bij de varkens als konijnen de bindingsfactor, 
siaalzuur, in hun neus ontbreekt. Samengesteld, de gecompileerde data/informatie in dit 
proefschrift bewijzen dat onderzoek naar MERS-CoV receptoren en bindingsfactoren nieuwe 
inzichten kan brengen op de gebieden van transmissie en pathogenese. Deze gegevens zijn 
essentieel om zo ons begrip van MERS-CoV epidemiologie te verbeteren en de ontwikkeling 
van nieuwe interventies te inspireren.
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MERS-CoV adalah virus yang umumnya menginfeksi unta di jazirah Arab dan benua Afrika. 
Namun, di penghujung tahun 2012, virus ini diketahui dapat menginfeksi paru-paru manusia 
dan menyebabkan penyakit radang paru-paru ringan hingga berat, bahkan terkadang 
mematikan. Guna menginfeksi sel di paru-paru, virus MERS perlu terlebih dahulu menempel 
pada beberapa molekul di permukaan sel. Dua diantaranya adalah protein bernama dipeptidil 
peptidase-4 (DPP4) dan monosakarida yang disebut asam sialat. Virus MERS tidak dapat 
menginfeksi sel tanpa keberadaan DPP4. Tanpa keberadaan asam sialat, virus ini masih 
dapat menginfeksi sel, namun kemampuan infeksinya menurun. Penelitian kami bertujuan 
untuk mengetahui letak kedua molekul tersebut serta mempelajari regulasi produksi DPP4 
di sejumlah jaringan tubuh hewan dan manusia. Data yang kami peroleh dapat memberikan 
petunjuk terkait penyebaran virus MERS dan bagaimana virus ini menimbulkan penyakit, 
khususnya pada manusia. Hasil penelitian kami menunjukkan bahwa lokasi kedua molekul 
ini bervariasi antar spesies. DPP4 diproduksi di paru-paru manusia, sementara di unta, DPP4 
diproduksi di hidung. Hal ini menyebabkan virus MERS berkembangbiak di jaringan yang 
berbeda saat menginfeksi unta dan manusia. Perbedaan ini kemungkinan menyebabkan 
virus MERS endemik di unta, namun tidak mudah menyebar antar manusia. Kami juga 
menemukan bahwa DPP4 tidak banyak diproduksi di paru-paru manusia dalam kondisi 
sehat. Namun produksi DPP4 dapat meningkat pada penderita penyakit radang paru kronik 
dan radang paru akut akibat infeksi virus lain, yang diketahui beresiko menderita radang paru 
berat saat terinfeksi virus MERS. Hal ini dapat merupakan salah satu penyebab mengapa 
pasien yang terinfeksi virus MERS dapat menderita radang paru ringan hingga berat. Selain 
unta dan manusia, kami juga meneliti lokasi DPP4 di jaringan tubuh hewan-hewan lain. 
Pada kelelawar pemakan serangga, DPP4 tidak banyak diproduksi di saluran pernafasan, 
namun banyak ditemukan di usus. Hal ini mengindikasikan bahwa virus MERS dapat 
berkembang biak di usus dan menyebar lewat tinja hewan-hewan ini. DPP4 juga diproduksi 
di dalam hidung babi dan kelinci, sesuai dengan lokasi berkembang biak virus MERS di 
kedua hewan tersebut. Namun, kedua hewan tersebut tidak dapat menyebarkan virus MERS 
seperti layaknya unta. Kemungkinan, salah satu penyebabnya adalah tidak adanya asam 
sialat yang menjadi faktor pendukung infeksi virus MERS di hidung babi dan kelinci. Secara 
keseluruhan, data yang disajikan dalam tesis ini menunjukkan bahwa upaya mempelajari 
molekul-molekul yang berinteraksi dengan virus MERS dapat membantu kita mempelajari 
bagaimana virus MERS menyebar dan menyebabkan penyakit. Untuk itu, penelitian kami 
dapat pula bermanfaat untuk memahami lebih lanjut mengenai epidemiologi virus MERS, dan 
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